AU758983B2 - Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation - Google Patents
Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation Download PDFInfo
- Publication number
- AU758983B2 AU758983B2 AU39486/99A AU3948699A AU758983B2 AU 758983 B2 AU758983 B2 AU 758983B2 AU 39486/99 A AU39486/99 A AU 39486/99A AU 3948699 A AU3948699 A AU 3948699A AU 758983 B2 AU758983 B2 AU 758983B2
- Authority
- AU
- Australia
- Prior art keywords
- phenyl
- methylsulfonyl
- fluorophenyl
- benzenesulfonamide
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 title claims description 95
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 title claims description 95
- 239000002464 receptor antagonist Substances 0.000 title claims description 91
- 229940044551 receptor antagonist Drugs 0.000 title claims description 91
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title claims description 74
- 229940111134 coxibs Drugs 0.000 title claims description 68
- 206010061218 Inflammation Diseases 0.000 title description 6
- 230000004054 inflammatory process Effects 0.000 title description 6
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims description 256
- -1 2 -thiazolyl Chemical group 0.000 claims description 149
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 110
- 150000001875 compounds Chemical class 0.000 claims description 108
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 79
- 125000003003 spiro group Chemical group 0.000 claims description 79
- 239000001257 hydrogen Substances 0.000 claims description 72
- 229910052739 hydrogen Inorganic materials 0.000 claims description 72
- 150000003839 salts Chemical class 0.000 claims description 59
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 53
- 125000000217 alkyl group Chemical group 0.000 claims description 52
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 44
- 208000027866 inflammatory disease Diseases 0.000 claims description 42
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 39
- 150000002431 hydrogen Chemical class 0.000 claims description 38
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 37
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 34
- 125000005843 halogen group Chemical group 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 32
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 30
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 28
- 125000001424 substituent group Chemical group 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 26
- 125000004432 carbon atom Chemical group C* 0.000 claims description 24
- 125000004145 cyclopenten-1-yl group Chemical group [H]C1=C(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 22
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 22
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 21
- 125000001624 naphthyl group Chemical group 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 20
- 125000001072 heteroaryl group Chemical group 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- 125000004076 pyridyl group Chemical group 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- 125000001153 fluoro group Chemical group F* 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 15
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 15
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims description 15
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 13
- 239000001301 oxygen Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 230000002829 reductive effect Effects 0.000 claims description 13
- 125000001544 thienyl group Chemical group 0.000 claims description 13
- BLFBQEGMHIZRFA-UHFFFAOYSA-N 6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=C=CC=C[N]1 BLFBQEGMHIZRFA-UHFFFAOYSA-N 0.000 claims description 12
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 12
- JCDWETOKTFWTHA-UHFFFAOYSA-N methylsulfonylbenzene Chemical compound CS(=O)(=O)C1=CC=CC=C1 JCDWETOKTFWTHA-UHFFFAOYSA-N 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 150000003254 radicals Chemical class 0.000 claims description 12
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 11
- 239000011737 fluorine Substances 0.000 claims description 11
- 229910052731 fluorine Inorganic materials 0.000 claims description 11
- 125000000623 heterocyclic group Chemical group 0.000 claims description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- ATRQECRSCHYSNP-UHFFFAOYSA-N 2-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=CC=N1 ATRQECRSCHYSNP-UHFFFAOYSA-N 0.000 claims description 10
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 10
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims description 10
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 10
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 125000003386 piperidinyl group Chemical group 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 9
- 125000002252 acyl group Chemical group 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 125000002541 furyl group Chemical group 0.000 claims description 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 8
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 8
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 8
- 229910052708 sodium Inorganic materials 0.000 claims description 8
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 7
- AGCRHVNIFLDQNI-UHFFFAOYSA-N 2-[4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-1,3-oxazol-2-yl]acetic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)N=C(CC(O)=O)O1 AGCRHVNIFLDQNI-UHFFFAOYSA-N 0.000 claims description 7
- APMIVVBYHLSFJD-UHFFFAOYSA-N 5-(difluoromethyl)-4-(4-methylsulfonylphenyl)-3-phenyl-1,2-oxazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C(F)F)ON=C1C1=CC=CC=C1 APMIVVBYHLSFJD-UHFFFAOYSA-N 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 7
- MSBIKMWKHZYAQU-UHFFFAOYSA-N ethyl 2-[4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-1,3-oxazol-2-yl]-3-phenylpropanoate Chemical compound N=1C(C=2C=CC(F)=CC=2)=C(C=2C=CC(=CC=2)S(C)(=O)=O)OC=1C(C(=O)OCC)CC1=CC=CC=C1 MSBIKMWKHZYAQU-UHFFFAOYSA-N 0.000 claims description 7
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 7
- 125000005493 quinolyl group Chemical group 0.000 claims description 7
- RIFQFNJQEHYKKZ-UHFFFAOYSA-N 4-(4-chloro-3,5-diphenylpyrazol-1-yl)benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC=CC=2)=C(Cl)C(C=2C=CC=CC=2)=N1 RIFQFNJQEHYKKZ-UHFFFAOYSA-N 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 claims description 6
- 241000036848 Porzana carolina Species 0.000 claims description 6
- 239000005864 Sulphur Substances 0.000 claims description 6
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 6
- OGQVROWWFUXRST-UHFFFAOYSA-N hepta-1,3-diene Chemical compound CCCC=CC=C OGQVROWWFUXRST-UHFFFAOYSA-N 0.000 claims description 6
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 6
- 125000001041 indolyl group Chemical group 0.000 claims description 6
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 6
- 125000002971 oxazolyl group Chemical group 0.000 claims description 6
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 125000006413 ring segment Chemical group 0.000 claims description 6
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 6
- 125000001425 triazolyl group Chemical group 0.000 claims description 6
- HUVCBGHNHBHJBX-UHFFFAOYSA-N 1-[2-(4-chlorophenyl)-4,4-dimethylcyclopenten-1-yl]-4-methylsulfonylbenzene Chemical compound C1C(C)(C)CC(C=2C=CC(Cl)=CC=2)=C1C1=CC=C(S(C)(=O)=O)C=C1 HUVCBGHNHBHJBX-UHFFFAOYSA-N 0.000 claims description 5
- VKUCTHVTLJBHDT-UHFFFAOYSA-N 1-[4,4-dimethyl-2-(4-methylsulfonylphenyl)cyclopenten-1-yl]-4-fluorobenzene Chemical compound C1C(C)(C)CC(C=2C=CC(F)=CC=2)=C1C1=CC=C(S(C)(=O)=O)C=C1 VKUCTHVTLJBHDT-UHFFFAOYSA-N 0.000 claims description 5
- UPXZCQZUZDWZHE-UHFFFAOYSA-N 2-(4-chlorophenyl)-4-(4-fluorophenyl)-1-(4-methylsulfonylphenyl)imidazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=NC(C=2C=CC(F)=CC=2)=C1 UPXZCQZUZDWZHE-UHFFFAOYSA-N 0.000 claims description 5
- NECDCTAHUMBLQG-UHFFFAOYSA-N 2-bromo-6-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)pyridine-3-carbonitrile Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C#N)=C(Br)N=C1C1=CC=C(F)C=C1 NECDCTAHUMBLQG-UHFFFAOYSA-N 0.000 claims description 5
- YTLPYUWXEWWKRU-UHFFFAOYSA-N 4-(4-fluorophenyl)-3-(4-methylsulfonylphenyl)-1-(2-phenylethyl)pyrazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=C1)C=2C=CC(F)=CC=2)=NN1CCC1=CC=CC=C1 YTLPYUWXEWWKRU-UHFFFAOYSA-N 0.000 claims description 5
- QDPWDPOAKFQYJR-UHFFFAOYSA-N 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-phenyl-1,3-oxazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)N=C(C=2C=CC=CC=2)O1 QDPWDPOAKFQYJR-UHFFFAOYSA-N 0.000 claims description 5
- MPHUNBLFEKLVLF-UHFFFAOYSA-N 4-[3-(difluoromethyl)-5-(4-methylphenyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 MPHUNBLFEKLVLF-UHFFFAOYSA-N 0.000 claims description 5
- ZFFYQVIHYPYXPI-UHFFFAOYSA-N 4-[3-(difluoromethyl)-5-phenylpyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC=CC=2)=CC(C(F)F)=N1 ZFFYQVIHYPYXPI-UHFFFAOYSA-N 0.000 claims description 5
- KBNOHTKUNAPKEI-UHFFFAOYSA-N 4-[5-(4-chlorophenyl)-3-(5-chlorothiophen-2-yl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(C=2SC(Cl)=CC=2)=N1 KBNOHTKUNAPKEI-UHFFFAOYSA-N 0.000 claims description 5
- NSQNZEUFHPTJME-UHFFFAOYSA-N 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(C(F)(F)F)=N1 NSQNZEUFHPTJME-UHFFFAOYSA-N 0.000 claims description 5
- PYXNITNKYBLBMW-UHFFFAOYSA-N 5-(trifluoromethyl)-1h-pyrazole Chemical compound FC(F)(F)C1=CC=NN1 PYXNITNKYBLBMW-UHFFFAOYSA-N 0.000 claims description 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 5
- GJGZQTGPOKPFES-UHFFFAOYSA-N SC-57666 Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)CCC1 GJGZQTGPOKPFES-UHFFFAOYSA-N 0.000 claims description 5
- JHBIMJKLBUMNAU-UHFFFAOYSA-N SC-58125 Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(C=2C=CC(F)=CC=2)=CC(C(F)(F)F)=N1 JHBIMJKLBUMNAU-UHFFFAOYSA-N 0.000 claims description 5
- 229910003667 SRa Inorganic materials 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 4
- LWIFWMYFVZYWMS-UHFFFAOYSA-N 1,2-difluoro-3-[2-(4-methylsulfonylphenyl)cyclopenten-1-yl]benzene Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C(=C(F)C=CC=2)F)CCC1 LWIFWMYFVZYWMS-UHFFFAOYSA-N 0.000 claims description 4
- JQDLRYPRLMZWFM-UHFFFAOYSA-N 1-methylsulfanyl-4-[2-(4-methylsulfonylphenyl)cyclopenten-1-yl]benzene Chemical compound C1=CC(SC)=CC=C1C1=C(C=2C=CC(=CC=2)S(C)(=O)=O)CCC1 JQDLRYPRLMZWFM-UHFFFAOYSA-N 0.000 claims description 4
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 4
- NXERGIJHYVUXHM-UHFFFAOYSA-N 3-(3-fluorophenyl)-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound CC1(C)OC(=O)C(C=2C=C(F)C=CC=2)=C1C1=CC=C(S(C)(=O)=O)C=C1 NXERGIJHYVUXHM-UHFFFAOYSA-N 0.000 claims description 4
- OCROGSYJFYKXMO-UHFFFAOYSA-N 3-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-6-prop-2-ynoxy-2-(trifluoromethyl)pyridine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(OCC#C)=NC(C(F)(F)F)=C1C1=CC=C(F)C=C1 OCROGSYJFYKXMO-UHFFFAOYSA-N 0.000 claims description 4
- NTIRVNBDXWODFR-UHFFFAOYSA-N 4-[2-(4-fluorophenyl)-4,4-dimethylcyclopenten-1-yl]benzenesulfonamide Chemical compound C1C(C)(C)CC(C=2C=CC(F)=CC=2)=C1C1=CC=C(S(N)(=O)=O)C=C1 NTIRVNBDXWODFR-UHFFFAOYSA-N 0.000 claims description 4
- DVWHCFFOQZQHTQ-UHFFFAOYSA-N 4-[5-[4-(dimethylamino)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(N(C)C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 DVWHCFFOQZQHTQ-UHFFFAOYSA-N 0.000 claims description 4
- 241000689227 Cora <basidiomycete fungus> Species 0.000 claims description 4
- 229910003827 NRaRb Inorganic materials 0.000 claims description 4
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims description 4
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 4
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims description 4
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- QABHNMGULNULIM-UHFFFAOYSA-M sodium;2-(4-chlorophenyl)-3-(4-methylsulfonylphenyl)-4-oxopent-2-enoate Chemical compound [Na+].C=1C=C(S(C)(=O)=O)C=CC=1C(C(=O)C)=C(C([O-])=O)C1=CC=C(Cl)C=C1 QABHNMGULNULIM-UHFFFAOYSA-M 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- RFPZMXMBYMEQHZ-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-(4-methylsulfonylphenyl)benzene Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC=CC=C1C1=CC=C(F)C=C1 RFPZMXMBYMEQHZ-UHFFFAOYSA-N 0.000 claims description 3
- ULFYMTMZNITFSB-UHFFFAOYSA-N 2-(3,5-difluorophenyl)-3-(4-methylsulfonylphenyl)cyclopent-2-en-1-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=C(F)C=C(F)C=2)C(=O)CC1 ULFYMTMZNITFSB-UHFFFAOYSA-N 0.000 claims description 3
- SEOHAKCJVHNLFU-UHFFFAOYSA-N 4-[2-(4-chlorophenyl)cyclopenten-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=C(C=2C=CC(Cl)=CC=2)CCC1 SEOHAKCJVHNLFU-UHFFFAOYSA-N 0.000 claims description 3
- FHQRDEDZJIFJAL-UHFFFAOYSA-N 4-phenylmorpholine Chemical compound C1COCCN1C1=CC=CC=C1 FHQRDEDZJIFJAL-UHFFFAOYSA-N 0.000 claims description 3
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 125000002837 carbocyclic group Chemical group 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 3
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 3
- DTQNEFOKTXXQKV-HKUYNNGSSA-N (2s,3s)-n-[(2-methoxyphenyl)methyl]-2-phenylpiperidin-3-amine Chemical compound COC1=CC=CC=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)NCCC1 DTQNEFOKTXXQKV-HKUYNNGSSA-N 0.000 claims description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims description 2
- KYHMFVRVHASKGM-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-isoindol-4-ol Chemical compound OC1CCCC2CNCC12 KYHMFVRVHASKGM-UHFFFAOYSA-N 0.000 claims description 2
- MSULOQJDYOQZPZ-UHFFFAOYSA-N 4-[2-(3-chloro-4-methoxyphenyl)-4,5-difluorophenyl]benzenesulfonamide Chemical compound C1=C(Cl)C(OC)=CC=C1C1=CC(F)=C(F)C=C1C1=CC=C(S(N)(=O)=O)C=C1 MSULOQJDYOQZPZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 206010006811 Bursitis Diseases 0.000 claims description 2
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 claims description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 208000000491 Tendinopathy Diseases 0.000 claims description 2
- 206010043255 Tendonitis Diseases 0.000 claims description 2
- 125000004442 acylamino group Chemical group 0.000 claims description 2
- 125000004423 acyloxy group Chemical group 0.000 claims description 2
- 125000004450 alkenylene group Chemical group 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 claims description 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 2
- 125000003705 anilinocarbonyl group Chemical group O=C([*])N([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 150000001450 anions Chemical class 0.000 claims description 2
- 125000003435 aroyl group Chemical group 0.000 claims description 2
- 125000005116 aryl carbamoyl group Chemical group 0.000 claims description 2
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims description 2
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims description 2
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 claims description 2
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000004970 halomethyl group Chemical group 0.000 claims description 2
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 150000002460 imidazoles Chemical class 0.000 claims description 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000002346 iodo group Chemical group I* 0.000 claims description 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 125000005646 oximino group Chemical group 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 150000003413 spiro compounds Chemical class 0.000 claims description 2
- 201000004595 synovitis Diseases 0.000 claims description 2
- 201000004415 tendinitis Diseases 0.000 claims description 2
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims description 2
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- RHDGNLCLDBVESU-UHFFFAOYSA-N but-3-en-4-olide Chemical compound O=C1CC=CO1 RHDGNLCLDBVESU-UHFFFAOYSA-N 0.000 claims 18
- KLBJMDOPSOFTGI-UHFFFAOYSA-N 4-[3,5-bis(4-methylphenyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(C)=CC=C1C1=NN(C=2C=CC(=CC=2)S(N)(=O)=O)C(C=2C=CC(C)=CC=2)=C1 KLBJMDOPSOFTGI-UHFFFAOYSA-N 0.000 claims 9
- ILPBINAXDRFYPL-UHFFFAOYSA-N 2-octene Chemical compound CCCCCC=CC ILPBINAXDRFYPL-UHFFFAOYSA-N 0.000 claims 8
- BPWDIXPFAHESAF-UHFFFAOYSA-N 1-[3,3-dimethyl-5-(4-methylsulfonylphenyl)cyclopenta-1,4-dien-1-yl]-4-fluorobenzene Chemical compound C=1C(C)(C)C=C(C=2C=CC(F)=CC=2)C=1C1=CC=C(S(C)(=O)=O)C=C1 BPWDIXPFAHESAF-UHFFFAOYSA-N 0.000 claims 7
- MEAMLMDMYOLDGW-UHFFFAOYSA-N 2-(3-fluoro-5-methylphenyl)-1-(4-methylsulfonylphenyl)-4-(trifluoromethyl)imidazole Chemical compound CC1=CC(F)=CC(C=2N(C=C(N=2)C(F)(F)F)C=2C=CC(=CC=2)S(C)(=O)=O)=C1 MEAMLMDMYOLDGW-UHFFFAOYSA-N 0.000 claims 7
- XDFQOAFLRJSBEX-UHFFFAOYSA-N 2-[(3,5-dichlorophenoxy)methyl]-4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-1,3-thiazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)N=C(COC=2C=C(Cl)C=C(Cl)C=2)S1 XDFQOAFLRJSBEX-UHFFFAOYSA-N 0.000 claims 7
- AMTZZFUBJIWXKB-UHFFFAOYSA-N 2-tert-butyl-4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-1,3-oxazole Chemical compound O1C(C(C)(C)C)=NC(C=2C=CC(F)=CC=2)=C1C1=CC=C(S(C)(=O)=O)C=C1 AMTZZFUBJIWXKB-UHFFFAOYSA-N 0.000 claims 7
- SOOKCKQNOCMHPV-UHFFFAOYSA-N 2-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-1,3-thiazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)N=C(C=2C=C(Cl)C(F)=CC=2)S1 SOOKCKQNOCMHPV-UHFFFAOYSA-N 0.000 claims 6
- UFSJAWLGOHKVBH-UHFFFAOYSA-N 2-(3-fluoro-4-methoxyphenyl)-1-(4-methylsulfonylphenyl)-4-(trifluoromethyl)imidazole Chemical compound C1=C(F)C(OC)=CC=C1C1=NC(C(F)(F)F)=CN1C1=CC=C(S(C)(=O)=O)C=C1 UFSJAWLGOHKVBH-UHFFFAOYSA-N 0.000 claims 6
- VSQLZYPQFJIORU-UHFFFAOYSA-N 4-[3-(difluoromethyl)-5-(4-methoxyphenyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 VSQLZYPQFJIORU-UHFFFAOYSA-N 0.000 claims 6
- UUGSJYRNELHGOL-UHFFFAOYSA-N 4-[3-cyano-5-(4-fluorophenyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC(F)=CC=2)=CC(C#N)=N1 UUGSJYRNELHGOL-UHFFFAOYSA-N 0.000 claims 6
- ZPMVBXDFUCFRLF-UHFFFAOYSA-N 5-(4-fluorophenyl)-2-methyl-4-(4-methylsulfonylphenyl)-1,3-thiazole Chemical compound S1C(C)=NC(C=2C=CC(=CC=2)S(C)(=O)=O)=C1C1=CC=C(F)C=C1 ZPMVBXDFUCFRLF-UHFFFAOYSA-N 0.000 claims 6
- VIHAEDVKXSOUAT-UHFFFAOYSA-N but-2-en-4-olide Chemical compound O=C1OCC=C1 VIHAEDVKXSOUAT-UHFFFAOYSA-N 0.000 claims 6
- KYNAWJZJGXEMMS-UHFFFAOYSA-N 2-chloro-1-methoxy-4-[2-(4-methylsulfonylphenyl)cyclopenten-1-yl]benzene Chemical compound C1=C(Cl)C(OC)=CC=C1C1=C(C=2C=CC(=CC=2)S(C)(=O)=O)CCC1 KYNAWJZJGXEMMS-UHFFFAOYSA-N 0.000 claims 5
- ZTHDILTXFNKYMK-UHFFFAOYSA-N 2-methyl-4-[1-(4-methylsulfonylphenyl)-4-(trifluoromethyl)imidazol-2-yl]pyridine Chemical compound C1=NC(C)=CC(C=2N(C=C(N=2)C(F)(F)F)C=2C=CC(=CC=2)S(C)(=O)=O)=C1 ZTHDILTXFNKYMK-UHFFFAOYSA-N 0.000 claims 5
- PHBYRHUAGNXCFU-UHFFFAOYSA-N 4-[2-(3-chloro-4-methylphenyl)-4-(trifluoromethyl)imidazol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(C)=CC=C1C1=NC(C(F)(F)F)=CN1C1=CC=C(S(N)(=O)=O)C=C1 PHBYRHUAGNXCFU-UHFFFAOYSA-N 0.000 claims 5
- LGLNOLKJZSIGPL-UHFFFAOYSA-N 4-[2-(3-methylphenyl)-4-(trifluoromethyl)imidazol-1-yl]benzenesulfonamide Chemical compound CC1=CC=CC(C=2N(C=C(N=2)C(F)(F)F)C=2C=CC(=CC=2)S(N)(=O)=O)=C1 LGLNOLKJZSIGPL-UHFFFAOYSA-N 0.000 claims 5
- RDVMVFHKIXFZDK-UHFFFAOYSA-N 4-[5-(4-chlorophenyl)-3-(4-methoxyphenyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(OC)=CC=C1C1=NN(C=2C=CC(=CC=2)S(N)(=O)=O)C(C=2C=CC(Cl)=CC=2)=C1 RDVMVFHKIXFZDK-UHFFFAOYSA-N 0.000 claims 5
- SZDMSAGZJBRJNW-UHFFFAOYSA-N 4-[5-(4-chlorophenyl)-3-(4-methylphenyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(C)=CC=C1C1=NN(C=2C=CC(=CC=2)S(N)(=O)=O)C(C=2C=CC(Cl)=CC=2)=C1 SZDMSAGZJBRJNW-UHFFFAOYSA-N 0.000 claims 5
- YDUQOLMYSBDZFO-UHFFFAOYSA-N 4-[5-(4-chlorophenyl)-3-phenylpyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(C=2C=CC=CC=2)=N1 YDUQOLMYSBDZFO-UHFFFAOYSA-N 0.000 claims 5
- STYMBXOUYUGRIR-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-3,3-dimethylcyclopenta-1,4-dien-1-yl]benzenesulfonamide Chemical compound C=1C(C)(C)C=C(C=2C=CC(F)=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 STYMBXOUYUGRIR-UHFFFAOYSA-N 0.000 claims 5
- DVSOGWILWKEIDD-UHFFFAOYSA-N 4-[5-(difluoromethyl)-3-phenyl-1,2-oxazol-4-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=C(C(F)F)ON=C1C1=CC=CC=C1 DVSOGWILWKEIDD-UHFFFAOYSA-N 0.000 claims 5
- 229940022663 acetate Drugs 0.000 claims 5
- QUKGYYKBILRGFE-UHFFFAOYSA-N benzyloxyacetoaldehyde Natural products CC(=O)OCC1=CC=CC=C1 QUKGYYKBILRGFE-UHFFFAOYSA-N 0.000 claims 5
- TTZNQDOUNXBMJV-UHFFFAOYSA-N mavacoxib Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC(F)=CC=2)=CC(C(F)(F)F)=N1 TTZNQDOUNXBMJV-UHFFFAOYSA-N 0.000 claims 5
- MBUIIOVYVHAZOU-UHFFFAOYSA-N 1-[2-(4-chlorophenyl)cyclopenten-1-yl]-4-methylsulfonylbenzene Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(Cl)=CC=2)CCC1 MBUIIOVYVHAZOU-UHFFFAOYSA-N 0.000 claims 4
- ZZBKFGAUXXMYNA-UHFFFAOYSA-N 2-(4-chlorophenyl)-1-(4-methylsulfonylphenyl)-4-phenylimidazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=NC(C=2C=CC=CC=2)=C1 ZZBKFGAUXXMYNA-UHFFFAOYSA-N 0.000 claims 4
- UJAMUMWHXRVKDM-UHFFFAOYSA-N 2-methyl-6-[1-(4-methylsulfonylphenyl)-4-(trifluoromethyl)imidazol-2-yl]pyridine Chemical compound CC1=CC=CC(C=2N(C=C(N=2)C(F)(F)F)C=2C=CC(=CC=2)S(C)(=O)=O)=N1 UJAMUMWHXRVKDM-UHFFFAOYSA-N 0.000 claims 4
- REOYUHOBMGSZBB-UHFFFAOYSA-N 3-[1-(4-methylsulfonylphenyl)-4-(trifluoromethyl)imidazol-2-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(C=2C=C(C=CC=2)S(N)(=O)=O)=NC(C(F)(F)F)=C1 REOYUHOBMGSZBB-UHFFFAOYSA-N 0.000 claims 4
- IQHFIMRYUJFZQW-UHFFFAOYSA-N 4-(3-ethyl-5-phenyl-1,2-oxazol-4-yl)benzenesulfonamide Chemical compound CCC1=NOC(C=2C=CC=CC=2)=C1C1=CC=C(S(N)(=O)=O)C=C1 IQHFIMRYUJFZQW-UHFFFAOYSA-N 0.000 claims 4
- KHZNXVYATAUMBJ-UHFFFAOYSA-N 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-1-phenyl-3-(trifluoromethyl)pyrazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)C(C(F)(F)F)=NN1C1=CC=CC=C1 KHZNXVYATAUMBJ-UHFFFAOYSA-N 0.000 claims 4
- DEXPHZXXTBGSGZ-UHFFFAOYSA-N 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-n-propyl-1,3-thiazol-2-amine Chemical compound S1C(NCCC)=NC(C=2C=CC(F)=CC=2)=C1C1=CC=C(S(C)(=O)=O)C=C1 DEXPHZXXTBGSGZ-UHFFFAOYSA-N 0.000 claims 4
- IRKVLCOCTJNMRX-UHFFFAOYSA-N 4-[2-(3-chloro-4-fluorophenyl)cyclopenten-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=C(C=2C=C(Cl)C(F)=CC=2)CCC1 IRKVLCOCTJNMRX-UHFFFAOYSA-N 0.000 claims 4
- UFAWCYIJMWUQEO-UHFFFAOYSA-N 4-[2-(4-chlorophenyl)-4,4-dimethylcyclopenten-1-yl]benzenesulfonamide Chemical compound C1C(C)(C)CC(C=2C=CC(Cl)=CC=2)=C1C1=CC=C(S(N)(=O)=O)C=C1 UFAWCYIJMWUQEO-UHFFFAOYSA-N 0.000 claims 4
- NSRMOHFGSWCCFK-UHFFFAOYSA-N 4-[2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)imidazol-1-yl]benzenesulfonamide Chemical compound CC1=CN=CC(C=2N(C=C(N=2)C(F)(F)F)C=2C=CC(=CC=2)S(N)(=O)=O)=C1 NSRMOHFGSWCCFK-UHFFFAOYSA-N 0.000 claims 4
- XTLWCXHGQOCFCI-UHFFFAOYSA-N 4-[2-(6-methylpyridin-3-yl)cyclopenten-1-yl]benzenesulfonamide Chemical compound C1=NC(C)=CC=C1C1=C(C=2C=CC(=CC=2)S(N)(=O)=O)CCC1 XTLWCXHGQOCFCI-UHFFFAOYSA-N 0.000 claims 4
- FQZPECQXBKABHG-UHFFFAOYSA-N 4-[2-phenyl-4-(trifluoromethyl)imidazol-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC=CC=2)=NC(C(F)(F)F)=C1 FQZPECQXBKABHG-UHFFFAOYSA-N 0.000 claims 4
- JQPZVKLFKGOLHG-UHFFFAOYSA-N 4-[5-(4-chlorophenyl)-3-(2-hydroxyphenyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(C=2C(=CC=CC=2)O)=N1 JQPZVKLFKGOLHG-UHFFFAOYSA-N 0.000 claims 4
- JDCWOBTUQSMXDU-UHFFFAOYSA-N 4-[5-(4-chlorophenyl)-3-(difluoromethyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(C(F)F)=N1 JDCWOBTUQSMXDU-UHFFFAOYSA-N 0.000 claims 4
- NAWWYLUQZOLWBT-UHFFFAOYSA-N 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(OC)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 NAWWYLUQZOLWBT-UHFFFAOYSA-N 0.000 claims 4
- UJSFKTUZOASIPA-UHFFFAOYSA-N 4-[5-(hydroxymethyl)-3-phenyl-1,2-oxazol-4-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=C(CO)ON=C1C1=CC=CC=C1 UJSFKTUZOASIPA-UHFFFAOYSA-N 0.000 claims 4
- IPSWLWPSIVTXOW-UHFFFAOYSA-N 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-(trifluoromethyl)-1,3-thiazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)SC(C(F)(F)F)=N1 IPSWLWPSIVTXOW-UHFFFAOYSA-N 0.000 claims 4
- JSEDBZHLLXWYHV-UHFFFAOYSA-N 6-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-phenylpyridine-3-carbonitrile Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C#N)=C(C=2C=CC=CC=2)N=C1C1=CC=C(F)C=C1 JSEDBZHLLXWYHV-UHFFFAOYSA-N 0.000 claims 4
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- FULAPETWGIGNMT-UHFFFAOYSA-N firocoxib Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OCC1CC1 FULAPETWGIGNMT-UHFFFAOYSA-N 0.000 claims 4
- NWVGCEQIXKQQPS-UHFFFAOYSA-N 2-(3,4-difluorophenyl)-1-(4-methylsulfonylphenyl)-4-(trifluoromethyl)imidazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(C=2C=C(F)C(F)=CC=2)=NC(C(F)(F)F)=C1 NWVGCEQIXKQQPS-UHFFFAOYSA-N 0.000 claims 3
- RSABMOYFBOLDLO-UHFFFAOYSA-N 2-(3-methylphenyl)-1-(4-methylsulfonylphenyl)-4-(trifluoromethyl)imidazole Chemical compound CC1=CC=CC(C=2N(C=C(N=2)C(F)(F)F)C=2C=CC(=CC=2)S(C)(=O)=O)=C1 RSABMOYFBOLDLO-UHFFFAOYSA-N 0.000 claims 3
- RIZFWOPNUQFLEF-UHFFFAOYSA-N 2-(4-chlorophenyl)-4-methyl-1-(4-methylsulfonylphenyl)imidazole Chemical compound N=1C(C)=CN(C=2C=CC(=CC=2)S(C)(=O)=O)C=1C1=CC=C(Cl)C=C1 RIZFWOPNUQFLEF-UHFFFAOYSA-N 0.000 claims 3
- PEUVGLHBVHFKPT-UHFFFAOYSA-N 2-(4-methylphenyl)-1-(4-methylsulfonylphenyl)-4-(trifluoromethyl)imidazole Chemical compound C1=CC(C)=CC=C1C1=NC(C(F)(F)F)=CN1C1=CC=C(S(C)(=O)=O)C=C1 PEUVGLHBVHFKPT-UHFFFAOYSA-N 0.000 claims 3
- KCPPTAVUOWTXDZ-UHFFFAOYSA-N 2-[1-(4-methylsulfonylphenyl)-4-(trifluoromethyl)imidazol-2-yl]pyridine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(C=2N=CC=CC=2)=NC(C(F)(F)F)=C1 KCPPTAVUOWTXDZ-UHFFFAOYSA-N 0.000 claims 3
- YRVHNSYUGHFPFQ-UHFFFAOYSA-N 2-[4-(4-fluorophenyl)-3-(4-methylsulfonylphenyl)-5-(trifluoromethyl)pyrazol-1-yl]-n-phenylacetamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=C1C(F)(F)F)C=2C=CC(F)=CC=2)=NN1CC(=O)NC1=CC=CC=C1 YRVHNSYUGHFPFQ-UHFFFAOYSA-N 0.000 claims 3
- INRQTVDUZFESAO-UHFFFAOYSA-N 4-(3,4-difluorophenyl)-3-(4-methylsulfonylphenyl)-2h-furan-5-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=C(F)C(F)=CC=2)C(=O)OC1 INRQTVDUZFESAO-UHFFFAOYSA-N 0.000 claims 3
- FQJOALWXRJKJFW-UHFFFAOYSA-N 4-(4-fluorophenyl)-2-methyl-5-(4-methylsulfonylphenyl)-1,3-oxazole Chemical compound O1C(C)=NC(C=2C=CC(F)=CC=2)=C1C1=CC=C(S(C)(=O)=O)C=C1 FQJOALWXRJKJFW-UHFFFAOYSA-N 0.000 claims 3
- HLSMDYHXAPYMPD-UHFFFAOYSA-N 4-(4-fluorophenyl)-3-(4-methylsulfonylphenyl)-1-(2-phenylethyl)-5-(trifluoromethyl)pyrazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=C1C(F)(F)F)C=2C=CC(F)=CC=2)=NN1CCC1=CC=CC=C1 HLSMDYHXAPYMPD-UHFFFAOYSA-N 0.000 claims 3
- ISMZMNIRFHOTII-UHFFFAOYSA-N 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-thiophen-2-yl-1,3-thiazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)N=C(C=2SC=CC=2)S1 ISMZMNIRFHOTII-UHFFFAOYSA-N 0.000 claims 3
- UUVBGFWWLRWVAV-UHFFFAOYSA-N 4-(4-methylsulfonylphenyl)-5-thiophen-2-yl-2-(trifluoromethyl)-1h-imidazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2SC=CC=2)NC(C(F)(F)F)=N1 UUVBGFWWLRWVAV-UHFFFAOYSA-N 0.000 claims 3
- TXRHVHRTTYBPNN-UHFFFAOYSA-N 4-[1-ethyl-4-(4-fluorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]benzenesulfonamide Chemical compound FC(F)(F)C=1N(CC)N=C(C=2C=CC(=CC=2)S(N)(=O)=O)C=1C1=CC=C(F)C=C1 TXRHVHRTTYBPNN-UHFFFAOYSA-N 0.000 claims 3
- JPWKLILKLRXARO-UHFFFAOYSA-N 4-[2-(2-methylpyridin-3-yl)-4-(trifluoromethyl)imidazol-1-yl]benzenesulfonamide Chemical compound CC1=NC=CC=C1C1=NC(C(F)(F)F)=CN1C1=CC=C(S(N)(=O)=O)C=C1 JPWKLILKLRXARO-UHFFFAOYSA-N 0.000 claims 3
- MTVAVVIWMMYFTG-UHFFFAOYSA-N 4-[2-(3-chloro-4-methoxyphenyl)-4-(trifluoromethyl)imidazol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(OC)=CC=C1C1=NC(C(F)(F)F)=CN1C1=CC=C(S(N)(=O)=O)C=C1 MTVAVVIWMMYFTG-UHFFFAOYSA-N 0.000 claims 3
- KQWMBKXAUUWQNW-UHFFFAOYSA-N 4-[2-(3-chlorophenyl)-4-(trifluoromethyl)imidazol-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=C(Cl)C=CC=2)=NC(C(F)(F)F)=C1 KQWMBKXAUUWQNW-UHFFFAOYSA-N 0.000 claims 3
- RSYPHTZEXAJUHX-UHFFFAOYSA-N 4-[2-(3-fluoro-4-methoxyphenyl)cyclopenten-1-yl]benzenesulfonamide Chemical compound C1=C(F)C(OC)=CC=C1C1=C(C=2C=CC(=CC=2)S(N)(=O)=O)CCC1 RSYPHTZEXAJUHX-UHFFFAOYSA-N 0.000 claims 3
- PISBIZMMMDTULP-UHFFFAOYSA-N 4-[2-(4-fluorophenyl)cyclopenten-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=C(C=2C=CC(F)=CC=2)CCC1 PISBIZMMMDTULP-UHFFFAOYSA-N 0.000 claims 3
- FEQFZJTZQQDSKI-UHFFFAOYSA-N 4-[2-(4-methylphenyl)-4-(trifluoromethyl)imidazol-1-yl]benzenesulfonamide Chemical compound C1=CC(C)=CC=C1C1=NC(C(F)(F)F)=CN1C1=CC=C(S(N)(=O)=O)C=C1 FEQFZJTZQQDSKI-UHFFFAOYSA-N 0.000 claims 3
- JSMWYOPCPZTWAA-UHFFFAOYSA-N 4-[3,5-bis(4-methoxyphenyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(OC)=CC=C1C1=NN(C=2C=CC(=CC=2)S(N)(=O)=O)C(C=2C=CC(OC)=CC=2)=C1 JSMWYOPCPZTWAA-UHFFFAOYSA-N 0.000 claims 3
- ONDHXPGHTRDUMN-UHFFFAOYSA-N 4-[5-(3-fluoro-4-methoxyphenyl)-2-(trifluoromethyl)-1,3-oxazol-4-yl]benzenesulfonamide Chemical compound C1=C(F)C(OC)=CC=C1C1=C(C=2C=CC(=CC=2)S(N)(=O)=O)N=C(C(F)(F)F)O1 ONDHXPGHTRDUMN-UHFFFAOYSA-N 0.000 claims 3
- GETBJRSHOBBZKB-UHFFFAOYSA-N 4-[5-(3-fluoro-4-methoxyphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 GETBJRSHOBBZKB-UHFFFAOYSA-N 0.000 claims 3
- KJIAFIBHGWAADR-UHFFFAOYSA-N 4-[5-(4-chlorophenyl)-3-(4-nitrophenyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(C=2C=CC(=CC=2)[N+]([O-])=O)=N1 KJIAFIBHGWAADR-UHFFFAOYSA-N 0.000 claims 3
- CHJMEHVGESAPSR-UHFFFAOYSA-N 4-fluoro-2-methyl-1-[2-(4-methylsulfonylphenyl)cyclopenten-1-yl]benzene Chemical compound CC1=CC(F)=CC=C1C1=C(C=2C=CC(=CC=2)S(C)(=O)=O)CCC1 CHJMEHVGESAPSR-UHFFFAOYSA-N 0.000 claims 3
- ONJHHYBWKLDIFI-UHFFFAOYSA-N 5,5-dimethyl-4-(4-methylsulfonylphenyl)-3-propan-2-yloxyfuran-2-one Chemical compound CC1(C)OC(=O)C(OC(C)C)=C1C1=CC=C(S(C)(=O)=O)C=C1 ONJHHYBWKLDIFI-UHFFFAOYSA-N 0.000 claims 3
- WUEKCGZKOFCGOF-UHFFFAOYSA-N 5,5-dimethyl-4-(4-methylsulfonylphenyl)-3-propoxyfuran-2-one Chemical compound CC1(C)OC(=O)C(OCCC)=C1C1=CC=C(S(C)(=O)=O)C=C1 WUEKCGZKOFCGOF-UHFFFAOYSA-N 0.000 claims 3
- CJAWPKAYKMKKAD-UHFFFAOYSA-N 5-(4-fluorophenyl)-6-(4-methylsulfonylphenyl)spiro[2.4]hepta-4,6-diene Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=C1)C=2C=CC(F)=CC=2)=CC11CC1 CJAWPKAYKMKKAD-UHFFFAOYSA-N 0.000 claims 3
- OIXFVGJRZFMIBH-UHFFFAOYSA-N 6-(4-fluorophenyl)-2-methoxy-5-(4-methylsulfonylphenyl)pyridine-3-carbonitrile Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C=C(C#N)C(OC)=NC=1C1=CC=C(F)C=C1 OIXFVGJRZFMIBH-UHFFFAOYSA-N 0.000 claims 3
- QFRDGIZQIJYOJO-UHFFFAOYSA-N 6-bromo-3-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-(trifluoromethyl)pyridine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(Br)=NC(C(F)(F)F)=C1C1=CC=C(F)C=C1 QFRDGIZQIJYOJO-UHFFFAOYSA-N 0.000 claims 3
- CUVUXNULRBGYON-UHFFFAOYSA-N L787257 Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(Cl)=CN=C1C1=CC=CN=C1 CUVUXNULRBGYON-UHFFFAOYSA-N 0.000 claims 3
- 229940007550 benzyl acetate Drugs 0.000 claims 3
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 claims 3
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 3
- 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 claims 3
- YIYBQIKDCADOSF-UHFFFAOYSA-N pent-2-enoic acid Chemical compound CCC=CC(O)=O YIYBQIKDCADOSF-UHFFFAOYSA-N 0.000 claims 3
- PWULVHYHVZUTFR-UHFFFAOYSA-N spiro[2.4]hept-5-ene Chemical compound C1CC11CC=CC1 PWULVHYHVZUTFR-UHFFFAOYSA-N 0.000 claims 3
- SZHKSRZKPUOAGO-UHFFFAOYSA-N 1-[2-(4-methylsulfonylphenyl)cyclopenten-1-yl]-4-(trifluoromethyl)benzene Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(=CC=2)C(F)(F)F)CCC1 SZHKSRZKPUOAGO-UHFFFAOYSA-N 0.000 claims 2
- RAUHMMADXJJVRP-UHFFFAOYSA-N 1-methoxy-4-[2-(4-methylsulfonylphenyl)cyclopenten-1-yl]benzene Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC(=CC=2)S(C)(=O)=O)CCC1 RAUHMMADXJJVRP-UHFFFAOYSA-N 0.000 claims 2
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 claims 2
- KSFMAASFLCWROX-UHFFFAOYSA-N 2,4-dichloro-1-[2-(4-methylsulfonylphenyl)cyclopenten-1-yl]benzene Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C(=CC(Cl)=CC=2)Cl)CCC1 KSFMAASFLCWROX-UHFFFAOYSA-N 0.000 claims 2
- VCLNQQUCGTWUKD-UHFFFAOYSA-N 2-(2-chlorophenyl)-4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-1,3-thiazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)N=C(C=2C(=CC=CC=2)Cl)S1 VCLNQQUCGTWUKD-UHFFFAOYSA-N 0.000 claims 2
- ZXTHWIZHGLNEPG-UHFFFAOYSA-N 2-phenyl-4,5-dihydro-1,3-oxazole Chemical compound O1CCN=C1C1=CC=CC=C1 ZXTHWIZHGLNEPG-UHFFFAOYSA-N 0.000 claims 2
- VTXIMXSYKSVSGP-UHFFFAOYSA-N 3-(4-fluorophenyl)-6-methoxy-4-(4-methylsulfonylphenyl)-2-(trifluoromethyl)pyridine Chemical compound C=1C=C(F)C=CC=1C=1C(C(F)(F)F)=NC(OC)=CC=1C1=CC=C(S(C)(=O)=O)C=C1 VTXIMXSYKSVSGP-UHFFFAOYSA-N 0.000 claims 2
- AJYWXMJXJSEWLW-UHFFFAOYSA-N 4-(4-chloro-5-phenylpyrazol-1-yl)benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC=CC=2)=C(Cl)C=N1 AJYWXMJXJSEWLW-UHFFFAOYSA-N 0.000 claims 2
- OHEHAWXOSFKVTI-UHFFFAOYSA-N 4-(4-fluorophenyl)-3-(4-methylsulfonylphenyl)-1-prop-2-enyl-5-(trifluoromethyl)pyrazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=NN(CC=C)C(C(F)(F)F)=C1C1=CC=C(F)C=C1 OHEHAWXOSFKVTI-UHFFFAOYSA-N 0.000 claims 2
- QFKFDESGBPKPPL-UHFFFAOYSA-N 4-[2-(3-fluoro-5-methylphenyl)-4-(trifluoromethyl)imidazol-1-yl]benzenesulfonamide Chemical compound CC1=CC(F)=CC(C=2N(C=C(N=2)C(F)(F)F)C=2C=CC(=CC=2)S(N)(=O)=O)=C1 QFKFDESGBPKPPL-UHFFFAOYSA-N 0.000 claims 2
- HTWCOXZWZHJHKU-UHFFFAOYSA-N 4-[2-(4-methylpyridin-2-yl)-4-(trifluoromethyl)imidazol-1-yl]benzenesulfonamide Chemical compound CC1=CC=NC(C=2N(C=C(N=2)C(F)(F)F)C=2C=CC(=CC=2)S(N)(=O)=O)=C1 HTWCOXZWZHJHKU-UHFFFAOYSA-N 0.000 claims 2
- FVYLDRLDRJJWDM-UHFFFAOYSA-N 4-[2-(6-methylpyridin-3-yl)-4-(trifluoromethyl)imidazol-1-yl]benzenesulfonamide Chemical compound C1=NC(C)=CC=C1C1=NC(C(F)(F)F)=CN1C1=CC=C(S(N)(=O)=O)C=C1 FVYLDRLDRJJWDM-UHFFFAOYSA-N 0.000 claims 2
- XGONYOLEZPFZPF-UHFFFAOYSA-N 6-ethoxy-3-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-(trifluoromethyl)pyridine Chemical compound C=1C=C(F)C=CC=1C=1C(C(F)(F)F)=NC(OCC)=CC=1C1=CC=C(S(C)(=O)=O)C=C1 XGONYOLEZPFZPF-UHFFFAOYSA-N 0.000 claims 2
- BZKFMUIJRXWWQK-UHFFFAOYSA-N Cyclopentenone Chemical compound O=C1CCC=C1 BZKFMUIJRXWWQK-UHFFFAOYSA-N 0.000 claims 2
- WAZQAZKAZLXFMK-UHFFFAOYSA-N deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 claims 2
- 125000004212 difluorophenyl group Chemical group 0.000 claims 2
- ACMHHODLBDGSDF-UHFFFAOYSA-N ethyl 2-[4-(4-fluorophenyl)-3-(4-methylsulfonylphenyl)-5-(trifluoromethyl)pyrazol-1-yl]acetate Chemical compound FC(F)(F)C=1N(CC(=O)OCC)N=C(C=2C=CC(=CC=2)S(C)(=O)=O)C=1C1=CC=C(F)C=C1 ACMHHODLBDGSDF-UHFFFAOYSA-N 0.000 claims 2
- WIRTYVGMQVIVDM-UHFFFAOYSA-N pyridine-3-carbonitrile Chemical compound N#CC1=C=NC=C[CH]1 WIRTYVGMQVIVDM-UHFFFAOYSA-N 0.000 claims 2
- FZYAFLPJDVKKQI-KRWDZBQOSA-N (5s)-5-ethyl-5-methyl-4-(4-methylsulfonylphenyl)-3-propan-2-yloxyfuran-2-one Chemical compound CC[C@]1(C)OC(=O)C(OC(C)C)=C1C1=CC=C(S(C)(=O)=O)C=C1 FZYAFLPJDVKKQI-KRWDZBQOSA-N 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 1
- YLFBPUKBMRJHLM-UHFFFAOYSA-N 2-(3-chlorophenyl)-1-(4-methylsulfonylphenyl)-4-(trifluoromethyl)imidazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(C=2C=C(Cl)C=CC=2)=NC(C(F)(F)F)=C1 YLFBPUKBMRJHLM-UHFFFAOYSA-N 0.000 claims 1
- KJMXVHBTWJSSBL-UHFFFAOYSA-N 2-(trifluoromethyl)-1h-imidazole Chemical compound FC(F)(F)C1=NC=CN1 KJMXVHBTWJSSBL-UHFFFAOYSA-N 0.000 claims 1
- WGIAUTGOUJDVEI-UHFFFAOYSA-N 2-phenylpiperidine Chemical compound N1CCCCC1C1=CC=CC=C1 WGIAUTGOUJDVEI-UHFFFAOYSA-N 0.000 claims 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 1
- CCTOCAZCUXUVKE-UHFFFAOYSA-N 3-(3,4-difluorophenyl)-5-ethyl-5-methyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound CCC1(C)OC(=O)C(C=2C=C(F)C(F)=CC=2)=C1C1=CC=C(S(C)(=O)=O)C=C1 CCTOCAZCUXUVKE-UHFFFAOYSA-N 0.000 claims 1
- TVJUHXXTIIKHSU-UHFFFAOYSA-N 3-(cyclopropylmethoxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)-2h-furan-2-ol Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(O)C=1OCC1CC1 TVJUHXXTIIKHSU-UHFFFAOYSA-N 0.000 claims 1
- ZBRDJMFLJXFIGJ-UHFFFAOYSA-N 3-phenyl-1,2-oxazole Chemical compound O1C=CC(C=2C=CC=CC=2)=N1 ZBRDJMFLJXFIGJ-UHFFFAOYSA-N 0.000 claims 1
- SAVMISCIBLZUAE-UHFFFAOYSA-N 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(trifluoromethyl)-1,3-thiazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)N=C(C(F)(F)F)S1 SAVMISCIBLZUAE-UHFFFAOYSA-N 0.000 claims 1
- XRHRZRHLXNWUTF-UHFFFAOYSA-N 4-[4-chloro-5-(4-chlorophenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=C(Cl)C(C(F)(F)F)=N1 XRHRZRHLXNWUTF-UHFFFAOYSA-N 0.000 claims 1
- RSVKRWJGUDWYLS-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)spiro[2.4]hept-5-en-6-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C(C1)=C(C=2C=CC(F)=CC=2)CC11CC1 RSVKRWJGUDWYLS-UHFFFAOYSA-N 0.000 claims 1
- PXGGFOXZOPEICZ-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)spiro[2.4]hepta-4,6-dien-6-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C(C(=C1)C=2C=CC(F)=CC=2)=CC11CC1 PXGGFOXZOPEICZ-UHFFFAOYSA-N 0.000 claims 1
- IKLZMKNMJGKUGX-UHFFFAOYSA-N 4-[6-(3,4-dichlorophenyl)spiro[2.4]hept-5-en-5-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C(C1)=C(C=2C=C(Cl)C(Cl)=CC=2)CC11CC1 IKLZMKNMJGKUGX-UHFFFAOYSA-N 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- MAXZMDTWDWQPHA-UHFFFAOYSA-N 5,5-dimethyl-4-(4-methylsulfonylphenyl)-3-(1,3-thiazol-2-ylmethoxy)furan-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OCC1=NC=CS1 MAXZMDTWDWQPHA-UHFFFAOYSA-N 0.000 claims 1
- ZUCJKEXQVGBQCH-UHFFFAOYSA-N 5,5-dimethyl-4-(4-methylsulfonylphenyl)-3-propan-2-yloxy-2h-furan-2-ol Chemical compound CC1(C)OC(O)C(OC(C)C)=C1C1=CC=C(S(C)(=O)=O)C=C1 ZUCJKEXQVGBQCH-UHFFFAOYSA-N 0.000 claims 1
- MOHZCSPHJUIPJF-UHFFFAOYSA-N 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-(trifluoromethyl)-1h-imidazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)NC(C(F)(F)F)=N1 MOHZCSPHJUIPJF-UHFFFAOYSA-N 0.000 claims 1
- DFLGRTIPTPCKPJ-UHFFFAOYSA-N 5-(trifluoromethyl)-1h-imidazole Chemical compound FC(F)(F)C1=CN=CN1 DFLGRTIPTPCKPJ-UHFFFAOYSA-N 0.000 claims 1
- IXOVKZSZDFZOQP-UHFFFAOYSA-N 6-(3,5-dichloro-4-methoxyphenyl)-5-(4-methylsulfonylphenyl)spiro[2.4]hept-5-ene Chemical compound C1=C(Cl)C(OC)=C(Cl)C=C1C(C1)=C(C=2C=CC(=CC=2)S(C)(=O)=O)CC11CC1 IXOVKZSZDFZOQP-UHFFFAOYSA-N 0.000 claims 1
- USQCUKQZXOWUDF-YWZLYKJASA-N 6-chloro-n-[(3s)-1-[(2s)-1-(4-methyl-5-oxo-1,4-diazepan-1-yl)-1-oxopropan-2-yl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide Chemical compound O=C([C@@H](N1C([C@@H](NS(=O)(=O)C=2C=C3C=CC(Cl)=CC3=CC=2)CC1)=O)C)N1CCN(C)C(=O)CC1 USQCUKQZXOWUDF-YWZLYKJASA-N 0.000 claims 1
- 241000566113 Branta sandvicensis Species 0.000 claims 1
- PIQSLEWGIQXBPR-UHFFFAOYSA-N CC1(C(=C(CO1)OC(C)C)C1=CC=C(C=C1)S(=O)(=O)C)C Chemical compound CC1(C(=C(CO1)OC(C)C)C1=CC=C(C=C1)S(=O)(=O)C)C PIQSLEWGIQXBPR-UHFFFAOYSA-N 0.000 claims 1
- 101150005130 Ezy-1 gene Proteins 0.000 claims 1
- 101000713575 Homo sapiens Tubulin beta-3 chain Proteins 0.000 claims 1
- 229920006063 Lamide® Polymers 0.000 claims 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims 1
- 102100036790 Tubulin beta-3 chain Human genes 0.000 claims 1
- AXMNGEUJXLXFRY-UHFFFAOYSA-N azaspirodecane Chemical compound C1CCCC21CCNCC2 AXMNGEUJXLXFRY-UHFFFAOYSA-N 0.000 claims 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims 1
- HCSFFMYIHYYVTK-UHFFFAOYSA-N n-benzyl-4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-1,3-thiazol-2-amine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)N=C(NCC=2C=CC=CC=2)S1 HCSFFMYIHYYVTK-UHFFFAOYSA-N 0.000 claims 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims 1
- BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical compound NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 claims 1
- RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 claims 1
- KPDOKSJMJMDRQA-UHFFFAOYSA-N spiro[2.4]hepta-4,6-diene Chemical compound C1CC11C=CC=C1 KPDOKSJMJMDRQA-UHFFFAOYSA-N 0.000 claims 1
- BVYQTYMCVWOAEY-UHFFFAOYSA-N spiro[3.4]oct-6-ene Chemical compound C1CCC21CC=CC2 BVYQTYMCVWOAEY-UHFFFAOYSA-N 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical group C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 238000003556 assay Methods 0.000 description 21
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 17
- 239000003826 tablet Substances 0.000 description 17
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 11
- 238000010079 rubber tapping Methods 0.000 description 11
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 11
- 241000699694 Gerbillinae Species 0.000 description 10
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 9
- 229940076134 benzene Drugs 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 229920002261 Corn starch Polymers 0.000 description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 8
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 239000008120 corn starch Substances 0.000 description 8
- 210000002683 foot Anatomy 0.000 description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 8
- 239000008108 microcrystalline cellulose Substances 0.000 description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 102100024304 Protachykinin-1 Human genes 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 229960001375 lactose Drugs 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 208000004454 Hyperalgesia Diseases 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 4
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 description 4
- 101000600903 Homo sapiens Substance-P receptor Proteins 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 229960001021 lactose monohydrate Drugs 0.000 description 4
- 150000003180 prostaglandins Chemical class 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000035154 Hyperesthesia Diseases 0.000 description 3
- 241000282339 Mustela Species 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 3
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
- 101800003906 Substance P Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940090044 injection Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- HQKPTSSZOJLFBZ-LJADHVKFSA-N (2s)-n-[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-1-[(2s)-2-[[(2s)-2-(5-aminopentanoylamino)-3-phenylpropanoyl]amino]-3-phenylpropanoyl]-n-methylpyrrolidine-2-carboxamide Chemical compound CSCC[C@@H](C(N)=O)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CCCCN)CC1=CC=CC=C1 HQKPTSSZOJLFBZ-LJADHVKFSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- AJFTZWGGHJXZOB-UHFFFAOYSA-N DuP 697 Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)SC(Br)=C1 AJFTZWGGHJXZOB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000282341 Mustela putorius furo Species 0.000 description 2
- KTDZCOWXCWUPEO-UHFFFAOYSA-N NS-398 Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1CCCCC1 KTDZCOWXCWUPEO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000003141 Tachykinin Human genes 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 2
- 125000005236 alkanoylamino group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000001949 anaesthesia Methods 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 229950005722 flosulide Drugs 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- CXJONBHNIJFARE-UHFFFAOYSA-N n-[6-(2,4-difluorophenoxy)-1-oxo-2,3-dihydroinden-5-yl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCC(=O)C=2C=C1OC1=CC=C(F)C=C1F CXJONBHNIJFARE-UHFFFAOYSA-N 0.000 description 2
- HDUWKQUHMUSICC-UHFFFAOYSA-N n-[6-(2,4-difluorophenyl)sulfanyl-1-oxo-2,3-dihydroinden-5-yl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCC(=O)C=2C=C1SC1=CC=C(F)C=C1F HDUWKQUHMUSICC-UHFFFAOYSA-N 0.000 description 2
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 2
- 229960000965 nimesulide Drugs 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 108060008037 tachykinin Proteins 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- RENWFOYENNEQJW-HLAWJBBLSA-N (2s)-2-[3,5-bis(trifluoromethyl)phenyl]-2-[(2r,3s)-3-(4-fluorophenyl)-4-(1h-1,2,4-triazol-5-ylmethyl)morpholin-2-yl]oxyethanol Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](CO)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC=1N=CNN=1 RENWFOYENNEQJW-HLAWJBBLSA-N 0.000 description 1
- MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 description 1
- UGIPKCIBIXXIEF-HNAYVOBHSA-N (2s,3s)-3-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenylpiperidin-1-amine Chemical compound COC1=CC=C(OC(F)(F)F)C=C1C[C@H]1[C@@H](C=2C=CC=CC=2)N(N)CCC1 UGIPKCIBIXXIEF-HNAYVOBHSA-N 0.000 description 1
- 125000006624 (C1-C6) alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- RLXUXICUOSILHE-UHFFFAOYSA-N 1-(trifluoromethyl)imidazole Chemical compound FC(F)(F)N1C=CN=C1 RLXUXICUOSILHE-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- USRYEHHMJIRICK-ZNZBMKLDSA-N 1-[5-[[(2r,3s)-2-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-2h-triazol-4-yl]-n,n-dimethylmethanamine Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNN=C1CN(C)C USRYEHHMJIRICK-ZNZBMKLDSA-N 0.000 description 1
- MFKDAOCUEASALN-QQTNTEGQSA-N 1-[5-[[(2r,3s)-2-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-phenylmorpholin-4-yl]methyl]-2h-triazol-4-yl]-n,n-dimethylmethanamine Chemical compound O([C@@H]([C@@H]1C=2C=CC=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNN=C1CN(C)C MFKDAOCUEASALN-QQTNTEGQSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- FLNMQGISZVYIIK-UHFFFAOYSA-N 1-ethylpyrazole Chemical compound CCN1C=CC=N1 FLNMQGISZVYIIK-UHFFFAOYSA-N 0.000 description 1
- KEXGMIUVXTZMBV-UHFFFAOYSA-N 2,5-dihydrofuran-2-ol Chemical compound OC1OCC=C1 KEXGMIUVXTZMBV-UHFFFAOYSA-N 0.000 description 1
- XMXXKSHWUKNLPQ-UHFFFAOYSA-N 2-(trifluoromethyl)-1,3-thiazole Chemical compound FC(F)(F)C1=NC=CS1 XMXXKSHWUKNLPQ-UHFFFAOYSA-N 0.000 description 1
- CGZDWVZMOMDGBN-UHFFFAOYSA-N 2-Ethylthiazole Chemical compound CCC1=NC=CS1 CGZDWVZMOMDGBN-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- VZWOXDYRBDIHMA-UHFFFAOYSA-N 2-methyl-1,3-thiazole Chemical compound CC1=NC=CS1 VZWOXDYRBDIHMA-UHFFFAOYSA-N 0.000 description 1
- BNLUKQUPRXZCDA-UHFFFAOYSA-N 2-phenyl-5-(trifluoromethyl)-1h-imidazole Chemical compound N1C(C(F)(F)F)=CN=C1C1=CC=CC=C1 BNLUKQUPRXZCDA-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- OYTKXVQRRLZCDC-UHFFFAOYSA-N 2-thiophen-2-yl-1,3-thiazole Chemical compound C1=CSC(C=2SC=CN=2)=C1 OYTKXVQRRLZCDC-UHFFFAOYSA-N 0.000 description 1
- MENAYYMPBRSAAE-AWEZNQCLSA-N 3-[[5-[[(2s)-1-carboxy-3-oxopropan-2-yl]carbamoyl]pyridin-2-yl]methylsulfamoyl]benzoic acid Chemical compound N1=CC(C(=O)N[C@@H](CC(=O)O)C=O)=CC=C1CNS(=O)(=O)C1=CC=CC(C(O)=O)=C1 MENAYYMPBRSAAE-AWEZNQCLSA-N 0.000 description 1
- DOVPXYFBYMYZRL-UHFFFAOYSA-N 3-phenyl-3h-furan-2-one Chemical compound O=C1OC=CC1C1=CC=CC=C1 DOVPXYFBYMYZRL-UHFFFAOYSA-N 0.000 description 1
- YNKQMZRTPPVLLL-UHFFFAOYSA-N 4,4-dimethyl-2-buten-4-olide Natural products CC1(C)OC(=O)C=C1 YNKQMZRTPPVLLL-UHFFFAOYSA-N 0.000 description 1
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- FZYAFLPJDVKKQI-UHFFFAOYSA-N 5-ethyl-5-methyl-4-(4-methylsulfonylphenyl)-3-propan-2-yloxyfuran-2-one Chemical compound CCC1(C)OC(=O)C(OC(C)C)=C1C1=CC=C(S(C)(=O)=O)C=C1 FZYAFLPJDVKKQI-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 101100087393 Caenorhabditis elegans ran-2 gene Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 description 1
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699684 Meriones unguiculatus Species 0.000 description 1
- 229920000881 Modified starch Chemical class 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229920005439 Perspex® Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical group N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 108010086192 chymostatin Proteins 0.000 description 1
- 229940105442 cisplatin injection Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- XOVJAYNMQDTIJD-UHFFFAOYSA-N cyclopentobarbital Chemical compound C1CC=CC1C1(CC=C)C(=O)NC(=O)NC1=O XOVJAYNMQDTIJD-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 238000011554 guinea pig model Methods 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- QXUAFCKBYYPTPQ-ZWKAXHIPSA-L magnesium (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol octadecanoate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O QXUAFCKBYYPTPQ-ZWKAXHIPSA-L 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229920000609 methyl cellulose Chemical class 0.000 description 1
- 239000001923 methylcellulose Chemical class 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- LBTPIFQNEKOAIM-UHFFFAOYSA-N n-phenylmethanesulfonamide Chemical class CS(=O)(=O)NC1=CC=CC=C1 LBTPIFQNEKOAIM-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000013389 whole blood assay Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Description
WO 99/59635 PCT/GB99/01632 USE OF A COX-2 INHIBITOR AND A NK-1 RECEPTOR ANTAGONIST FOR TREATING INFLAMMATION The present invention involves a drug combination comprising an inhibitor of cyclooxygenase-2 in combination with a neurokinin-1 (NK-1) receptor antagonist.
Inhibitors of cyclooxygenase-2 are a sub-class of the class of drugs known as non-steroidal antiinflammatory drugs (NSAIDs). The NSAIDs are active in reducing the prostaglandin-induced pain and swelling associated with the inflammation process but are also active in affecting other prostaglandin-regulated processes such as maintenance of the gastric lining. Thus, use of high doses of most common NSAIDs can produce severe side effects, including life threatenting ulcers, that limit their therapeutic potential. An alternative to NSAIDs is the use of corticosteroids, which have even more serious side effects, especially when long term therapy is involved.
Previous NSAIDs have been found to prevent the production of prostaglandin by inhibiting enzymes in the human arachidonic acid/prostaglandin pathway including the enzyme cyclooxygenase (COX).
There are two isoforms of the COX enzyme, the first, COX-1, is constitutively expressed and is involved with physiological functions and the second, COX-2, is induced locally in inflamed tissue. While conventional NSAIDs block both forms of the enzyme, the inducible COX-2 enzyme associated inflammation has provided a more focussed drug target which should enable effective antiinflammatory analgesia with reduced gastrointestinal side effects. Many compounds which have activity as COX-2 inhibitors have been identified, and clinical trials are reported to be in progress.
Neurokinin 1 (NK-1; substance P) receptor antagonists are being developed for the treatment of a number of physiological disorders associated with an excess or imbalance of tachykinins, and in particular substance P. Substance has been implicated in the pathology of a number of inflammatory conditions (see, for instance, International (PCT) patent specification Nos.
WO 95/16679, WO 95/18124 and WO 95/23798).
Improved therapies for treating and preventing inflammatory disorders are currently being sought for the large number of individuals who are at risk from these disorders.
The present invention addresses this problem by providing a combination therapy comprised of a COX-2 inhibitor with a NK- 1 receptor antagonist. When administered as part of a combination therapy, the COX-2 inhibitor together with the NK-1 receptor antagonist provide enhanced treatment options as compared with administration of either to the COX-2 inhibitor or the NK- 1 receptor antagonist alone.
According to a first embodiment, the present invention provides use of a selective COX-2 inhibitor and a NK- 1 receptor antagonist for the manufacture of a medicament for the treatment or prevention of an inflammatory disorder, wherein said selective COX-2 inhibitor is selected from the group consisting of: 3 -phenyl- 4 -(4-(methylsulfonyl)phenyl)-2-(5H)- uranone; 3 3 4 -difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-fjranone; 5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-3 -(3-fluorophenyl)-5H-furan-2-one; 5,5-dimethyl-4-(4-methylsulfonyl)phenyl)3-2poxy5Hfrn-ne 3 4 -(methysu lfonyl)pheny1)-2-(2methyl..-pyridinyl)pyridine; 2-(3,5-difluorophenyl)-3 4 -(methylsulfonyl)phenyl)-2-cyclopenten- 1 -one; i 5(S)-5-ethyl-5 -methyl-4 -(4-(methyl sulfonyl)phenyl)-3 -propoxy)-5H-furan-2-one -ethyl-5-methyl-4-(4-(methylsulfonyl)phenyl)-3.(3 ,4-dufluorophenyl)-5H-flran-2-one; 2 -thiazolyl)methoxy)-4-(4(methylsulfonyl)phenyly5,5dimethyl5Hfuran2.one; 3-propyloxy-4-(4-methylsulfonyl)phenyly5,5-dimethyl-5H-furan-2-one; 3-(1 -cyclppylethoxy)-5,5-dimethyl-4-(4-(m sodium 2-(4-chlorophenyl)-3 4 -(methylsulfonyl)phenyl)-4-oxo-2-pentenoate; ,5-dimethyl-4-(4-(methylsulfony)phenylysH-fran-2-one; ,-dimethyl-4-(4-(methylsulfonyl)phenyl>2,sdihydrofran2ol; 3-isopropoxy-5 ,-dimethy-4-(4-(methylsulfony)phenyl)-2,5-dihydrofuran2-ol; [R:\LIBH]03976.doc:aak 5,5-dimethyl-3.(3-fluoropheny)2.hydroxy-4.(4..(methylsulfonyl)phenyl)- 5-hoo3(-mtysloy~hey)2(-yiiy~yiie 4 -(5-methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; 5-(4-fluorophenyl)-1- [4-(methylsulfonyl)phenylJ -3- (trifluoromethyl)pyrazole; 4-(4-fluorophenyl)-5- [4-(methylsulfonyl)phenylJ -1-phenyl-3- (trifluoromethyl)pyrazole; 4 4 -chlorophenyl)-3-(4-methoxyphenyl)1Hpyrazol-1.
yl)benzenesulfonamnide; 4 3 ,5-bis(4-methylpheny)-lHpyrazo1...y1)benzenesufonanide; 4 4 -chlorophenyl)-3-(4-methylphenyl).lHpyrazol1..
yl)benzenesulfonamide; 4 4 -chlorophenyl)-3-(4nitrophenyl).lHpyrazol.1.
yl)benzenesulfonamide; 4 4 -chlorophenyl)-3-(5-choro2thienyl)1lH..pyazol-lyl)benzenesulfonamide;* 4 4 -chloro-3,5-dipheny11H-pyazol.1-y1)benzenesulfonamide; 4 4 -chlorophenyl)-3-(trifluoromethyl)lH-pyrazol-lyl)benzenesulfonamide; 4 4 -fluoropheny)-3-(trifluoromethyly..1Hpyraz11...
yl)benzenesulfonamide; 4 4 -methoxyphenyl)-3-(trifluoromethyl)>1H..pyazol-l-.
yl)benzenesulfonamide; 4 4 -chlorophenyl)-3-(difluoromethyl)1Hpyrazol-lyl)benzenesulfonamide; 4 4 -methylphenyl)-3-trifluoromethyl)y1H-pyaz1.. x Yl)benzenesulfonamide; yl)benzenesulfonamide; 4 3 -(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol1..
yl)benzenesulfonamide; 4-3(ilooehl--hnll-przl1y~eznsloaie 4 3 -(difluoromethyl)-5-(4-methoxyphenyl).lH-pyrazol-l-.
yl)benzenesulfonamide; 4 3 -cyano-5-(4-fluoropheny)-Hpyrazo11y)benzenesufonamide; 4 3 -(difluoromethy1)-5-(3-fluoro-4-methoxyphenyl)1lHjpyrazol-lyl)benzenesulfonamide; 4 3 -fluoro-4methoxypheny)3-(trfuoromethyl)1lH..pyazol-lyl)benzenesulfonamide; 4-4cloo5phnllHprzo-: ~ezneufnaie 4 4 -chlorophenyl)-3-(hydroxyphenyl)1Hpyrazol.1.
yl)benzenesulfonamide; 4 4 -(N,N-dimethylamino)phenyl)-3-(trifluoromethyl)-1Hpyrazol.. 1 yl)benzenesulfonamide; 5-V14-Iuoropfeny)-t-(4-(methylsulfonyl)pheny1)spiro [2.4lhept-5-ene; 4 6 4 -fluoropheny)spiro[2.4]hept-5.en.5y1)benzenesulfonamide; 6 4 -fluorophenyl)-7-(4-(methylsulfonyl)phenyl)spiro [3 .4loct-6-ene; 3 -chloro-4-methoxyphenyl)-6-(4(methylsulfonyl)phenyl)spiro 12.41 hept- 4 6 3 -chloro-4-methoxyphenyl)spiro [2.4lhept-5-en-5yl)benzenesulfonamide; 5-( 3 ,5-dichloro-4-methoxyphenyl)-6(4.(methylsulfony1)phenyl)- Spiro [2.4]hept-5-ene; 3 -chloro-4-fluorophenyl)-6-(4-(methylsulfonyl)phenyl)spiro [2.41 ene; 4 -(6-(3,4-dichlorophenyl)spiro [2.41 2 3 -chloro-4-fluoropheny)-4-(4-fluoropheny)5.(4.
methylsulfonylphenyl)thiazole; 2 2 -chlorophenyl)-4-(4-fluorophenyly..s.(4-.methylsulfonylphenyl)thiazole; 4 -fluorophenyl)-4-(4-methylsulfonylphenyl).2-methylthiazole; 4 4 -fluorophenyl)-5-(4-methylsulfonylphenyl).2trifluoromethylthiazole; 4 4 -fluorophenyl)-5-(4-methylsulfonylphenyl)2(2-thienyl)thiazole; 4 4 -fluorophenyl)-5-(4-methylsulfonylphenyl).2-benzylamsnothiazole; 4 4 -fluorophenyl)-5-(4-methylsulfonylphenyl)2(l-propylamhio)thiazole; 2 3 ,5-dichlorophenoxy)methy).4-(4-fluoropheny)-5-(4- (methylsulfonyl)phenyl)thiazole; 5-4furpey)4(-ehlufnypey)2tilooehlhaoe 1-methylsulfonyl-4-(1, l-dimethyl-4-(4-fluorophenyl)cyclopenta-2,4Aien-3yl)benzene; 4 -(4-(4-fluorophenyl)-1, l-dimethylcyclopenta-2,4-dien-3yl)benzenesulfonamide; 4 -fluorophenyl)-6-(4-(methylsulfonyl)phenyl)spiro hepta-4,6-diene; 4-(6-(4-fluorophenyl)spiro 2 4 lhepta-4,6-dien-5-yL)benzenesulfonainide; 6-( 4 -fluorophenyl)-2-methoxy-5(4-(methysufony)phenyl..pyidine-3.
carbonitrile; 2 -bromo-6-(4-fluoropheny)5-4(methysufony)pheny).pyrdine3carbonitrile; 6 4 -fluoropheny)-5-(4-(methylsulfony1)phenyl)-2-.pheny..pyidine.3 **carbonitrile; 4 2 4 -methylpyridin-2-yl)-4-(trifluoromethyl).lHiidazol-1.
yl)benzenesulfonamide; 4 2 -(5-methylpyridin-3-yl)4-(trifluoromethy)lHimjdazol-l yl)benzenesulfonamnide; 4 2 2 -methylpyridin-3-yl)-4-(trifluoromethyl)..lHimidazol-l-.
yl)benzenesulfonamide; 3 4 -(methylsulfonyl)phenyl)-4-(trifluoromethyly..lH-imidazol-2 yl)benzenesulfonamide; 2 4 -(methylsulfony1)pheny1)-4-(trifluoromethyl)-lH-imdazo12.
yl)pyridine; 2d 2-methyl-4-(l 4(ehlufnlpey)4(tilooehl-Hindzl 2-yl)pyridine; 2-ehl6(-4(ehlufnlpeyl--tilooehl-Hiadzl 2 -yl)pyridine; 4 2 6 -methylpyridin-3-y)4-(trifluoromethy)lHjimidazol-lyl)benzenesulfonamide; 2 3 4 -difluoropheny)-1-(4-(methylsulfonyl)phenyl).4.(tlifluoromethyl)lHimidazole; 4 2 4 -methylphenyl)-4-(trifluoromethyl)1IHimdazol.lyl)benzenesulfonamide; 2 4 -chlorophenyl)4(4-fluorophenyly..1.(4-.(methylsulfonyl)phenyl)lHimidazole; 2 3 -fluoro- 4 -methoxypheny)-l-(4.(methysufony)pheny).4- (trifluoromethyl)-lH-imidazole; 2 4 -methylphenyl)-l-(4-(methylsulfony)pheny)4.tifluoromethy11Himidazole; 20 4 2 3 -chloro-4-methylpheny)4(trifluoromethy).1H-imidazol-l yl)benzenesulfonamide; 2 3 -fluoro-5-methypheny)-(4-(methysufony)pheny)4.
(trifluoromethyl)-1H-imidazole; 4 2 3 -fluoro-5-methylpheny)-4-(trifluoromethy)1Himidazo...1.
yl)benzenesulfonamide; 2 3 -methylphenyl)-1-(4-(methylsulfonyl)phenyl)..4(trifluoromethyl)1Himidazole; 4 2 3 -methylphenyl)-4-(trifluoromethyl..lHimidazol.1.
yl)benzenesulfonamide; l-( 4 -(methylsulfonyl)pheny1)2(-choropheny)4(trifluoromethyl)lHimidazole; 4 2 3 -chlorophenyl)-4-(trifluoromethyl)-lH-imidazol-lyl)benzenesulfonaniide; 4 2 -phenyl-4-(trifluoromethyl)-1H-imidazol..1.yl)benzenesulfonamide; 4 2 4 -methoxy-3-chlorophenyl)-4-(trfluoromethyl)1Himidazol-l1.
yl)benzenesulfonamide; l-allyl- 4 4 -fluorophenyl)-3-(4-(methylsulfonyl)phenyl).5-(tifluoromethyl).
IH-pyrazole; 4 -(l-ethyl- 4 -(4-fluorophenyl)-5-(trifluoromethyl)1lHpyrazol-3 yl)benzenesulfonamide; N-pheny1-(4-(4-fluoropheny)-3-(4-(methysufony)pheny).5 ethyl 4 4 -fluorophenyl)-3-(4-(methylsulfonyl)phenyl)5(tifluoromethyl)lH-pyrazol-1-yl)acetate; 4 4 -fluorophenyl)-3-(4-(methylsulfonyl)phenyl).1.(2-.phenylethyl)1H.
pyrazole; 4 4 -fluorophenyl)-3-(4-(methylsulfonyl)phenyl)1..{2phenylethyl)5.
(trifluoromethyl)pyrazole; l-ethyl- 4 4 -fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-5(trifluoromethyl).
1H-pyrazole; 20 5-( 4 -fluorophenyl)-4-(4-(methylsulfonyl)phenyl)2(tirifluoromethyl)IH- :*..*imidazole; 4 4 -(methylsulfonyl)phenyl)-5-(2-tiophenyl).2..(trifluoromethyl)1H.
imidazole; 4 -fluorophenyl)-2-methoxy-4-(4-(methylsulfonyl)phenyl)6- (trifluoromethyl)pyridine; 2 -ethoxy-5-(4-fluorophenyl)-4-(4-(methylsufony)phenyl)6.
(trifluoromethyl)pyridine; 4 -fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(2propynyoxy)6- (trifluoromethyl)pyridine; 2 -bromo-5-(4-fluorophenyl)-4-(4..(methylsulfonyl)phenyl).6- (trifluoromethyl)pyridine; l-( 4 -fluorophenyl)-2-(4-(methylsulfonyl)phenyl)benzene; 5-difluoromethyl-4-(4-(methylsulfonyl)phenyl)-3phenylisoxazole; 4 3 -ethyl-5-phenylisoxazol-4-yl)benzenesulfonamide; 4 -(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide; l-( 2 4 -fluorophenyl)cyclopenten-1-yl)-4-(methysulfonyl)benzene; l-( 2 4 -fluoro- 2 -methylpheny)cyclopenten-1-y1)-4-(methylsulfonyl)ibenzene; 1-( 2 2 4 -dichlorophenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 1-( 2 4 -trifluoromethylphenyl)cyclopenten-1.y1)-4(methysufonyl)benzene; l-( 2 4 -methylthiophenylcyclopenten-.1y)4(methylsulfonyl)benzene; l-( 2 4 -fluorophenyl)-4,4-dimethylcyclopenten-1yl)4.
(methylsulfonyl)benzene; 4-2(-loohnl-,-iehlycoetn1y~eznsloa-ie l-( 2 4 -chlorophenyl)-4,4-dimethylcyclopenten-1yl).4 (methylsulfonyl)benzene; 4 2 4 -chlorophenyl)-4,4-dimethylcyclopenten-1.yl)benzenesulfonamide; a. 4 2 4 chlorophenyl)cyclopenten-1-yl)benzenesulfonanmjde; l-( 2 4 -methoxphenyl)cyclopenten1y).4(methylsulfony1)benzene; l-( 2 2 3 -difluorophenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 4-2(-loo4mtoyhnlccoetn1y~eznsloaie l-( 2 3 -chloro-4-methoxypheny)cyclopenten-1y1)-4 (methylsulfonyl)benzene; 4 2 3 -chloro-4-fluorophenyl)cyclopenten-1-yl)benzenesulfonamide; 4-2(-ehlyii--lccoetn1y~eznsloaie ethyl 2 4 -(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazol2yl)2benzyl-acetate; 2 4 4 -fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazol.2-y1)acetic acid; 2g According to a second embodiment the present invention provides a pharmaceutical composition for the treatment or prevention of an inflammatory disorder comprising a selective COX-2 inhibitor and a NK-1 receptor antagonist, together with at least one pharmaceutically acceptable carrier or excipient, wherein said selective COX-2 inhibitor is selected from the compounds of the first embodiment.
According to a third embodiment the present invention provides a product comprising a selective COX-2 inhibitor and a NK-1 receptor antagonist as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of an inflammatory disorder, wherein said selective COX-2 inhibitor is selected from the compounds of the first embodiment.
According to a fourth embodiment the present invention provides a method for the treatment or prevention of an inflammatory disorder, which method comprises -administration to a patient in need thereof of an amount of a selective COX-2 inhibitor *and an amount of a NK-1 receptor antagonist, such that together they give effective relief 15 wherein said selective COX-2 inhibitor is selected from the compounds of the first embodiment.
According to a fifth embodiment the present invention provides a process for preparing a pharmaceutical composition comprising combining a selective COX-2 .•inhibitor and a NK-1 receptor antagonist with a pharmaceutically acceptable carrier, wherein said selective COX-2 inhibitor is selected from the compounds of the first 0000 embodiment.
O 0 00 According to a sixth embodiment the present invention provides the use of a NK-1 receptor antagonist for the manufacture of a medicament for the combined use with a selective cyclooxygenase-2 inhibitor for preventing or reducing the risk of developing an inflammatory disorder, for halting or slowing the progression of an inflammatory disorder, or for preventing or reducing the risk of occurrence or recurrence of an inflammatory disorder, wherein said selective COX-2 inhibitor is selected from the compounds of the first embodiment.
According to a seventh embodiment the present invention provides the use of a selective cyclooxygenase-2 inhibitor for the preparation of a medicament for the combined use with a NK-1 receptor antagonist for preventing or reducing the risk of developing an inflammatory disorder, for halting or slowing the progression of an inflammatory disorder, or for preventing or reducing the risk of occurrence or recurrence SRA,, of an inflammatory disorder, wherein said selective COX-2 inhibitor is selected from the S 35 ompounds of the first embodiment.
[R:\LIBH]03976.doc:aak 2h According to an eighth embodiment the present invention provides a method of preventing or reducing the risk of developing an inflammatory disorder, for halting or slowing the progression of an inflammatory disorder, or for preventing or reducing the risk of occurrence or recurrence of an inflammatory disorder, said method comprising administration of an NK-1 receptor antagonist combined with administration of a selective cycloxygenase-2 inhibitor, wherein said COX-2 inhibitor is selected from the compounds of the first embodiment.
*S [R:\LIBH]03976.doc:aak WO 99/59635 PCT/G B99/0 632 -3- It will be appreciated that the COX-2 inhibitor and the NK-1 receptor antagonist, may be present as a combined preparation for simultaneous, separate or sequential use for the treatment or prevention of inflammatory disorders. Such combined preparations may be, for example, in the form of a twin pack.
In a further or alternative aspect of the present invention, there is therefore provided a product comprising a COX-2 inhibitor and a NK-1 receptor antagonist as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of inflammatory disorders.
It will be appreciated that when using a combination of the present invention, both the COX-2 inhibitor and the NK-1 receptor antagonist will be administered to a patient, within a reasonable period of time. The compounds may be in the same pharmaceutically acceptable carrier and therefore administered simultaneously. They may be in separate pharmaceutical carriers such as conventional oral dosage forms which are taken simultaneously. The term "combination" also refers to the case where the compounds are provided in separate dosage forms and are administered sequentially. Therefore, by way of example, the COX-2 inhibitor may be administered as a tablet and then, within a reasonable period of time, the NK-1 receptor antagonist may be administered either as an oral dosage form such as a tablet or a fast-dissolving oral dosage form. By a "fast dissolving oral formulation" is meant, an oral delivery form which when placed on the tongue of a patient, dissolves within about 10 seconds.
By "reasonable period of time" is meant a time period that is not in excess of about 1 hour. That is, for example, if the COX-2 inhibitor is provided as a tablet, then within one hour, the NK-1 receptor antagonist should be administered, either in the same type of dosage form, or another dosage form which provides effective delivery of the medicament.
WO 99/59635 PCT/G B99/01632 -4- It will be appreciated that the combination of the present invention will be particularly useful in the treatment of a COX-2 mediated disease or disorder. COX-2 mediated diseases and disorders includes inflammatory diseases susceptible to treatment with a non-steroidal anti-inflammatory agent. Such "inflammatory disorders" include rheumatoid arthritis, degenerative joint diseases (osteoarthritis), bursitis, tendinitis, ankylosing spondylitis, gout and synovitis.
The terms "inhibitor of cyclooxygenase-2", "cyclooxygenase-2 inhibitor" and "COX-2 inhibitor" as used herein embrace compounds which selectively inhibit cyclooxygenase-2 over cyclooxygenase-1. Employing the human whole blood COX-1 assay and the human whole blood COX-2 assay described in C. Brideau ct al, Inflanmm. Res. 45: 68-74 (1996), herein incorporated by reference, preferably, the compounds have a cyclooxygenase-2 ICso of less than about 2 tM in the human whole blood COX-2 assay, yet have a cyclooxygenase-1 ICso of greater than about 5 uM in the human whole blood COX-1 assay. Also preferably, the compounds have a selectivity ratio of cyclooxygenase-2 inhibition over cyclooxygenase-1 inhibition of at least 10, and more preferably of at least The resulting selectivity may indicate an ability to reduce the incidence of common NSAID-induced side effects.
As explained in J. Talley, Exp. Opin. Ther. Patents (1997), pp.
55-62, three distinct structural classes of selective COX-2 inhibitor compounds have been identified. One class is the methane sulfonanilide class of inhibitors, of which NS-398, flosulide, nimesulide and L-745,337 are example members.
WO 99/59635 WO 9959635PCT/G B99/0 1632 N HS0 2
CH
3 NH S0 2
CH
3 NHS0 2
CH
3
NO
2 N0 2 0 L-745,337, X =S Flosulide, X 0 NS-398 Nimesulide A second class is the tricyclic inhibitor class, which can be further divided into the sub-classes of tricyclic inhibitors with a central carbocyclic ring (examples include SC-57666, 1, and those with a central monocyclic heterocyclic ring (examples include DuP 697, SC-58125, SC-58635, and 3, 4 and and those withi a central bicyclic heterocyclic ring (examples include 6, 7, 8, 9 and 10). Compounds 3, 4 and 5 are described in U.S. Patent No. 5,474,995.
CH
3
SO
2
NF'
2 S0 2
CH
3
SO
2 SC-57666 0H 3 S0 2
CH
3
SO
2 _a 'N
F
F SC-58 125 DuP 697 WO 99/59635 WO 9959635PCT/G B99/01 632 -6-
CH
3
SO
2
-CF
3 SC-58635
CH
3 SO; CH 3
S'
0
N
CH
3
SO
2
F
CH
3
SO
2
NN
N
7 NH 2 SO 2
FC
NH
2
SO
2
CF
3 CH 3 0 WO 99/59635 PCT/GB99/01632 -7- The third identified class can be referred to as those which are structurally modified NSAIDS, and includes L-761,066 and structure 11 as example members.
CO
2 H N Br& -CI
CH
r
CH
3 L-761,066 0 11 In addition to the structural classes, sub-classes, specific COX-2 inhibitor compound examples, and reference journal and patent publications described in the Talley publication which are all herein incorporated by reference, examples of compounds which selectively inhibit cyclooxygenase-2 have also been described in the following patent publications, all of which are herein incorporated by reference: U.S.
Patent No.'s 5,344,991, 5,380,738, 5,393,790, 5,409,944, 5,434,178, 5,436,265, 5,466,823, 5,474,995, 5,510,368, 5,536,752, 5,550,142, 5,552,422, 5,604,253, 5,604,260, 5,639,780; and International Patent Specification Nos. 94/13635, 94/15932, 94/20480, 94/26731, 94/27980, 95/00501, 95/15316, 96/03387, 96/03388, 96/06840; and International Publication No.'s WO 94/20480, WO 96/21667, WO 96/31509, WO 96/36623, WO 97/14691, WO 97/16435.
Additional COX-2 inhibitor compounds which are included in the scope of this invention include: 0 0 WO 99/59635 WO 9959635PCT/G B99/O 1632
F
0~ N0
S,
16 0 00 0 18 0 19 o 0
'A
0 Cl I v WO 99/59635 WO 9959635PCT/G B99/01 632 -9- I on OH OH Q/O 22 23 0
F
OH
24 0 NHNR
S
0
N
XI
26 Some of the compounds above can also be identified by the following chemical names: 3: 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone; 4: 3-(3 ,4-difluorophenyl)-4-(4-(methylsulfonyl )phenyl 5 ,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-3-(3 2-one; 12: 5 dime thyl ethylsulfo nyl )ph enyl prop oxy) -5H-fu ran-2 one; WO 99/59635 WO 9959635PCT/GB99/01 632 10 13: 5 -chlIo ro-3 ethyl sul fonyl )phenyl ethyl -5 -pyri di nyl )pyri dine; 14: 2-(3 ,5-difl uorophenyl)-3-(4-(methylsulfonyl )phenyl)-2-cyclopenten- 1one; 5 -ethyl -5 -methyl-4-(4-(methylsulfonyl)phenyl)-3-(2-propoxy)-5Hfuran-2-one; 16: 5 -ethyl -5-m ethyl -4-(4-(methylsul fonyl)phenyl)-3 ,4 -difl u oroph enyl)- 5H-furan-2-one; 17: 3 -thi azolyl)methoxy)-4 ethyl sulfonyl )phenyl ,5 -dim ethyl furan-2-one; 18: 3 -pro pyloxy-4-(4 -(mnethyl sulIfonyl) phe nyl)- 5,5 -dim ethyl 5H-furan -2-one; 19: 3 -cyclopropylethoxy)-5,5 -dim ethyl -4-(4-methylsul fonyl)phenyl)- furan-2 -one; sodium 2-(4-chlorophenyl )-3-(4-(methylsulfonyl)phenyl)-4-oxo-2pentenoate; 21: 3 -(cycl opropylm ethoxy)-5 ,5-dim ethyl -4-(4-(methylsulIfonyl) phenyl furan-2-one;- 22: 3 cyci opropylm ethoxy 5,5-di inethyl ethylsul fonyl )ph e ny)-2 ,5 dihydrofuran-2-ol;, 23: 3 -i sopropoxy- 5,5-d 1imethyl -444-(mnethyls ul fonyl)phen-yl 2,5 dihydrofuran-2-ol; 24: 5,5 -dim ethyl-3-(3 -fluorophenyl)-2-hydroxy-4-(4- 5-chloro-3-(4-(methylsulfonyl)phenyl)-2-(3-pyridinyl)pyridine; 26: 4 -mnethyl -3 -phenyl-4-i soxazolyl)b enzenesulfonamide.
The following publications describe and/or provide methods for making the compounds as indicated: compounds 12, 15, 17, 18, 19 and 2 1, WO 97/14691; compounds 22, 23 and 24, WO 97/16435; compound 20, WO 96/36623; compound 14, U.S. Patent No. 5,536,752; compound 16, U.S.
Patent No. 5,474,995. See Examples herein for compounds 13 and compound 26, U.S. Patent No. 5,633,272.
WO 99/59635 WO 9959635PCT/G B99/O 1632 11 Also incorporated herein by reference are those compounds described in WO 96/41645 as having structural Formula I, shown below, and the definition and preferred definitions and species described therein: 0
R
2 A"
AA
1/ ~0R Particularly preferred compounds of formula include: 5-(4-fluorophenyl [4-(methylsulfonyl)phenyll -3- (tri fl uorom ethyl) pyra zol e; 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl 1-ph1-enyl-3- (trifi uoromethyl )pyrazole; 4-(5-(4-chlorophenyl)-3-(4-m eth-oxyphen-yl H-p~yrazol- 1yl )benzenesulfonamide; 4-(3 ,5-bis(4-methylphenyl 1H-pyrazol- 1-yl)benzenesulfoinamide;, 4-(5-(4-chlor-ophenyl)-3-pheniyl- 1H-pyrazol-1-yl)benzenesulfonamide; 4-(3 ,5-bis(4-methoxyphenyl)- 1H-pyrazol- 1-yl )benzeinesulfonamide; 4-(5-(4-chlorophenyl)-3-(4-methylphenyl)- 1H-pyr-azol- 1yl )benzenesulfonamide; 4-(5-(4-chlorophenyl)-3-(4-nitrophenyl )-1H.-pyrazol- 1yl)benzenesulfonamide; 4-(5-(4-chlorophenyl)-3-(5-chloro-2-thienyl)- 1H-pyrazol- 1yl)benzenesulfonamide; 4-(4-chloro-3 ,5-diphenyl- 1H-pyrazol- 1-yl)benzenesulfonamide; 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)- 1H-pyrazol- 1yl)benzenesulfonamide; 4-(5-phenyl)-3-(trifluoromethyl)-iHI-pyrazol- 1-yl)benzenesulfonamide; 5-(4-fluorophenyl trifi uorom ethyl 1iH-pyrazol- 1 yl)benzenesulfonamide; WO 99/59635 WO 9959635PCT/GB99/OI 632 12 methoxyphenyl)-3 -(tri fl uorom ethyl) 1 H-pyrazol- 1yl )benzenes ulfonamide; 4-(5-(4-chlorophenyl)-3-(difluoromethyl 1H-pyrazol- 1yl)benzenesulfonamide; -methylphenyl)-3 -(trifluorom ethyl)- 1H-pyrazol-1Iyl )benzenesulfonamide; 4-(4-chloro-5-(4-chlorophenyl)-3-(trifluoromethyl)-iHI-pyrazol- 1yl)benzenesulfonamide; 4-(3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol- 1yl)benzenesulfonamide; 4-(3-(difl uoromethyl )-5-phenyl- 1H-pyrazol- 1 -yl)benzenesulfonamide; 4-(3-(difl uorornethyl)-5-(4-methoxyphenyl)- iH-pyrazol- 1yl )benzenesulfonamide; 4-(3-cyano-5-4-fl uorophenyl)- 1H-pyrazol-1-yI)benzenesulfonarnide; 4-(3-(di fl uorornethyl)-5-(3-fluoro-4-methoxyphenyl)-1IH-pyrazol-1 yl)benzenesulfonamide; 4-(5-(3-fluoro-4-methoxyphenyl )-3-(trifl uorom ethyl)- iHI-pyrazol- 1 yl )benzenesulfonamide; 4-(4-chloro-5-phenyl-iHI-pyrazol- l-yl )benzenesulfonamide;, 4-(5-(4-chlorophenyl)-3-(hydroxyphenyl 1H-pyrazol-1yl)benzenesulfonamide; 4-(5-(4-(N,N-dimethylamino)phenyl)-3-(trifluoromethyl)- 1H-pyrazol- 1yl)benzenesulfonamide; 5-(4-fluorophenyl)-6-(4-(methylsulfonyl )phenyl )spirol2.4lhept-5-ene; 4-(6-(4-fluorophenyl)spiro[2.4lhept-5-en-5-yl)benzenesulfonamide- 6-(4-fluorophenyl)-7-(4-(methylsulfonyl )phenyl)spiro[3 .4loct-6-ene; 5-(3-chloro-4-methoxyphenyl)-6-(4-(methylsulfonyl)phenyl)spiro hept- 46-(3-chiloro-4-methoxyph enyl )spiro [2.41 he pt-5 yl)benzenesulfonamide; WO 99/59635 WO 9959635PCTIG B9910 1632 13 5-(3 ,5-dichloro-4-methoxyphenyl (m ethyl su lfonylphe nyl)s pi ro 5-43 -chl oro-4-flu oroph enyl ethyl sul fonyl) ph enyl Ospi ro ene; 4(6-(3,4-dichlorophenyl~spiro 2-(3-chloro-4.-fluorophenyl )-4-(4-fluorophenyl)-5-(4m ethyl s ulfonylphenyl)thi azol e; 2 (2-chl orophenyl)-4-(4-fl uoro phenyl 5-(4-m ethyl sulfonyl phe nyl )thi azol e; 5-4441fu orophenyl)-4-(4-m ethyl sul fonyl phenyl -m ethylthi az ole; 4-4-flu oroph-enyl)-5-(4 -m ethyl sulfonyl phenyl)-2-trifl uorom ethylthi azol e; 4-(4-fluorophenylI)-5-(4-m ethyl sul fonylphenyl )-2-(2-thienyl)thi azol e; 4-(4-fluorophenyl)-5 ethyl sulfonylphenyl )-2-benzylani n othiazol e; 4-(4-fl uorophenyl)-5-(4-m ethylsulfonylphenyl)-2-( 1-propylarnino)thI azole;, ,5-dichlorophenoxy)rnethyl )-4-(4-fluorophenyl (m-ethylsulfonyl)phenyl)thiazole; -(4-fl uoroph enyl ethyls ulIfonylIphe nyl )-2-Aniflu ororn ethylithiazol e; 1 -rethylsulfonyl-4-( 1, 1 -dlirethyl-4-4-fl uorophenyl)cyclopenta-2,4-dien-3 yl)benzene; 44-(4-fluorophenyl)- 1, 1-dimethiylcyclopenta-2,4-dien-3yl)benzenesulfonamide; 5-(4-fl uorophenyl ethyl sul fonyl)phenyl)spiro hepta-4 ,6-diene; 4-(6-(4-fluorophenyl)spiro[2 .4lhepta-4,6-dien-5-yl)benzenesulfonamide; 6-(4-fluorophenyl)-2-methoxy-5-(4-(methylsulfonyl)phenyl)-pyridine-3carhonitrile; 2-bromo-6-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)-pyridine-3carbonitrile; 6-(4-fluorophenyl ethyl sulfonyl~phenyl)-2-pheny I -pyri dine-3carbonitrile; 4-(2-(4-methyl pyridi n-2-yl )-4-(tri fl uorom ethyl 1H-imidazol 1 yl)benzenesulfonamide;, WO 99/59635 WO 9959635PCT/GB99/01632 14 4424(5 -methyl pyri din -3 -yl)-4-(tri fl uoromethyl 1H-imidazol- 1yl )benzenesulfonamide;- 4-(2-(2-methylpyridin-3-yl)-4-(trifluorornethyl 1H-imidazol-1yl )benzenesulfonarnide; 1-(4-(methylsulfonyl )phenyl)-4-(trifluorom ethyl)- 1H-imidazol-2yl)benzenesulfonarnide; 2 1-(4 ethyls ulfonyl) phenyl)-4-(trifl uorornethyl)- 1H-iinidazol -2yl )pyridine; 2-methyl 1(4 -(rethylsulfonyl)phenyl)-4 -(trif u orom ethyl)- I1H-Irid azol 2-yl)pyridine; 2 -m ethyl -6 1-(4 -(me thyls ulfo iyl )phenyl (tri fl uorornethyl)- 1 H-irn1ida zol 2-yl )pyridine;, 4-(2-(6-methylpyridin-3-yl)-4-(trifl uoromethyl)- 1H-irnidazol-1IyI)benzenesulfonarnide; 2-(3,4-difluorophenyl)- 1-(4-(methylsulfonylI)phenyl)-4-(trifluoromethyl)-1IHimidazole; 42-4-rnethylphenyl tri fl uorornethyl 1H-imidazol- 1yl)benzenesulfonarnide; 2-(4-chlorophenyl 1-(4-(methylsulfonyl )phelnyl )-4-rnethyl- iR-irnidazole; 2-(4-chlorophenyl)- 1444 4-rethyl sul fonyl) phenyl)-4-phenyl 1H-imidazole; 2-(4-chlorophenyl )-4-(4-fluorophenyl)-1-(4-(methylsulfonyl)phenyl)- 1Himidazole; 2-(3-fluoro-4-methoxyphenyl)- 1-(4-(methylsulfonyl)phenyl)-4- (trifluoromethyl 1H-imidazole; 1-(4-(methyisulfonyl)phenyl)-2-phenyl-4-trifluoromethyl-1H-imidazole; 2-(4-methylphenyl)- 1-(4-(methyls ulfonyl) phenyl) -4-trifl uorom ethyl- I1Himidazole; 4424(3-chl oro-4-m ethyl phenyl) -4-(tri flu oromniethyl 1H-ini da zol- 1 yl )benzenesulfonarnide; 24(3-fl uoro-5 -m ethyl phenyl 1-4-(m ethyl sul fonyl )phenyl (tri fl uorom ethyl 1H-imidazole; WO 99/59635 WO 9959635PCT/G B99/O 1632 15 4-(2-(3-fl uoro-5-methylphenyl trifluoromethyl)- 1H-imidazol- 1yl )benzenesulfonamide;, 2-(3-methylphenyl)- 1-(4(m ethyl sul fonyl) phenyl) -4 -(tri flu orom ethyl 1Himidazole; 4-(2-(3-methylphenyl)-4-(trifluorornethyl)-1H-imidazol- 1yl)benzenesulfonamide; ethyl sul fonyl)phenyl) -24(3-chl orophenyl)-4-(tri fluoromethyl 1Himidazole; 4424(3-chl orophenyl)-4-(trifl uorom ethyl)- 1 H-imi d azol 1 yl)benzenesulfonamide; 4-(2-ph enyl-4-(triflu orom ethyl) 1H-imidazol- Il-yl )benzenesulfonamide; 4- -m ethoxy-3 -chl orophe nyl) -4 -(tri fl uorom ethyl 1H-irnidazol- 1 yl )benzenesulfonamide; 1-allyl-4-(4-fl uorophenyl -(methyls ul fonyl )phenyl tifl uorom ethyl 1H-pyrazole; 441 -ethyl -4-4-fluorophenyl 5- (tri fl uorom ethyl 1 H-pyrazol -3 yl )benzenesulfonami de; N-phenyl-(4-(4-fluorophenyl -(4-(methylsulfonyl)phenyl (trifluoromethyl)- iR-pyrazol- l-yl )acetamide; ethyl (4-(4-fl uorophenyl)-3 ethyl sul fonyl)ph enyl)-5-(tri fl uorom ethyl 1H-pyrazol- l-yl )acetate; 4-(4-fluorophenyl)-3-(4-(methylsulfonyl )phenyl)- 1-(2-phenylethyl)- 1Hpyrazole; 4-441luorophenyl)-3-(4-(methyl sulfo nyl) ph enyl) 1-(2-phenyl ethyl)-5 (trifluoromethylbpyrazole; 1-ethyl-4-(4-fluorophenyl)-3-(4-(methylsulfonyl 1H-pyrazole; 5-(4-fluorophenyl )-4-(4-(methylsulfonyl)phenyl)-2-(trifluoromethyl )-l1Himidazole; 4-(4-(methylsulfonyl)phenyl)-5-(2 -thiophenyl)-2-(trifluorom ethyl)-1IHimidazole; WO 99/59635 WO 9959635PCT/G B99/O 1632 16 5-(4-fluorophenyl)-2-m ethoxy-4-(4-(methylsulfonyl )phenyl)-6- (tri fl uorom ethyl) )pynid ine; 2-ethoxy--5-(4-fluorophenyl )-4-(4-(nethylsulfonyl)phenyl (trifluoromethyl)pyridine; 5-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(2-propynyloxy)-6- (trifluoromethyl)pyridine;, 2-brom o-5-44 -fl uorophenylI)-4-(4-(m ethyl sulfonyl)phenyl)-6- (trifluorom ethyl)pyri dine', 4-(2-(3-chloro-4-methoxyphenyl)-4,5-difluorophenyl)benzenesulfonamide; 1 -(4-fluorophenyl)-2-(4-(methylsulfonyl)phenyl)benzene; 5-difluoromethyl-4-(4-(rnethylsulfonyl )phenyl )-3-phenylisoxazole;, 4-(3-ethyl-5-phenylisoxazol-4-yl )benzenesulfonarnide; 4-(5-difluoromethyl-3-phenylisoxazol-4-yl)benzenesulfoinaride; 445-hydroxym ethyl 3-p henylis oxa zo 1-4 -yl)be nzenesul fonam 1ide; 5-methyl-3 -phienylisoxazol-4-yl)benzenesulfonanide, 14(2-4-flu oroph enyl)cycl opente n- 1 -yl)-4 ethyl sulfonyl)benz ene; 1-(2-4-fluoro-2-rnethyl phenyl)cyclopenteii- 1l-yl )-4-(methylsulfonyl)benzene; 1 -(2-(4-chlorophenyl )cyclopenten- l-yl )-4-(methylsulfonylbenzene; 1-(2-(2,4-dichlorophenyl )cyclopenten- methylsulfonyl )benzene; 1-(2-4-tri fl uorom ethyl phenyl)cycl openten- 1 -yl.)-4-(rnethyl sulfonyl)benzene; 1-(2-(4-methylthiophenyl)cyclopenten- 1-yl)-4-(methylsulfonyl)benzene; 1-(2-(4-fluorophenyl )-4,4-dimethylcyclopenten- l-yl)- 4 (methylsulfonyl)benzene; 4-(2-(4-fluorophenyl)-4 ,4-dimethylcyclopenten-1-yl )benzenesulfonamide; 1-(2-(4-chlorophenyl)-4,4-dimethylcyclopenten-1-yl)-4- (methylsulfonyl )benzene; 44(2-(4-chloro phe nyl) -4,4 -di methyl cyclopen ten- I1-yl)benzenes ul fonamid e; 4-(2-(4-fluorophenyl)cyclopenten- l-yl )benzenesulfonarnilde; 4-(2-(4-chlorophenyl)cyclopenten- 1-yl)benzenesulfonamide;, 1 -(2-(4-rnethoxyphenyl )cyclopenten- l-yl )-4-(methylsulfonyl )benzene; 1-(2-(2,3-difluorophenyl )cyclopenten- 1-yl)-4-(methylsulfonyl )benzene; WO 99/59635 WO 9959635PCT/G B99/O 1632 17 44(2-3-fl uor-o-4-methoxyphenyl)cyclopenten- 1-yl)benzenesulfonamide; 1-(2-(3-chloro-4-methoxyphenyl )cyclopenten- 1l-yl)- 4 (methylsulfonyl)benzene,- 442-43 -chiloro-4-41luorophenyl)cycl ope nten- 1 -yl )benzenes ul fonami de; 44(2-(2-methyl pyri din- 5-yl)cycl open te n- I1-yl)benzenesul fonamide; ethyl 2-(4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazol-2-yl)-2benzyl-acetate; 2-(4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazol-2-yl)acetic acid; 2-(tert-butyl orophenyl)-5 ethyl su Ifonyl )phenyl)oxazol e; 4-(4-fluorophenyl )-5-(4-(methylsulfonyl )phenyl )-2-phenyloxazole; 4-(4-fl uorophenyl ethyl ethylsulfonyl )phenyl )oxazole;- and 445-(3-fl uoro-4-methoxyphenyl )-2-trifi uorom ethyl -4oxazolyl )benzenesulfonamide; or a pharmaceutically acceptable salt thereof.
NK-1 receptor antagonists of use in the present invention are described in published European Patent Specification Nos. 0 360 390, 0 394 989, 0 429 366, 0 443 132, 0 482 539, 0 512 901, 0 512 902, 0 514 273, 0 514 275, 0 517 589, 0 520 555, 0 522 808, 0 528 495, 0 532 456, 0 533 280, 0 536 817, 0 545 478, 0 577 394, 0 590 152, 0 599 538, 0 610 793, 0 634 402, 0 686 629, 0 693 489, 0 694 535, 0 699 655, 0 699 674, 0 707 006, 0 708 101, 0 714 891, 0 723 959, 0 733 632 and 0 776 893; and in International Patent Specification Nos.
90/05525, 90/05729, 91/09844, 91/18899, 92/01688, 92/06079, 92/12151, 92/15585, 92/17449, 92/20661, 92/20676, 92/21677, 93/00330, 93/0033 1, 93/01159, 93/01165, 93/01169, 93/01170, 93/06099, 93/09116, 93/10073, 93/14113, 93/18023, 93/19064, 93/21155, 9321181, 93/23380, 93/24465, 94/01402, 94/02461, 94/03429, 94/03445, 94/04494, 94/04496, 94/05625, 94/07843, 94/10165, 94/10167, 94/10168, 94/10170, 94/11368, 94/13639, 94/13663, 94/14767, 94/15903, 94/19320, 94/19323, 94/20500, 94/26735, 94/26740, 94/29309, 95/02595, 95/04040, 95/04042, 95/06645, 95/07886, 95/07908, 95/08549, 95/1 1880, 95/140 17, 95/153 11, 95/16679, 95/17382, WO 99/59635 PCT/GB99/01632 18- 95/18124, 95/18129, 95/19344, 95/20575, 95/21819, 96/22525, 95/23798, 95/26338, 95/28418, 95/30674, 95/30687, 96/05193, 96/05203, 96/06094, 96/07649, 96/10562, 96/16939, 96/18643, 96/20197, 96/21661, 96/29304, 96/29317, 96/29326, 96/29328, 96/31214, 96/32385, 96/37489, 97/01553, 97/01554, 97/03066, 97/08144, 97/14671, 97/17362, 97/18206, 97/19084, 97/19942, 97/21702, 97/30055, 97/49710 and 98/01450; and in British Patent Specification Nos. 2 266 529, 2 268 931, 2 269 170, 2 269 590, 2 271 774, 2 292 144, 2 293 168, 2 293 169, 2 302 689 and 2 309 458.
Particularly preferred NK-1 receptor antagonists are those described in European Patent Specification No. 0 577 394, especially compounds of formula 3 4 <X R 4 I R (1)
R
2 N R'
R
or a pharmaceutically acceptable salt thereof, wherein: RI is selected from the group consisting of: Cl-ialkyl, substituted with one or more of the substituents selected from: heterocycle, wherein the heterocycle is selected from the group consisting of: benzimidazolyl, imidazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, pyrazinyl, pyrazolyl, pyridyl, pyrrolyl, WO 99/59635 WO 9959635PCT/G B99/O 1632 19 tetrazolyl, thiadiazolyl, triazolyl, and piperidinyl, and wherein the heterocycle is unsubstituted or substituted with one or more substituent(s) selected from:
CI-
6 alkyl, unsubstituted or substituted with halo, -CF 3
-OCH
3 or phenyl, (11) Cl-6alkoxy, .0 (iii) OXO, (iv) thioxo, (v cyano, (vi -SCH 3 (vii) phenyl, (viii) hydroxy, (ix) tri fl uorom ethyl, (x -(CH 2 1
,-NRR
1 wherein in is 0, 1 or 2, and R 9 and RIO areindependently selected from: hydrogen, (11) C 1.6alkyl, (111) hydroxyCl-6alkyl, and (IV) phenyl, (xi) -NR 9 CORIO, wherein R 9 and RIO are as defined above, and (xii) -CONR 9 RiO, wherein R 9 and Rio are as defined above,
R
2 and R 3 are independently selected from the group consisting of: hydrogen;, Cl.6alkyl
C
2 .6alkenyl, and phenyl; xis WO 99/59635 WO 9959635PCT/G B99/O 1632 20 R4 is z
R
R
5 is phenyl, unsubstituted or substituted with halo;,
R
6
R
7 and W 8 are independently selected from the group consisting of: hydrogen, C1l6alkyl, halo, and
-CF
3 Y is and Z is hydrogen or CI4alkyl; and pharmaceutically acceptable salts thereof'.
Particularly preferred comnpounds of formula are: 1,2,4-triazolo)methyl ,5-bis(trifluoromethyl )benzyloxy)-3(S)phenyl-morpholine; 1,2,4-triazolo)methyl)-2(S )-(3,5-bis(trifluoromethyl)berizyloxy)-3(R)phenyl -morpholine; 4-(3-(5-oxo- 1H,4H-1,2,4-tr-iazolo)methyl)-2(S)-(3,5bis(trifluoromethyl)benzyloxy)-3(S)-phenyl-morpholine; and ,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)- 4-(3-(5-oxo- 1H,4H- 1,2,4-triazolo)methyl)morpholine; or a pharmaceutically acceptable salt thereof.
Further preferred NK-1 receptor antagonists are those described in International (PCT) Patent Specification No. WO 95/18124, especially compounds of formula (II) and pharmaceutically acceptable salts thereof: WO 99/59635 PCT/GB99/01632 -21-
A
l O O
N
R
6
A
3
(II)
wherein: A' is fluorine or CF 3
A
2 is fluorine or CF 3 A is fluorine or hydrogen;
R
6 is a 5-membered or 6-membered heterocyclic ring containing 2 or 3 nitrogen atoms optionally substituted by =S or a C3-4alkyl group, and optionally substituted by a group of the formula ZNR 7 R8 where Z is Ci-calkylene or C3-6cycloalkylene;
R
7 is hydrogen, C1- 4 alkyl, C3-7cycloalkyl or C37cycloalkylC1-4alkyl, or C2- 4 alkyl substituted by C1-4alkoxy or hydroxyl;
R
8 is hydrogen, C1i 4 alkyl, C3-7cycloalkyl or C3-7cycloalkylC1- 4 alkyl, or C2- 4 alkyl substituted by one or two substituents selected from C1- 4 alkoxy, hydroxyl or a 4, 5 or 6 membered heteroaliphatic ring containing one or two heteroatoms selected from N, O and S; or R 7
R
8 and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by a hydroxy group, and optionally containing a double bond, which ring may optionally contain an oxygen or sulphur ring atom, a group S(0) or S(0)2 or a second nitrogen atom which will be part of a NH or NR c moiety where Rc is C1.
4 alkyl optionally substituted by hydroxy or C1-4alkoxy; or R 7
R
8 and the nitrogen atom to which they are attached form a non-aromatic azabicyclic ring system of 6 to 12 ring atoms; WO 99/59635 PCT/GB99/01632 -22or Z, R 7 and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms which may optionally contain an oxygen ring atom; X is an alkylene chain of 1 to 4 carbon atoms optionally substituted by oxo; and Y is a C1.4alkyl group optionally substituted by a hydroxyl group; with the proviso that if Y is Ci14alkyl, R 6 is susbstituted at least by a group of formula ZNR 7 R8 as defined above.
Particularly preferred compounds of formula (II) include: 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(dimethylamino) methyl-1,2,3-triazol-4-yl)methyl-3-(S)-phenylmorpholine; 2-(R)-(l-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(dimethylamino) methyl- 1,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)morpholine; 2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4fluorophenyl)-4-(1,2,4-triazol-3-yl)methylmorpholine; and pharmaceutically acceptable salts thereof.
Further preferred NK-1 receptor antagonists are those described in European Patent Specification No. WO 95/23798, especially compounds of formula (III):
R
G
R
3 X Y
R
z R (III) R 2 N P A S 13 R12 B R or a pharmaceutically acceptable salt thereof, wherein:
R
2 and R 3 are independently selected from the group consisting of: hydrogen, C1.6alkyl, WO 99/59635 PCT/G B99/01632 -23- C2-6alkenyl, and phenyl;
R
6
R
7 and R s are independently selected from the group consisting of: hydrogen, Cil6alkyl, fluoro, chloro, bromo, iodo, and
-CF
3
R
11
R
12 and R 13 are independently selected from the group consisting of: fluoro, chloro, bromo, and iodo; A is unsubstituted 1-6alkyl; B is selected from the group consisting of: H X X N-N X X HH N-N N-N N-N N s 0 0 iN N N X H N-H X H X N-N H X N-N N-N N-N N /x X X N S N
N
X H X N-N N N-N N SN N N X X WO 99/59635 WO 9959635PCT/G B99/0 1632 x
N
H
N
x 24
IN
x
H
/-N
N0 x
N
H
H
N
K N p is 0 or 1; X is selected from: -PO(OH)0- e wherein M' is a pharmaceutically acceptable monovalent counterion, -PO(0-) 2 *2M+, -PO(0-) 2
D
2 wherein D 2 is a pharmaceutically acceptable divalent counterion, -CH(R4)-PO(OH)O- wherein R4 is hydrogen Or CI-3alkyl, 2
-CO-CH
2
CH
2 -C0 2
-CH(CH
3
)-O-CO-R
5 wherein R 5 is selected from the group consisting of: WO 99/59635 WO 9959635PCT/G B99/O 1632 25 H 2 M (ii) 0 OH2M 0 GO,, M+ 02' NH3 (vi) 0-C0 2
'M
CO0 M+ C0,; M (Vii) ;and Y is Z is hydrogen or Cl-6alkyl; and pharmaceutically acceptable salts thereof.
Particularly preferred compounds of formula (III) include: 2-(S)-(3,5-bis(trifluoromethyl)benzyloxy)-3-(S)-phenyl-4-(3-(5-oxo- 1H,4H-1,2,4-triazolohriethyl)morpholine N-oxide; WO 99/59635 WO 9959635PCT/G B99/O 1632 26 ,5-bis(trifluoromethyl)benzyloxy)-3-(S)-phenyl-4-(3-(4- (ethoxycarbonyloxy- 1-ethyl)-5-oxo- 11-- 1,2,4triazolo)methyl)morpholine; ,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4fluorophenyl)-4-(3-(4-monophosphoryl-5-oxo- 1H-1,2 ,4triazolo)methyl)morpholine; 1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4fluorophenyl)-4-(3-( 1-monophosphoryl-5-oxo-1H- 1,2,4triazolo)rnethyl)morpholine; 1-(R)-(3,5-bis(trifluoron-ethyl)phenyl)ethoxy)-3-(S)-(4fluorophenyl )-4-(3-(2-monophosphoryl-5-oxo- 1H- 1,2,4triazolo)methyl )morpholine; 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4fluorophenyl )-4-(3-(5-oxyphosphoryl- 11-- 1,2,4triazolo)methyl)morpholine; ,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4fluorophenyl)-4-(3-( 1-monophosphoryI -5-oxo-4H- 1,2,4triazolo)methyl)rnorpholine; and pharmaceutically acceptable salts thereof.
Further preferred NK-1 receptor antagonists are those described in International Patent Specification No. WO 97/49710, especially compounds of formula (LV): R R k
X//
(IV)
N 3~
H
wherein WO 99/59635 PTGB9O 3 PCT/G B99/01632 27 RI represents hydrogen, hydroxy, C1-6alkyl, C2-6alkenyl, C3-7CYCloalkyl, C3- 7 cycloalkylC i-4alkyl, C 1-6alkoxy, fluoroC 1.6alkoxy, CI-6alkoxyCl-4alkyl, C l-6alkoxyC l4alkoxy, fluoroC l6alkoxyC 1-4alkyl, C2-6alkenyloxy, C3-7cycloalkoxy, C3.7cycloalkylC l-alkoxy, phenoxy, benzyloxy, cyano, halogen, NRaRb, SRa, SORa, SO 2 Ra, OSO 2 Ra, NRaCOR14, CORa, CO 2 Ra or CONRaRb where Ra and Rb each independently represent hydrogen, C1-4alkyl or fluoroCl-4alkyl;
R
2 represents hydrogen, halogen, Cl-6alkyl or C1l6alkoxy; or RI and R 2 may be joined together such that there is formed a 5- or 6-membered saturated or unsaturated ring containing one or two atoms selected from nitrogen, oxygen and sulphur, which ring is optionally substituted by a group selected from C14alkyl, CF 3 =0 Or=S R3 represents hydrogen, halogen, C1b6alkyl, fluoroCI-6alkyl, C 1-6alkoxy, fi uoroC 1-6alkoxy, C3-7CYCloalkyl, C3-7cycloalkylC l4alkyl, cyano, SRa, SORa, SO 2 Ra, NRaRb, NRaCOR14, CORa, CO 2 Ra, CONRaRb or C1- 4 alkyl substituted by cyano, CO 2 Ra or CONRaRb where Ra and Rb are as previously defined; R4 represents hydrogen, halogen, CI.6alkyl, Cl-6alkoxy, CF 3
OCF
3 N0 2 CN, SRa, SORa, SO 2 Ra, CO 2 Ra, CONRaRb, C2-6alkenyl, C2-6alkynyl or C1 4 alkyl substituted by Cl4alkoxy, where Ra and Rb are as previously defined; and the broken line represents an optional double bond; and pharmaceutically acceptable salts thereof.
Particularly preferred compounds of formula (IV) include: 3 R,5R,6S)-3-(2-methoxy-5-(trifluoromethoxy)phenyl)-6-phenyl- 1-oxa-7aza-spiro decane; (3R ,5R ,6S)-3-(2-methoxy-5-(trifluoromethyl)phenyl )-6-phenyl-1-oxa-7-azaspiro [4.51 decane;, (3R, 5R ,6S)-7 -benzyl-3 2 -methoxy-5-(trifluor omethoxy)phenyl] -6-phenyl- 1 oxa-7 -aza-spiro [4.51ldecane; (3R, 5R ,6S)-3 -(2-methoxy-5-tri fluorom ethoxyphenyl )-6-phenyl- I1-oxa-7 -aza- WO 99/59635 WO 9959635PCT/G B99/0 1632 28 (3R, 5R,6S)-3,6-bis(phenyl )-1I-oxa-7-aza-spiro [4.51 decane; ,6S)-7-benzyl-3-(2-methoxy-5-trifluoromethoxyphenyl )-6-phenyl- 1oxa-7-aza-spiro decane; 5R*,6' 3(-ehxpenl--hnlloa7 (phenylmethoxycarbonyl)aza-spiro[4.51 decane; (3R,5R,6S)-3-(2-methoxyphenyl)-6-phenyl- 1-oxa-7-aza-spiro [4.51 decane; (3S, 5R,6S)-3-(2-cyclopropoxy-5-(trifluoromethoxy)phenyl)-6-phenyl- 1 -oxa- 7-aza-spiro decane; (3R, 5R,6S)-3-[2-cyclopropoxy-5-(trifluoromethoxy)phenyl -6-phenyl-l1-oxa- 7-aza-spiro decane; (3S, 5R [2-cyclopropoxy-5-(trifluoromethyl )phenyl] -6-phenyl- 1 -oxa-7aza-spiro decane; and pharmaceutically acceptable salts thereof.
Another class of NK-1 receptor antagonists of use in the present invention is that described in European Patent Specification No.
0 436 334, i.e. compounds of formula R 2
(V)
1 6
R
or a pharmaceutically acceptable salt thereof, wherein Y is (CH 2 wherein n is an integer from 1 to 4, and wherein any one of the carbon-carbon single bonds in said (CH 2 )n may optionally be replaced by a carbon-carbon double bond, and wherein any one of the carbon atoms of said (CH 2 )n may optionally be substituted with R 4 and wherein any one of the carbon atoms of said (CI- 2 )n may optionally be substituted with R 7 WO 99/59635 PCT/GB99/01632 -29- Z is (CH 2 )m wherein m is an integer from 0 to 6, and wherein any one of the carbon-carbon single bonds of (CH2)m may optionally be replaced by a carbon-carbon double bond or a carbon-carbon triple bond, and any one of the carbon atoms of said (CH 2 )m may optionally be substituted with R8;
R
1 is hydrogen or Clisalkyl optionally substituted with hydroxy, C1i 4 alkoxy or fluoro;
R
2 is a radical selected from hydrogen, C 1 6 straight or branched alkyl, C3-7cycloalkyl wherein one of the CH 2 groups in said cycloalkyl may optionally be replaced by NH, oxygen or sulphur; aryl selected from phenyl and naphthyl; heteroaryl selected from indanyl, thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl and quinolyl; phenyl-C26alkyl, benzhydryl and benzyl, wherein each of said aryl and heteroaryl groups and the phenyl moieties of said benzyl, phenyl C2-6alkyl and benzhydryl may optionally be substituted with one or more substituents independently selected from halo, nitro, C 1 -6 alkyl, Ci-lalkoxy, trifluoromethyl, amino, C.-6alkylamino, Ci.-alkyl-O-CO, Ci- 6 alkyl-O-CO- Ci-6alkyl, C1-6alkyl-CO-O, Ci-6alkyl-CO-C-.6alkyl-O-, CI-6alkyl-CO, Ci-6alkyl-CO-C -6alkyl-, di-Ci-alkylamino, -CONH-Ci-6alkyl, Cl-6alkyl-CO-NH-Cl-ealkyl, -NHCOH and -NHCO-Ci- 6 alkyl; and wherein one of the phenyl moieties of said benzhydryl may optionally be replaced by naphthyl, thienyl, furyl or pyridyl;
R
5 is hydrogen, phenyl or C1l6alkyl; or R 2 and R 5 together with the carbon to which they are attached, form a saturated ring having from 3 to 7 carbon atoms wherein one of the
CH
2 groups in said ring may optionally be replaced by oxygen, NH or sulfur;
R
3 is aryl selected from phenyl and naphthyl; heteroaryl selected from indanyl, thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl and quinolyl; and cycloalkyl having 3 to 7 WO 99/59635 PCT/GB99/01632 carbon atoms wherein one of the (CH 2 groups in said cycloalkyl may optionally be replaced by NH, oxygen or sulphur; wherein each of said aryl and heteroaryl groups may optionally be substituted with one or more substituents, and said C3.7cycloalkyl may optionally be substituted with one or two substituents, each of said substituents being independently selected from halo, nitro, Cl-6alkyl, Ci-6alkoxy, trifluoromethyl, amino, Ci-6alkylamino, -CO-NH- C1.6alkyl, CI-6alkyl-CO-NH-C 1.alkyl, -NHCOH and -NHCO-Ci-6alkyl;
R
4 and R 7 are each independently selected from hydroxy, halogen, halo, amino, oxo, cyano, methylene, hydroxymethyl, halomethyl, Ci-6alkylamino, di-Ci-6alkylamino, Ci.-alkoxy, Cl-6alkyl-O-CO, C1-6alkyl-O-CO-C.-6alkyl, Ci.6alkyl-CO-O, Ci-6alkyl-CO-Ci-6alkyl-O-, Cil.alkyl-CO-, Ci.6alkyl-CO-CI.-alkyl, and the radicals set forth in the definition of R 2
R
6 is -NHCOR 9
-NHCH
2
R
9
SO
2
R
8 or one of the radicals set forth in any of the definitions of R 2
R
4 and R 7
R
8 is oximino (=NOH) or one of the radicals set forth in any of the definitions of R 2
R
4 and R 7
R
9 is C1.6alkyl, hydrogen, phenyl or phenylCi6alkyl; with the proviso that when m is 0, R 8 is absent, when R 4
R
6
R
7 or
R
8 is as defined in R 2 it cannot form together with the carbon to which it is attached ,a ring with R5, and when R 4 and R 7 are attached to the same carbon atom, then either each of R 4 and R 7 is independently selected from hydrogen, fluoro and C1-6alkyl, or R 4 and R 7 together with the carbon to which they are attached, for a C3- 6 saturated carbocyclic ring that forms a spiro compound with the nitrogen-containing ring to which they are attached.
A particularly preferred compound of formula is (2S,3S)-cis-3-(2methoxybenzylamino)-2-phenylpiperidine; or a pharmaceutically acceptable salt thereof.
WO 99/59635 PCT/GB99/01632 -31 Another class of NK-1 receptor antagonists of use in the present invention is that described in International Patent Specification No. WO 93/21155, i.e. compounds of formula (VI): N CH-R'
(VI)
12
R
R 3
R
or a pharmaceutically acceptable salt thereof, wherein radicals R are phenyl radicals optionally 2- or 3-substituted by a halogen atom or a methyl radical; RI is optionally substituted phenyl, cyclohexadienyl, naphthyl, indenyl or optionally substituted heterocycle;
R
2 is H, halogen, OH, alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkyloxy, alkylthio, acyloxy, carboxy, optionally substituted alkyloxycarbonyl, benzyloxycarbonyl, amino or acylamino;
R
3 is optionally 2-substituted phenyl;
R
4 is OH or fluorine when R 5 is H; or R 4 and R 5 are OH or R 4 and R 5 together form a bond.
A particularly preferred compound of formula (VI) is (3aS, 4S, 7aS)- 7,7-diphenyl-4-(2-methoxyphenyl)-2-[(2S)-(2-methoxyphenyl)propionyl] perhydroisoindol-4-ol; or a pharmaceutically acceptable salt thereof.
Another class of NK-1 receptor antagonists of use in the present invention is that described in European Patent Specification No.
0 591 040, i.e. compounds of formula (VII): R
Q
Ar-T-CO-N-CH 2
-C-CH
2
-CH
2 -Am A (VII) Ar' wherein WO 99/59635 PCT/GB99/01632 -32- Ar represents an optionally substituted mono-, di- or tricyclic aromatic or heteroaromatic group; T represents a bond, a hydroxymethylene group, a C1.4alkoxymethylene group or a Ci-salkylene group; Ar' represents a phenyl group which is unsubstituted or substituted by one or more substituents selected from halogen, preferably chlorine or fluorine, trifluoromethyl, C1.
4 alkoxy, C1-4alkyl where the said substituents may be the same or different; a thienyl group; a benzothienyl group; a naphthyl group; or an indolyl group; R represents hydrogen, C1- 4 alkyl, o-C1-4alkoxyCi.
4 alkyl, or co-C2.4alkanoyloxyC2- 4 alkyl; Q represents hydrogen; or Q and R together form a 1,2-ethylene, 1,3-propylene or 1,4butylene group; Am represents the radical in which X 1
X
2 and X 3 together with the nitrogen atom to which they are attached, form an azabicyclic or azatricyclic ring system optionally substituted by a phenyl or benzyl group; and A- represents a pharmaceutically acceptable anion.
A particularly preferred compound of formula (VII) is (3,4-dichlorophenyl)-1-[(3-isopropoxyphenyl)acetyl]-3-piperidinyl] ethyl] -4phenyl-1-azabicyclo[2,2,2]octane; or a pharmaceutically acceptable salt, especially the chloride, thereof.
Another class of NK-1 receptor antagonists of use in the present invention is that described in European Patent Specification No.
0 532 456, i.e. compounds of formula (VIII): WO 99/59635 PCT/GB99/01632 -33- R -N X R 4
(VIII)
R
X
or a pharmaceutically acceptable salt thereof, wherein
R
I represents an optionally substituted aralkyl, aryloxyalkyl, heteroaralkyl, aroyl, heteroaroyl, cycloalkylcarbonyl, aralkanoyl, heteroarylalkanoyl, aralkoxycarbonyl or arylcarbamoyl group or the acyl group of an a-amino acid optionally N-substituted by a lower alkanoyl or carbamoyl-lower alkanoyl group;
R
2 represents cycloalkyl or an optionally substituted aryl or heteroaryl group;
R
3 represents hydrogen, alkyl, carbamoyl or an alkanoyl or alkenoyl group optionally substituted by carboxy or esterified or amidated carboxy;
R
4 represents an optionally substituted aryl group or an optionally partially saturated heteroaryl group; Xi represents methylene, ethylene, a bond, an optionally ketalised carbonyl group or an optionally etherified hydroxymethylene group;
X
2 represents alkylene, carbonyl or a bond; and
X
3 represents carbonyl, oxo-lower alkyl, oxo(aza)-lower alkyl, or an alkyl group optionally substituted by phenyl, hydroxymethyl, optionally esterified or amidated carboxy, or (in other than the a-position) hydroxy.
A particularly preferred compound of formula (VIII) is 4S*)-2benzyl-l-(3,5-dimethylbenzoyl)-N-(4-quinolinylmethyl)-4-piperidineamine; or a pharmaceutically acceptable salt thereof.
Another class of NK-1 receptor antagonists of use in the present invention is that described in European Patent Specification No.
0 443 132, i.e. compounds of formula (IX) WO 99/59635 PCT/GB99/01632 -34-
CH
2 R -Y-A-N CONHCHCON (IX) R4 or a pharmaceutically acceptable salt thereof, wherein
R
1 is aryl, or a group of the formula: z X is CH or N; and Z is O or N-R 5 in which R 5 is hydrogen or lower alkyl;
R
2 is hydroxy or lower alkoxy;
R
3 is hydrogen or optionally substituted lower alkyl;
R
4 is optionally substituted ar(lower)alkyl; A is carbonyl or sulfonyl; and Y is a bond or lower alkenylene.
A particularly preferred compound of formula (IX) is the compound of formula (IXa)
HO
0 I I (IXa) or a pharmaceutically acceptable salt thereof.
WO 99/59635 PCT/G B99/01632 Another class of NK-1 receptor antagonists of use in the present invention is that described in International Patent Specification No. WO 92/17449, i.e. compounds of the formula (X)
H
N R 2
H
(X)
or a pharmaceutically acceptable salt thereof, wherein
R
1 is aryl selected from indanyl, phenyl and naphthyl; heteroaryl selected from thienyl, furyl, pyridyl and quinolyl; and cycloalkyl having 3 to 7 carbon atoms, wherein one of said carbon atoms may optionally be replaced by nitrogen, oxygen or sulfur; wherein each of said aryl and heteroaryl groups may optionally be substituted with one or more substituents, and said C3.7cycloalkyl may optionally be substituted with one or two substituents, said substituents being independently selected from chloro, fluoro, bromo, iodo, nitro, Ci.ioalkyl optionally substituted with from one to three fluoro groups, Ci-ioalkoxy optionally substituted with from one to three fluoro groups, amino, Ci-ioalkyl-S-, Ciioalkyl-S(O)-, Ci-ioalkyl-SO2-, phenyl, phenoxy, Cl-o1alkyl-SO2NH-, Ci-loalkyl-SO 2 NH-Ci-ioakyl-, Ci-ioalkylamino-diCiioalkyl-, cyano, hydroxy, cycloalkoxy having 3 to 7 carbon atoms, C1.6alkylamino, Cl-6dialkylamino, HC(O)NH- and Cl-ioalkyl-C(O)NH-; and
R
2 is thienyl, benzhydryl, naphthyl or phenyl optionally substituted with from one to three substituents independently selected from chloro, bromo, fluoro, iodo, cycloalkoxy having 3 to 7 carbon atoms, Cl-loalkyl optionally substituted with from one to three fluoro groups and Ci-loalkoxy optionally substituted with from one to three fluoro groups.
A particularly preferred compound of formula is (2S,3S)-3-(2methoxy-5-trifluoromethoxybenzyl)-amino-2-phenylpiperidine; or a pharmaceutically acceptable salt thereof.
WO 99/59635 PCT/GB99/01632 -36- Another class of NK-1 receptor antagonists of use in the present invention is that described in International Patent Specification No.
WO 95/08549, i.e. compounds of formula (XI)
R
2
(CH
2
H
N N -3 H
R"
R
(XI)
or a pharmaceutically acceptable salt thereof, wherein
R
1 is a C1- 4 alkoxy group;
R
2 is 6
_N
N
N-N
R
3 is a hydrogen or halogen atom;
R
4 and R 5 may each independently represent a hydrogen or halogen atom, or a C1-4alkyl, C1-4alkoxy or trifluoromethyl group;
R
6 is a hydrogen atom, a C1-4alkyl, (CH2)mcyclopropyl, -S(O)nC1-4alkyl, phenyl, NR7R8, CH 2 C(O)CF3 or trifluoromethyl group;
R
7 and R 8 may each independently represent a hydrogen atom, or a C1.4alkyl or acyl group; x represents zero or 1; n represents zero, 1 or 2; and m represents zero or 1.
Particularly preferred compounds of formula (XI) are tetrazol-l-yl-benzyl)-([2S,3S]-2-phenyl-piperidin-3-yl)-amine; and [2- WO 99/59635 WO 9959635PCT/G B99/O1 632 37 m ethoxy-5 -tri flu orom ethyl -tetrazol 1 -yl)-benzyll-( [2S,3S1 -2-phenylpiperidin-3-yl)-amine; or a pharmaceutically acceptable salt thereof.
Another class of tachykinin antagonists of use in the present invention is that described in International Patent Specification No.
WO 95/14017, i.e. cornpounds of formula (XII) R
R
NH R (CO)p 1 1 (XII) or a pharmaceutically acceptable salt thereof, wherein i11 is zero, 1; 2 or 3; n is zero or 1; o is zero,l1or 2; p) is zero or 1; R is phenyl, 2- or 3-indolyl, 2- or 3-indolinyl, benzothienyl, benzofuranyl, or naphthyl; which R groups may be substituted with one or two halo, Cl-3alkoxy, trifluorom ethyl, C1- 4 alkyl, phenyl-CI.3alkoxy, or C1l4alkanoyl groups; R1 is trityl, phenyl, diphenylmethyl, phenoxy, phenylthio, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, indolinyl, indolyl, benzothienyl, hexamethyleneiminyl, benzofuranyl, tetrahydropyridinyl, quinolinyl, isoquinolinyl, reduced quinolinyl, reduced isoquinolinyl, phenyl-(C I.
4 alkyl)-, phenyl-(CI-4alkoxy)-, quinolinyl-(C 1-4alkyl)-, isoquinolinyl-(C i4alkyl)-, reduced quniolinyl-(C 1-4alkyl)-, reduced isoqui nolinyl-(CIl4alkyl)-, benzoyl-(C 1 -3alkyl C1-4alkyl, or -NH-CH 2 any one of which RI groups may be substituted with halo, Ci 4 alkyl, Cl4alkoxy, trifl uorom ethyl, amino, CI- 4 alkylamino, di(CI- 4 alkyl)amino, or C2- 4 alkanoylamino; WO 99/59635 WO 9959635PCT/G B99/O1 632 38 or any one of which RI groups may be substituted with phenyl, piperazinyl, C3-8CYCloalkyl, benzyl, CI-4alkyl, piperidinyl, pyridinyl, pyrimidinyl, C2.alkanoylamino, pyrrolidinyl, C2-6alkanoyl, or C 1-4alkoxycarbonyl; any one of which groups may be substituted with halo, CI- 4 alkyl, C i-4alkoxy, trifluoromethyl, amino, C 14alkylamino, di(C 1-4alkyl)amino, or C2-4alkanoylamino; or R 1 is amino, a leaving group, hydrogen, Cl-4alkylamino, or di(C -4alkyl)amino;,
R
5 is pyridyl, anilino-(Clv3alkyl)-, or anilinocarbonyl;
R
2 is hydrogen, C l4alkyl, C l-alkylsulfonyl, carboxy-(CI-3alkyl Cl-3alkoxycarbonyl-(Cl-3alkyl)-, or -CO-R 6
R
6 is hydrogen, C 1 4 alkyl, C 1.3haloalkyl, phenyl, C1l3alkoxy, C1.3hydroxyalkyl, amino, Cl-4alkylamino, di(CI-4alkyl)amino, or -(CH2)q-R 7 q is zero to 3;
R
7 is carboxy, C 1 4alkoxycarbonyl, C l4alkylcarbonyloxy, amino, C -4alkylamino, di(C 1 4 alkyl )amino, C 1-6alkoxycarbonylamino, or phenoxy, phenylthio, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, indolinyl, indolyl, benzothienyl, benzofuranyl, quinolinyl, phenyl-(C 1-4alkyl quinolinyl-(C I 4 alkyl isoquinolinyl-(C l4alkyl reduced quinolinyl- (Cl-4alkyl)-, reduced isoquinolinyl-(C I 4 alkyl)-, benzoyl-C 1-3alky1; any one of which aryl or heterocyclic R 7 groups may be substituted with halo, trifluoromethyl, C1I4alkoxy, CI-4alkyl, amino, Cl-4alkylamino, di(CI-4alkyl)amino, or C2-4alkanoylamino; or any one of which R 7 groups may be substituted with phenyl, piperazinyl, C3.8cycloalkyl, benzyl, piperidinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, C2-6alkanoyl, or C l4alkoxycarbonyl; any of which groups may be substituted withi halo, trifluoromethyl, amino, CI- 4 alkoxy, CI- 4 alkyl, CI-4alkylamino, di(CI- 4 alkyl)amino, or C24alkanoylamino;,
R
8 is hydrogen or Cl-6alkyl; WO 99/59635 PCT/GB99/01632 -39-
R
3 is phenyl, phenyl-(Ci-6alkyl)-, Ca.scycloalkyl, Cs-scycloalkenyl, Cl-alkyl, naphthyl, C2.8alkenyl, or hydrogen; any one or which groups except hydrogen may be substituted with one or two halo, C1.3alkoxy, Ci-3alkylthio, nitro, trifluoromethyl, or C1.3alkyl groups; and
R
4 is hydrogen or C-l3alkyl; with the proviso that if R 1 is hydrogen or halo, R 3 is phenyl, phenyl-(C -6alkyl)-, C3-8cycloalkyl, Cs-scycloalkenyl, or naphthyl.
A particularly preferred compound of formula (XII) is methoxybenzyl)acetylamino]-3-(1H-indol-3-yl)-2-[N-(2-(4-piperidin-1yl)piperidin-l-yl)acetylamino]propane; or a pharmaceutically acceptable salt thereof.
The preferred compounds of formulae (II) and (III) will have the 2- and 3-substituents on the morpholine ring in the cis arrangement, the preferred stereochemistry being as shown in the following general formula: O O N 2
R
Where the benzyloxy moiety is a-substituted, the preferred stereochemistry of the o-carbon is either when the substituent is an alkyl methyl) group or when the substituent is a hydroxyalkyl hydroxymethyl) group.
The preferred compounds of formula (IV) will have the stereochemistry of the 5- and 6-positions as shown below Where the optional double bond shown in formula (IV) is absent, the WO 99/59635 PCT/G B99/01632 40 particularly preferred compounds will have the stereochemistry of the 3-position as shown below 3- H
H
Unless otherwise defined herein, suitable alkyl groups include straight-chained and branched alkyl groups containing from 1 to 6 carbon atoms. Typical examples include methyl and ethyl groups, and straightchained or branched propyl and butyl groups. Particular alkyl groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl and tert-butyl.
Unless otherwise defined herein, suitable alkenyl groups include straight-chained and branched alkenyl groups containing from 2 to 6 carbon atoms. Typical examples include vinyl and allyl groups.
Unless otherwise defined herein, suitable alkynyl groups include straight-chained and branched alkynyl groups containing from 2 to 6 carbon atoms. Typical examples include ethynyl and propargyl groups.
Unless otherwise defined herein, suitable cycloalkyl groups include groups containing from 3 to 7 carbon atoms. Particular cycloalkyl groups are cyclopropyl and cyclohexyl.
Unless otherwise defined herein, suitable aryl groups include phenyl and naphthyl groups.
A particular aryl-Cl 6 alkyl, e.g. phenyl-Cl.-alkyl, group is benzyl.
Unless otherwise defined herein, suitable heteroaryl groups include pyridyl, quinolyl, isoquinolyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, furyl, benzofuryl, thienyl, benzthienyl, imidazolyl, oxadiazolyl and thiadiazolyl groups.
WO 99/59635 PCT/G B99/0 632 -41- The term "halogen" as used herein includes fluorine, chlorine, bromine and iodine.
Suitable pharmaceutically acceptable salts of the NK-1 receptor antagonists of use in the present invention include acid addition salts which may, for example, be formed by mixing a solution of the compound with a solution of a pharmaceutically acceptable non-toxic acid such as hydrochloric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid or sulphuric acid. Salts of amine groups may also comprise the quaternary ammonium salts in which the amino nitrogen atom carries an alkyl, alkenyl, alkynyl or aralkyl group. Where the compound carries an acidic group, for example a carboxylic acid group, the present invention also contemplates salts thereof, preferably non-toxic pharmaceutically acceptable salts thereof, such as the sodium, potassium and calcium salts thereof.
The compounds of use in this invention may have one or more chiral centers and the present compounds may occur as racemates, racemic mixtures and as individual diasteriomers or enantiomers with all such isomeric forms and mixtures thereof being included within the scope of this invention. Furthermore, some of the crystalline forms for compounds of the present invention may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds of the instant invention may form solvates with water or common organic solvents. Such solvates and hydrates, as well as anhydrous compositions, are encompassed within the scope of this invention. Some of the compounds described herein may contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers.
The COX-2 inhibitors that may be used with this invention encompass all pharmaceutically acceptable salt forms of the compounds.
Examples of such salt forms of COX-2 inhibitors include but are not limited to salts derived from inorganic bases including aluminum, WO 99/59635 PCT/G B99/01632 -42 ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like.
Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
The instant pharmaceutical combination comprising a COX-2 inhibitor in combination with a NK-1 receptor antagonist includes administration of a single pharmaceutical dosage formulation which contains both the COX-2 inhibitor and the NK-1 receptor antagonist, as well as administration of each active agent in its own separate pharmaceutical dosage formulation. Where separate dosage formulations are used, the COX-2 inhibitor and the NK-1 receptor antagonist can be administered at essentially the same time, concurrently, or at separately staggered times, i.e, sequentially. The instant pharmaceutical combination is understood to include all these regimens. Administration in these various ways are suitable for the present invention as long as the beneficial pharmaceutical effect of the COX-2 inhibitor and the NK-1 receptor antagonist are realized by the patient at substantially the same time. Such beneficial effect is preferably achieved when the target blood level concentrations of each active drug are maintained at substantially the same time. It is preferred that the COX-2 inhibitor and the NK-1 receptor antagonist be co-administered concurrently on a once-a-day WO 99/59635 PCT/GB99/01632 43 dosing schedule; however, varying dosing schedules, such as the COX-2 inhibitor once, twice or more times per day and the NK-1 receptor antagonist once per day, is also encompassed herein. A single oral dosage formulation comprised of both the COX-2 inhibitor and the NK-1 receptor antagonist is preferred. A single dosage formulation will provide convenience for the patient, which is an important consideration especially for patients who already have an inflammatory disorder such as rheumatoid arthritis and may be in need of multiple medications.
The term "therapeutically effective amount" is intended to mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, a system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician. The term "prophylactically effective amount" is intended to mean that amount of a pharmaceutical drug that will prevent or reduce the risk of occurrence of the biological or medical event that is sought to be prevented in a tissue, a system, animal or human by a researcher, veterinarian, medical doctor or other clinician. The dosage regimen utilizing a COX-2 inhibitor in combination with a NK-1 receptor antagonist is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt or ester thereof employed. Since two different active agents are being used together in a combination therapy, the potency of each of the agents and the interactive effects achieved by combining them together must also be taken into account. A consideration of these factors is well within the purview of the ordinarily skilled clinician for the purpose of determining the therapeutically effective or prophylactically effective dosage amounts needed to prevent, counter, or arrest the progress of the condition.
The term "patient" includes mammals, especially humans, who take a COX-2 inhibitor in combination with a NK-1 receptor antagonist for any WO 99/59635 PCT/G B99/0 1632 -44of the uses described herein. Administering of the drug combination to the patient includes both self-administration and administration to the patient by another person.
The inhibitor of cyclooxygenase-2 may be administered at a dosage level up to conventional dosage levels for NSAIDs. Suitable dosage levels will depend upon the antiinflammatory effect of the chosen inhibitor of cyclooxygenase-2, but typically suitable levels will be about 0.001 to mg/kg per day, preferably 0.005 to 30mg/kg per day, and especially 0.05 to per day. The compound may be administered on a regimen of up to 6 times per day, preferably 1 to 4 times per day, and especially once per day.
A suitable dosage level for the NK-1 receptor antagonist is about 0.05 to 1500mg per day, preferably about 0.25 to 1500mg per day, and especially about 0.25 to 500mg/kg per day. The compounds may be administered on a regimen of up to 6 times per day, preferably 1 to 4 times per day, especially 1 or 2 times daily.
The active agents employed in the instant combination therapy can be administered in such oral forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. The instant invention includes the use of both oral rapid-release and timecontrolled release pharmaceutical formulations. A particular example of an oral time-controlled release pharmaceutical formulation is described in U.S Patent No. 5,366,738. Oral formulations are preferred. Such pharmaceutical compositions are known to those of ordinary skill in the pharmaceutical arts; for example, see Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA.
In the methods of the present invention, the active agents are typically administered in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as "carrier" materials) suitably selected with respect to the intended form of WO 99/59635 PCT/G B99/01632 administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.
For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with a non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, modified sugars, modified starches, methyl cellulose and its derivatives, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and other reducing and non-reducing sugars, magnesium stearate, steric acid, sodium stearyl fumarate, glyceryl behenate, calcium stearate and the like.
For oral administration in liquid form, the drug components can be combined with non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring and flavoring agents can also be incorporated into the mixture.
Stabilizing agents such as antioxidants (BHA, BHT, propyl gallate, sodium ascorbate, citric acid) can also be added to stabilize the dosage forms. Other suitable components include gelatin, sweeteners, natural and synthetic gums such as acacia, tragacanth or alginates, carboxymethylcellulose, polyethylene glycol, waxes and the like.
The active drugs can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
Active drug may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. Active drug may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy-propyl-methacrylamide-phenol, polyhydroxy-ethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, active drug may be WO 99/59635 PCT/G B99/01632 -46coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels.
Although the active agents of the present method may be administered in divided doses, for example two or three times daily, a single daily dose of each of the COX-2 inhibitor and the NK-1 receptor antagonist is preferred, with a single daily dose of both agents in a single pharmaceutical composition being most preferred.
The instant invention also encompasses a process for preparing a pharmaceutical composition comprising combining the COX-2 inhibitor and the NK-1 receptor antagonist with a pharmaceutically acceptable carrier, as well as the pharmaceutical composition which is made by combining the COX-2 inhibitor and the NK-1 receptor antagonist with a pharmaceutically acceptable carrier.
A therapeutically effective amount of a COX-2 inhibitor and a NK-1 receptor antagonist can be used together for the preparation of a medicament useful for preventing or reducing the risk of developing an inflammatory disorder such as rheumatoid arthritis, halting or slowing the progression of an inflammatory disorder such as rheumatoid arthritis, once it has become clinically manifest, and preventing or reducing the risk of a first or subsequent occurrence of an inflammatory disorder such as rheumatoid arthritis. For example, the medicament may be comprised of a COX-2 inhibitor in combination with about 1 mg to 300 mg of a NK-1 receptor antagonist, or more particularly about 3 mg to 100 mg of the NK-1 receptor antagonist. More specific amounts of NK-1 receptor antagonist which may be used in the medicament preparation include 1 mg, 3 mg, 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg and 300 mg, as well as sub-milligram amounts of NK-1 receptor antagonists which have WO 99/59635 PCT/G B99/01632 -47 sufficient potency at such levels. As a further example, the medicament may be comprised of a NK-1 receptor antagonist, for example, at the above dosages, in combination with about 0.1 to 20 mg of a COX-2 inhibitor.
The instant invention also encompasses the use of a NK-1 receptor antagonist for the manufacture of a medicament for the combined use with a cyclooxygenase-2 inhibitor for preventing or reducing the risk of developing an inflammatory disorder, for halting or slowing the progression of an inflammatory disorder, or for preventing or reducing the risk of occurrence or recurrence of an inflammatory disorder; and the use of a cyclooxygenase-2 inhibitor for the preparation of a medicament for the combined use with a NK-1 receptor antagonist for preventing or reducing the risk of developing an inflammatory disorder, for halting or slowing the progression of an inflammatory disorder, or for preventing or reducing the risk of occurrence or recurrence of an inflammatory disorder.
The compounds of formulae (III), (VII), (VIII), (XI) and (XII) may be prepared by the methods described in EP-A-0 577 394 (or WO 95/16679), WO 95/18124, WO 95/23798, WO 97/49710, EP-A-0 436 334, WO 93/21155, EP-A-0 591 040, EP-A-0 532 456, EP-A-0 443 132, WO 92/17449, WO 95/08549 and WO 95/14017, respectively.
Particularly preferred NK-1 receptor antagonists of the formulae (III), (VII), (VIII), (XI) and (XII) for use in the present invention are compounds which are potent NK-1 receptor antagonists, i.e. compounds with an NK-1 receptor affinity (ICso) of less than 100nM. Most preferred are compounds of formulae (III) and
(IV).
Even more preferred NK-1 receptor antagonists of use in the present invention are compounds which are potent NK-1 receptor antagonists with an NK-1 receptor affinity (ICso) of less than favourably less than 2nM and preferably less than InM.
WO 99/59635 PCT/GB99/01632 -48- Especially preferred NK-1 receptor antagonists of use in the present invention are orally active, long acting, CNS-penetrant NK-1 receptor antagonists, identified using a combination of the following assays: ASSAY 1: NK-1 Receptor binding NK-1 receptor binding assays are performed in intact Chinese hamster ovary (CHO) cells expressing the human NK-1 receptor using a modification of the assay conditions described by Cascieri et al, J.
Pharmacol. Exp. Ther., 1992, 42, 458. Typically, the receptor is expressed at a level of 3x10 5 receptors per cell. Cells are grown in monolayer culture, detached from the plate with enzyme-free dissociation solution (Speciality Media Inc.), and washed prior to use in the assay. 125 1-TyrSsubstance P (0.lnM, 2000Ci/mmol; New England Nuclear) is incubated in the presence or absence of test compounds (dissolved in 51 dimethylsulphoxide, DMSO) with 5x10 4 CHO cells. Ligand binding is performed in 0.25ml of 50mM Tris-HC1, pH7.5, containing 5mM MnC1 2 150mM NaC1, 0.02% bovine serum albumin (Sigma), 50ig/ml chymostatin (Peninsula), 0.1nM phenylmethylsulphonyl fluoride, 2ag/ml pepstatin, 2pg/ml leupeptin and 2.8pg/ml furoyl saccharine. The incubation proceeds at room temperature until equilibrium is achieved (>40 minutes) and the receptor-ligand complex is harvested by filtration over GF/C filters presoaked in 0.1% polyethylenimine using a Tomtek 96-well harvester. Nonspecific binding is determined using excess substance P (ilM) and represents <10% of total binding.
ASSAY 2: Gerbil Foot-Tapping CNS-penetrant NK-1 receptor antagonists for use in the present invention can be identified by their ability to inhibit foot tapping in gerbils induced by central infusion of NK-1 receptor agonists such as GR73632, WO 99/59635 PCT/GB99/01632 -49based on the method of Rupniak Williams, Eur. J. Pharmacol., 1994, 265, 179.
Male or female Mongolian gerbils (35-70g) are anaesthetised by inhalation of an isoflurane/oxygen mixture to permit exposure of the jugular vein in order to permit administration of test compounds or vehicle in an injection volume of approximately 5ml/kg i.v. Alternatively, test compounds may be administered orally or by subcutaneous or intraperitoneal routes. A skin incision is then made in the midline of the scalp to expose the skull. The selective NK-1 receptor agonist (e.g.
GR73632 (d Ala[L-Pro 9 ,Me-Leu 1]-substance is infused directly into the cerebral ventricles 3pmol in 5pl depending on test substance) by vertical insertion of a cuffed 27 gauge needle to a depth of below bregma. The scalp incision is closed and the animal allowed to recover from anaesthesia in a clear perspex observation box (approximately 25cm x 20cm x 20cm). The duration and/or intensity of hind foot tapping is then recorded continuously for approximately minutes.
ASSAY 3: Ferret Emesis Individually housed male ferrets (1.0 -2.5 kg) are dosed orally by gavage with test compound. Ten minutes later they are fed with approximately 100g of tinned cat food. At 60 minutes following oral dosing, cisplatin (10mg/kg) is given i.v. via a jugular vein catheter inserted under a brief period of halothane anaesthesia. The catheter is then removed, the jugular vein ligated and the skin incision closed. The ferrets recover rapidly from the anaesthetic and are mobile within 10-20 minutes. The animals are observed continuously during recovery from the anaesthetic and for 4 hours following the cisplatin injection, after which time the animals are killed humanely. The numbers of retches and vomits occurring during the 4 hours after cisplatin administi-ation are recorded by trained observers.
WO 99/59635 PCT/G B99/01632 ASSAY 4: Footpad FCA Guinea Pig Model Male Dunkin Hartly guinea pigs (180g-200g) are housed in groups in a twelve hour dark/light cycle and given vitamin C supplemented food and water ad libitum. Inflammation is induced by injection of 100pl Freunds Complete Adjuvant (FCA) into the right hind footpad. The FCA is composed of 10mg/ml heat killed mycobacterium blended with sterile paraffin. For the purposes of the study 6 animals are included in each treatment group and are dosed with experimental compounds as provided on a daily basis.
Inflammation is assessed as follows: 1. The diameter of the hind footpads is measured with vernier calipers at a consistent mid plantar site.
2. Measurement of thermal hyperalgesia is determined by the Hargreaves Method on unrestrained animals. The method determines the withdrawal latency to an infra-red source (Ugo Basile). Hyperalgesia is assessed 4 hours after dosing.
3. Mechanical hyperalgesia is assessed using the Ugo Basile analgesymeter according to the Randall-Selitto test. Force is applied onto the foot pad at a designated site increasing at 4.8g per second.
Hyperalgesia is assessed 4 hours after dosing.
A suitable selection cascade for NKI antagonists of use according to the present invention is as follows: Determine affinity for human NK 1 receptor in radioligand binding studies (Assay select compounds with IC 5 o 10nM, preferably ICso 2nM, especially IC 5 o InM.
WO 99/59635 PCT/GB99/01632 -51- (ii) Determine ability of compounds to penetrate CNS by their ability to inhibit foot tapping in gerbils induced by central injection of an NKi agonist (Assay select compounds that inhibit foot tapping with
ID
50 3mg/kg and preferably ID 50 1mg/kg i.v. when administered immediately prior to central NKI agonist challenge, or ID 50 3 0mg/kg p.o., and preferably ID 5 o 10mg/kg p.o. 1 hour prior to challenge.
(iii) Determine central duration of action of compounds in gerbil foot tapping assay following intravenous administration 24 hours prior to central NK 1 agonist challenge; select compounds showing 25-fold loss of potency compared with ID 5 o determined in step (ii) above with the proviso that ID 0 o 10mg/kg and preferably 5mg/kg i.v. after 24 hour pre-treatment.
(iv) Determine oral bioavailability of compounds by pharmacokinetic analysis, activity in gerbil foot tapping assay following oral administration and/or by ability to inhibit cisplatin-induced emesis in ferrets (Assay select compounds with ID 90 3mg/kg and preferably
ID
9 0 I1mg/kg p.o.
Particularly preferred compounds of use in the present invention are identified using steps to (iv) followed by step Determine activity of compounds in assays for inhibition of pharmacologically evoked foot tapping in gerbils and/or inhibition of adjuvant arthritis in guinea-pigs (Assay Select compounds with ID 50 and preferably IDso Yet further preferred compounds of use in the present invention may be selected from those compounds which satisfy the NK-1 receptor binding criteria of step which, in addition, have 5-fold shift in affinity when incubated in the presence of human serum albumin (HSA) to show non-specific protein binding.
One example of a NK-1 receptor antagonist of use in the present invention is the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)- WO 99/59635 PCT/GB99/01632 -52 ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(5-oxo- H,4H-1,2,4-triazolo)methyl)morpholine, the preparation of which is described in International Patent Specification No. WO 95/16679. In the aforementioned assays, this compound has the following activity: human NK-1 receptor binding: ICso=0.1nM gerbil foot-tapping (5 mins.): ID50=0.36mg/kg i.v.
gerbil foot-tapping (24 hrs.): IDso=0.33mg/kg i.v.
ferret emesis: ID9o<3mg/kg p.o.
Another example of a NK-1 receptor antagonist of use in the present invention is the compound bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N,N-dimethylamino)methyl-1,2,3triazol-4-yl)methyl-3-(S)-phenylmorpholine, the preparation of which is described in International Patent Specification No. WO 95/18124. In the aforementioned assays, this compound has the following activity: human NK-1 receptor binding: IC 5 o=0.25nM gerbil foot-tapping (5 mins.): IDso=0.12mg/kg i.v.
gerbil foot-tapping (24 hrs.): IDso=0.17mg/kg i.v.
Especially preferred COX-2 inhibitors of use in the present invention are identified using the following one or more of the following selection criteria: Determine the affinity for human COX-2 in whole cell assay; select compounds with ID5 0 <40nM, and preferably ID 50 (ii) Determine oral bioavailability of compounds by pharmacokinetic analysis or inhibition of carrageenan-induced paw oedema in rats following oral administration. Select compounds with and preferably ED5o<2.5mg/kg p.o.
WO 99/59635 PCT/G B99/01632 -53- (iii) Determine the ability of compounds to induce gastric ulceration or increase in faecal 51 Cr excretion. Select compounds that have no adverse gastrointestinal effects at >100mg/kg when administered up to two times a day.
(iv) Determine antinociceptive effects of compounds in carrageenan-induced hyperalgesia in rats; select compounds with and preferably EDso52.5mg/kg p.o.
Determine the affinity for COX-2 in human whole blood assay which is used as an index for biochemical efficacy in the clinic and select compounds with ICsoIIpM for inhibition of PGE 2 The following examples illustrate pharmaceutical compositions according to the invention.
These formulations may be prepared with separate active ingredients or with a combination of active ingredients in one composition.
In such combined preparations, the ratio of the COX-2 inhibitor and the NK-1 receptor antagonist will depend upon the choice of active ingredients.
EXAMPLE 1 Amount (mg) per tablet NK-1 receptor antagonist 50.0 100.0 300.0 Microcrystalline cellulose 80.0 80.0 80.0 Modified food corn starch 80.0 80.0 80.0 Lactose 189.5 139.5 139.5 Magnesium Stearate 0.5 0.5 The active ingredient, cellulose, lactose and a portion of the corn starch are mixed and granulated with 10% corn starch paste. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate. The resulting granulation is WO 99/59635 PCT/GB99/01632 -54then compressed into tablets containing 50mg, 100mg and 3 0 0 mg of the NK-1 receptor antagonist per tablet.
NK-1 receptor antagonist COX-2 inhibitor Microcrystalline cellulose Modified food corn starch Lactose Magnesium Stearate EXAMPLE 2 Amount (mg) per tablet 50.0 100.0 300.0 20.0 20.0 20.0 80.0 80.0 80.0 80.0 80.0 80.0 169.5 119.5 119.5 0.5 0.5 The active ingredients, cellulose, lactose and a portion of the corn starch are mixed and granulated with 10% corn starch paste. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate. The resulting granulation is then compressed into tablets containing 20mg of the COX-2 inhibitor and 100mg and 300mg of the NK-1 receptor antagonist per tablet.
EXAMPLE 3 Wet granulated tablet composition COX-2 Inhibitor Microcrystalline cellulose Lactose monohydrate Hydroxypropyl cellulose Croscarmellose sodium Iron oxide Magnesium stearate 2 79 79 0 Amount (mg) !5 12.5 .7 86 .7 86 6 6 8 8 .6 0.6 per tablet 10 87.2 87.2 6 8 0.6 1 89.7 89.7 6 8 0.6 1 WO 99/59635 PCT/GB99/01632 Tablet dose strengths of between 5 and 25 mg can be accomodated by varying total tablet weight, and the ratio of the first three ingredients.
Generally it is preferable to maintain a 1:1 ratio for microcrystalline cellulose:lactose monohydrate.
EXAMPLE 4 Directly compressed tablet composition Amount (mg) per tablet COX-2 Inhibitor 25 12.5 10 Microcrystalline cellulose 106.9 113.2 42.5 Lactose anhydrate 106.9 113.2 42.5 Crosmellose sodium 7.5 7.5 4 4 Magnesium stearate 3.7 3.7 1 1 Tablet dose strengths of between 5 and 25 mg can be accomodated by varying total tablet weight, and the ratio of the first three ingredients.
Generally it is preferable to maintain a 1:1 ratio for microcrystalline cellulose:lactose monohydrate.
EXAMPLE Hard gelatin capsule composition Amount (mg) per capsule COX-2 Inhibitor Microcrystalline cellulose 37 Lactose anhydrate 37 Magnesium stearate 1 Hard gelatin capsule 1 capsule Capsule dose strengths of between 1 and 50 mg can be accomodated by varying total fill weight, and the ratio of the first three ingredients.
WO 99/59635 PCT/GB99/01632 -56- Generally it is preferable to maintain a 1:1 ratio for microcrystalline cellulose lactose monohydrate.
EXAMPLE 6 Oral solution Amount per 5 ml dose COX-2 Inhibitor 50 mg Polyethylene oxide 400 to 5 ml Solution dose strengths of between 1 and 50 mg/5ml can be accomodated by varying the ratio of the two ingredients.
EXAMPLE 7 Oral suspension Amount per 5 ml dose COX-2 Inhibitor 100 mg Polyvinylpyrrolidone 150 mg Polyoxyethylene sorbitan monolaurate 2.5 mg Benzoic acid 10 mg sorbitol solution to 5 ml Suspension dose strengths of between 1 and 50 mg/5ml can be accomodated by varying the ratio of the first two ingredients.
EXAMPLE 8 Intravenous infusion Amount per 200ml dose COX-2 inhibitor 1 mg Polyethylene oxide 400 0.2 mg Sodium chloride 1.8 mg Purified water to 2 00ml WO 99/59635 PCT/GB99/0 1632 -57- While the invention has been described and illustrated with reference to certain particular embodiments thereof, those skilled in the art will appreciate that various changes, modifications and substitutions can be made therein without departing from the spirit and scope of the invention. For example, effective dosages other than the particular dosages as set forth herein above may be applicable as a consequence of variations in the responsiveness of the mammal being treated for any of the indications for the active agents used in the instant invention as indicated above. Likewise, the specific pharmacological responses observed may vary according to and depending upon the particular active compound selected or whether there are present pharmaceutical carriers, as well as the type of formulation and mode of administration employed, and such expected variations or differences in the results are contemplated in accordance with the objects and practices of the present invention. It is intended, therefore, that the invention be defined by the scope of the claims which follow and that such claims be interpreted as broadly as is reasonable.
Claims (8)
1. Use of a selective COX-2 inhibitor and a NK-1 receptor antagonist for the manufacture of a medicament for the treatment or prevention of an inflammatory disorder, wherein said selective COX-2 inhibitor is selected from the group consisting of:
3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone; 3 4 -difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(SH)-furanone; 5,5-dimethyl-4-(4-(methylsulfonyl)pheny1)-3-(3-fluorophenyl)-5H-.firan2- 10 one; ,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-3-(2-propoxy)..sHuran-2one;
5-chloro-3-( 4 -(methylsulfonyl)phenyl)-2-(2-methyl.s.pyridinyl)pyidine; 2 3 ,5-difluorophenyl)-3-(4-(methylsulfonyl)phenyl)-2-cyclopenten.. -one; S(S)-5-ethyl- 5 -methyl-4-(4-(methylsulfonyl)phenyl)3-(2-propoxy)-5.H. furan-2-one; 5-ethyl-5-methyl-4-(4-(methylsulfonyl)phenyl)3.(3,4.difluorophenyl).SH furan-2-one; 3 2 -thiazolyl)methoxy)-4-(4-(methylsulfonyl)phenyl).s,s.dimethyl.5H- furan-2-one; .20 3 -propyloxy- 4 -(4-(methylsulfonyl)phenyl)-,..dimethylsHfuran2-one; l-cyclopropylethoxy)-5,5-dimethyl-4-(4-methylsulfonyl)phenyl).5H- furan-2-one; 3 -(cyclopropylmethoxy)-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl).SH. dirfuran-2-o 3 -(cyopropyoxy)-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)..2,s..dofuan 2-ol; -59- 5,5-dimethy1-3-(3-fluoropheny)-2-hydroxy-4-(4-(methysufony)pheny). 5-chloro-3-(4-(methylsulfonyl)phenyl)-2-(3-pyridinyl)pyridine; 4 -(5-methyl- 3 -phenyl-4-isoxazolyl)benzenesulfonamide; 5-(4-fluorophenyl)-1- [4-(methylsulfonyl)phenyl] -3- (trifluoromethyl)pyrazole; 4-(4-fluorophenyl)-5- [4-(methylsulfonyl)phenyl] -1-phenyl-3- (trifluoromethyl)pyrazole; 4 4 -chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-1- yl)benzenesulfonamiide; 4-(3,5-bis(4-methylphenyl)- 1H-pyrazol-1-yl)benzenesulfonamide; 9999 4 4 -chlorophenyl)-3-phenyl-1H-pyrazol-1-yl)benzenesulfonamide; 4-39bs4mthxpey)l*yrzl1y**zeeufnnie 4 4 -chlorophenyl)-3-(4-methylphenyl)- 1H-pyrazol-1- yl)benzenesulfonamide; 4 4 -chlorophenyl)-3-(4-nitrophenyl)-lH-pyrazol-l- yl)benzenesulfonamide; 4 4 -chlorophenyl)-3-(5-chloro-2-thienyl)-lH-pyrazol-l-.. yl)benzenesulfonamide;, 4 -(4-chloro-3,5-diphenyl- 1H-pyrazol-1-yl)benzenesulfonamide; 4 4 -chloropheny1)-3-(trifluoromethy)-lH-pyrazol-l- yl)benzenesulfonamide; 4 -(5-phenyl)-3-(trifluoromethyl)-1H-pyrazol-1..yl)benzenesulfonamide; 4 4 -fluorophenyl)-3-(trifluoromethyl)- 1H-pyrazol- 1- yl)benzenesulfonamide; 4 4 -methoxyphenyl)-3-(trifluoromethyl)- 1H-pyrazol-1- yl)benzenesulfonamide; 4 -(5-(4-chlorophenyl)-3-(difluoromethyl)- 1H-pyrazol-1- yl)benzenesulfonamide; 4 4 -methylphenyl)-3-(trifluoromethyl)-lH-pyrazol-l yl)benzenesulfonamide; 60 4 -(4-chloro-5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1- ylbenzenesulfonamide; 4 -(3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol-1- yl)benzenesulfonamide; 4-(3-(difluoromethyl)-5-phenyl-1H-pyrazol-1-yl)benzenesulfonamide; 4-(3-(difluoromethyl)-5-(4-methoxyphenyl)-1H-pyrazol-l- yl)benzenesulfonamide; 4 -(3-cyano-5-(4-fluorophenyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4 -(3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)- 1H-pyrazol-1- yl)benzenesulfonamide; 4 -(5-(3-fluoro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-l- S...yl)benzenesulfonamide; SS 4 4 -chloro-5-phenyl-1H-pyrazol-1-yl)benzenesulfonainide; 4 -(5-(4-chlorophenyl)-3-(hydroxyphenyl)-1H-pyrazol-l- yl)benzenesulfonamide; 4 4 -(N,N-dimethylamino)phenyl)-3-(trifluoromethyl)-1H-pyrazol- 1- yl)benzenesulfonamide; **Sa 5-( 4 -fluorophenyl)-6-(4-(methylsulfonyl)phenyl)spiro 4-(6-(4-fluorophenyl)spiro [2.4]hept-5-en-5-yl)benzenesulfonainide; 6 4 -fluorophenyl)-7-(4-(methylsulfonyl)phenyl)spiro [3 .4]oct-6-ene; a 0 3 -chloro-4-methoxyphenyl)-6-(4-(methylsulfonyl)phenyl)spiro [2.4]hept- 1.a. 4 -(6-(3-chloro-4-methoxyphenyl)spiro yl)benzenesulfonamide; 5-(3,5-dichloro-4-methoxyphenyl)-6-(4-(methylsulfonyl)phenyl)- spiro [2.4lhept-5-ene; 3 -chloro-4-fluorophenyl)-6-(4-(methylsulfonyl)phenyl)spiro ene; 4-(6-(3,4-dichlorophenyl)spiro 2 -(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-(4- methylsulfonylphenyl)thiazole; 61 2-(2-chlorophenyl)-4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)thiazole; 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-methylthiazole; 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-trifluoromethylthiazole; 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(2-thienyl)thiazole; 4-(4-fluorophenyl)-5-(4-methylsulfonylpheny1)-2-benzylaminothiazole; 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-( 1-propylamino)thiazole; 2-((3,5-dichlorophenoxy)methyl)-4-(4-fluorophenyl)-5-(4- (methylsulfonyl)phenyl)thiazole; 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-trifluoromethylthiazole; 1-methylsulfonyl-4-(1 ,1-dimethyl-4-(4-fluorophenyl)cyclopenta-2,4-dien-3- yl)benzene; 4-(4-(4-fluorophenyl)-1 ,1-dimethylcyclopenta-2,4-dien-3- yl)benzenesulfonamide; 0 5-(4-fluorophenyl)-6-(4-(methylsulfonyl)phenyl)spiro hepta-4,6-diene; 4-(6-(4-fluorophenyl)spiro [2.4lhepta-4,6-dien-5-yl)benzenesulfonamide;
6-(4-fluorophenyl)-2-methoxy-5-(4-(methylsulfonyl)phenyl)-pyridine-3- carbonitrile; 2-bromo-6-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)-pyridine-3- carbonitrile; 6-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)-2-phenyl-pyridine-3- carbonitrile; 4-(2-(4-methylpyridin-2-yl)-4-(trifluoromethyl)-1H-imidazol-1- yl)benzenesulfonamide; 4-(2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1- yl)benzenesulfonamide; 4-(2-(2-methylpyridin-3-yl)-4-(trifluoromethyl)- 1H-imidazol- 1- yl)benzenesulfonamide; 1-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)-1H-imidazol-2- yl)benzenesulfonamide; 1-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)- 1H-imidazol-2- yl)pyridine; 62 2 -methyl-4-(1-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)-lH-imidazol- 2-yl)pyridine; 2 -methyl-6-(1-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)-1H-imidazol- 2-yl)pyridine; 4 -(2-(6-methylpyridin-3-yl)-4-(trifluoromethyl)- 1H-imidazol-1- yl)benzenesulfonamide; 2 4 -difluorophenyl)-l-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)-lH- imidazole; 4-(2-(4-methylphenyl)-4-(trifluoromethyl)-lH-imidazol-l- yl)benzenesulfonamide; 2 4 -chlorophenyl)-1-(4-(methylsulfonyl)phenyl)-4-methyl-lH-iniidazole; 2 4 -chlorophenyl)-1-(4-(methylsulfonyl)phenyl)-4-phenyl-1H-imidazole; 2-(4-chlorophenyl)-4-(4-fluorophenyl)- 1-(4-(methylsulfonyl)phenyl)-1H- imidazole; 2-(3-fluoro-4-methoxyphenyl)- 1-(4-(methylsulfonyl)phenyl)-4- (trifluoromethyl)-1H-imidazole; l-(4-(methylsulfonyl)phenyl)-2-phenyl-4-trifluoromethyl-lH-imidazole; 2 4 -methylphenyl)-1-(4-(methylsulfonyl)phenyl)-4-trifluoromethyl- 1H- imidazole; 20 4 -(2-(3-chloro-4-methylphenyl)-4-(trifluoromethyl)- 1H-imidazol-1- yl)benzenesulfonamide; 2-(3-fluoro-5-methylphenyl)-1-(4-(methylsulfonyl)phenyl)-4- (trifluoromethyl)-1H-imidazole; 4 2 -(3-fluoro-5-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1- yl)benzenesulfonamide; 2 3 -methylphenyl)-1-(4-(methylsulfonyl)phenyl).4-(trifluoromethyl)-lH- imidazole; 4-(2-(3-methylphenyl)-4-(trifluoromethyl)- 1H-imidazol-1- yl)benzenesulfonamide; l-( 4 -(methylsulfonyl)phenyl)-2-(3-chlorophenyl)-4-(trifluoromethyl)-lH- ~Tr~.\i~dazole; 63 4-(2-(3-chlorophenyl)-4-(trifluoromethyl)- 1H-imidazol-1- yl)benzenesulfonamide; 4 -(2-phenyl-4-(trifluoromethyl)-1H-imidazol-1-yl)benzenesulfonamide; 4 2 -(4-methoxy-3-chlorophenyl)-4-(trifluoromethyl)- 1H-imidazol-1- yl)benzenesulfonamide; l-allyl- 4 -(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-5-(trifluoromethyl). 1H-pyrazole; 4 -(1-ethyl-4-(4-fluorophenyl)-5-(trifluoromethyl)- 1H-pyrazol-3- yl)benzenesulfonamide; N-phenyl-(4-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-5- (trifluoromethyl)-1H-pyrazol-1-yl)acetainide; ethyl 4 -(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-5-(trifluoromethyl)- 1H-pyrazol-1-yl)acetate; 4 -(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)- 1-(2-phenylethyl)-1H- pyrazole; 4 -(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)- 1-(2-phenylethyl)-5- (trifluoromethyl)pyrazole; l-ethyl- 4 -(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl).5.(trifluoromethyl)- 1H-pyrazole; 20 5-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(trifluoromethyl)-1H- imidazole; 0. 4-(4-(methylsulfonyl)phenyl)-5-(2-thiophenyl)-2-(trifluoromethyl)-lH- 0. 0.:imidazole; 4 -fluorophenyl)-2-methoxy-4-(4-(methylsulfonyl)phenyl)-6- (trifluoromethyl)pyridine; 2 -ethoxy-5-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-6. (trifluoromethyl)pyridine; 4 -fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(2-propynyloxy)-6- (trifluoromethyl)pyridine; 2-bromo-5-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)6. (trifluoromethylpyridine; -64- 4-(2-(3-chloro-4-methoxyphenyl)-4,5-difluorophenyl)benzenesulfonanide; 1-(4-fluorophenyl)-2-(4-(methylsulfonyl)phenyl)benzene; 5-difluoromethyl-4-(4-(methylsulfonyl)phenyl)-3-phenylisoxazole; 4-(3-ethyl-5-phenylisoxazol-4-yl)benzenesulfonamide; 4-(5-difluoromethyl-3-phenylisoxazol-4-yl)benzenesulfonamide; 4-(5-hydroxymethyl-3-phenylisoxazol-4-yl)benzenesulfonamide; 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide; 1-(2-(4-fluorophenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 1-(2-(4-fluoro-2-methylphenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 1-(2-(4-chlorophenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 1-(2-(2,4-dichlorophenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 1-(2-(4-trifluoromethylphdnyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 1-(2-(4-methylthiophenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 1-(2-(4-fluorophenyl)-4,4-dimethylcyclopenten- 1-yl)-4- (methylsulfonyl)benzene; 4 -(2-(4-fluorophenyl)-4,4-dimethylcyclopenten-1-yl)benzenesulfonamide; 1-(2-(4-chlorophenyl)-4,4-dimethylcyclopenten- l-yl)-4- (methylsulfonyl)benzene; 4-2(-hoohny)44dmtycylpne-*lbeznsloaie 4 -(2-(4-lorophenyl)-44dtycyclopenten-1-yl)benzenesulfona inide; 4 -(2-(4-lorophenyl)cyclopenten-1-yl)benzenesulfonamide; 4 -(2-(4-loromexphenyl)cyclopenten-1-yl)benzenesulfonamide; 1-(2-(3-ho4-methoxyphenyl)cyclopenten- 1-yl)-4-ylufnLbzn; l- 2 (,-iloohnlccoetn1y)4(methylsulfonyl)benzene; 4 -(2-(3-loro-4-metophenyl)cyclopenten-1-yl)benzenesulfonamide; 4 -(2-(2-methylpyridin-5-yl)cyclopenten-1-yl)benzenesulfonamide; ethyl 2-(4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazol-2-yl)-2- benzyl-acetate; 2 -(4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazol-2-yl)acetic acid; 65 2-(tert-butyl)-4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazole; 4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)-2-phenyloxazole; 4-(4-fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)phenyl)oxazole; and 4-(5-(3-fluoro-4-methoxyphenyl)-2-trifluoromethyl-4- oxazolyl)benzenesulfonamide; or a pharmaceutically acceptable salt thereof. 2. A pharmaceutical composition for the treatment or prevention of an inflammatory disorder comprising a selective COX-2 inhibitor and a NK-1 receptor antagonist, together with at least one ::.pharmaceutically acceptable carrier or excipient, wherein said selective COX-2 inhibitor is selected from the group consisting of: 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone; 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone; 5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-3-(3-fluorophenyl)-5H-furan-2- one; 5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-3-(2-propoxy)-5H-furan-2-one; 5-chloro-3-(4-(methylsulfonyl)phenyl)-2-(2-methyl-5-pyridinyl)pyridine; 2 3 ,5-difiuorophenyl)-3-(4-(methylsulfonyl)phenyl)-2-cyclopenten- 1-one; 20 5(S)-5-ethyl-5-methyl-4-(4-(methylsulfonyl)phenyl)-3-(2-propoxy)-5H- furan-2-one; S-ethyl-S -methyl-4-(4-(methylsulfonyl)phenyl)-3-(3,4-difluorophenyl)-5H- furan-2-one; 3 2 -thiazolyl)methoxy)-4-(4-(methylsulfonyl)phenyl)-5,5-.dimethyl-5H- furan-2-one; 3 -propyloxy-4-(4-(methylsulfonyl)phenyl)-5,5-dimethyl-5H-furan-2-one; l-cyclopropylethoxy)-5,5-dimethyl-4-(4-methylsulfonyl)phenyl)-5H- furan-2-one; sodium 2 -(4-chlorophenyl)-3-(4-(methylsulfonyl)phenyl)-4-oxo-2- pentenoate; 66 3-(cyclopropylmethoxy)-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-5H- furan-2-one; 3-(cyclopropylmethoxy)-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-2,5- dihydrofuran-2-ol; 3-isopropoxy-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-2,5-dihydrofuran- 2-ol; 5,5-dimethyl-3-(3-fluorophenyl)-2-hydroxy-4-(4-(methylsulfonyl)phenyl)- 5-chloro-3-(4-(methylsulfonyl)phenyl)-2-(3-pyridinylpyridine; 4-(5-methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; 5-(4-fluorophenyl)-1- [4-(methylsulfonyl)phenyl] -3- :5 (trifluoromethyl)pyrazole; 4-(4-fluorophenyl)-5- [4-(methylsulfonyl)phenyl] -1-phenyl-3- ~.(trifluoromethyl)pyrazole; 4-(5-(4-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-1- yl)benzenesulfonamide; 4-(3,5-bis(4-methylphenyl)-1H-pyrazol-1-yl)benzenesulfonamide 4-(5-(4-chlorophenyl)-3-phenyl-1H-pyrazol-1-yl)benizenesulfonamide; 4-(3,5-bis(4-methoxyphenyl)- 1H-pyrazol-1-yl)benzenesulfonamide; 4-(5-(4-chlorophenyl)-3-(4-methylphenyl)-1H-pyrazol-1- yl)benzenesulfonamide; :4-(5-(4-chlorophenyl)-3-(4-nitrophenyl)- 1H-pyrazol-1- yl)benzenesulfonamide; 4-(5-(4-chlorophenyl)-3-(5-chloro-2-thienyl)-1H-pyrazol-1- yl)benzenesulfonamide; 4-(4-chloro-3,5-diphenyl-1H-pyrazol-1-yl)benzenesulfonamide; 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1- yl)benzenesulfonamide; 4-(5-phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-(5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1- yl)benzenesulfonamide; 67 4 -(5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-l- yl)benzenesulfonamide; 4-(5-(4-chlorophenyl)-3-(difluoromethyl)- 1H-pyrazol-1- yl)benzenesulfonamide; 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-l- yl)benzeniesulfonainide; 4 -(4-chloro-5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1- yl)benzenesulfonamide; 4-(3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol-1- yl)benzenesulfonamide; :2 4 -(3-(difluoromethyl)-5-phenyl-1H-pyrazol-1-yl)benzenesulfonamide; 4 -(3-(difluoromethyl)-5-(4-methoxyphenyl)-1H-pyrazol-1- yl)benzenesulfonamide; 4-(3-cyano-5-(4-fluorophenyl)- 1H-pyrazol-1-yl)benzenesulfonamide; 4 3 -(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1- yl)benzenesulfonamide; 4 -(5-(3-fluoro-4-methoxyphenyl)-3-(trifluoromethyl)-lH-pyrazol-1- yl)benzenesulfonamide; 4 4 -chloro-5-phenyl-lH-pyrazol-1-yl)benzenesulfonamide; 4 -(5-(4-chlorophenyl)-3-(hydroxyphenyl)-lH-pyrazol-1- yl)benzenesulfonamide; 4 4 -(N,N-dimethylamino)phenyl)-3-(trifluoromethyl)-lH-pyrazol-1- yl)benzenesulfonamide; 4 -fluorophenyl)-6-(4-(methylsulfonyl)phenyl)spiro [2.4lhept-5-ene; 4 -(6-(4-fluorophenyl)spiro 6-(4-fluorophenyl)-7-(4-(methylsulfonyl)phenyl)spiro oct-6-ene; 3 -chloro-4-methoxyphenyl)-6-(4-(methylsulfonyl)phenyl)spiro hept- 4 -(6-(3-chloro-4-methoxyphenyl)spiro [2.4lhept-5-en-5- yl)benzenesulfonamide; 68 5-(3,5-dichloro-4-methoxyphenyl)-6-(4-(methylsulfonyl)phenyl)- Spiro 5-(3-chloro-4-fluorophenyl)-6-(4-(methylsulfonyl)phenyl)spiro [2.41 ene; 4-(6-(3,4-dichlorophenyl)spiro 2 -(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-(4- methylsulfonylphenylthiazole; 2 2 -chlorophenyl)-4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)thiazole; 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-methylthiazole; 4 4 -fluorophenyl)-5-(4-methylsulfonylphenyl)-2-trifluoromethylthiazole; 4 -(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(2-thienyl)thiazole; 4-4furpey) -4mtyslonlhnl..ezyaiohaoe 4 4 -fluorophenyl)-5-(4-methylsulfonylphenyl)-2-benzroylaminothiazole; 4 -fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(1-plurolmtnolthiazole; -(-dchloropenoxy-1,-dmethyl-4-(4-fluorophenyl)cyloena(4-den3 (mehylsulfonlmphey;haoe 5-( 4 -fluorophenyl)--(4-methylsulfonylphenyl)2-tiforom4]epthylthize; 1-mehlufny--1 -dmty--(4-fluorophenyl)spyclopenta-2,44,-dien-3-lbneesloaie 4-(4o-(4-fluorophenyl 1 -dimehylylloen-24-deny-3- idne ylbeniteeufnai 6 4 -fluoropheny1)2-hy-5-(4-(methyunyfohnyl)pheny-pyridine-3- carbonitrile; 4 2 -(4-methylpyridin-2-yl)-4-(trifluoromethyl)-1H-imidazol-1- yl)benzenesulfonamide; 69 4-(2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1- yl)benzenesulfonamide; 4-(2-(2-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-inidazol-1- yl)benzenesulfonamide; 3-(1-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)-1H-imidazol-2- yl)benzenesulfonamide; 2-(l-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)-lH-imidazol-2- yl)pyridine; 2 -methyl-4-(l-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)-1H-imidazol- 2-yl)pyridine; 2 -methyl-6-(1-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)-1H-imidazol- 2-yl)pyridine; 4-(2-(6-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-iniidazol-1- yl)benzenesulfonamide; 2-(3,4-difluorophenyl)- 1-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)-1H- imidazole; 4 -(2-(4-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1- **yl)benzenesulfonamide; 2 -(-hoohnl.-4(ehlufnlpey)4mty-Hiiaoe 2 -(4-chlorophenyl)-1-(4-(methylsulfonyl)phenyl)-4-metyl-1H-imidazole; 2 4 -chlorophenyl)-4-(4-fluorophenyl)-1-(4-(methylsulfonyl)phenyl)- 1H- iridazole; 2 -(3-fluoro-4-methoxyphenyl)-1-(4-(methylsulfonyl)phenyl)-4- (trifluoromethyl)-lH-imidazole; l-(4-(methylsulfonyl)phenyl)-2-phenyl-4-trifluoromethyl-lH-imidazole; 2 -(4-methylphenyl)-l-(4-(methylsulfonyl)phenyl)-4-trifluoromethyl-lH- imidazole; 4 -(2-(3-chloro-4-methylphenyl)-4-(trifluoromethyl)-lH-imidazol- 1- yl)benzenesulfonamide; 2-(3-fluoro-5-methylphenyl)- 1-(4-(methylsulfonyl)phenyl)-4- (trifluoromethyl)-1H-imidazole; 70 4 2 -(3-fluoro-5-methylphenyl)-4-(trifluoromethyl)-lH-imidazol-1- yl)benzenesulfonamide; 2 -(3-methylphenyl)-1-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl) 1H- imidazole; 4 -(2-(3-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1- yl)benzenesulfonamide; l-( 4 -(methylsulfonyl)phenyl)-2-(3-chlorophenyl)-4-(trifluoromethyl)-lH- imidazole; 4 -(2-(3-chlorophenyl)-4-(trifluoromethyl)-1H-imidazol-l- yl)benzenesulfonamide; 4 2 -phenyl-4-(trifluoromethyl)-1H-im-idazol-1-yl)benzenesulfonamide; 4 -(2-(4-methoxy-3-chlorophenyl)-4-(trifluoromethyl)- 1H-imidazol-1- 9: yl)benzenesulfonamide; l-allyl- 4 4 -fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-5-(trifluoromethyl). 1H-pyrazole; 4 -(l-ethyl-4-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-3- yl)benzenesulfonamide; :9 *.N-phenyl-(4-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-5-
9. (trifluoromethyl)-1H-pyrazol-1-yl)acetamide; 20 ethyl 4 4 -fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-5-(trifluoromethyl)- 1H-pyrazol-1-yl)acetate; 4 4 -fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-l-(2-phenylethyl)- 1H- pyrazole; 4 4 -fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-1-(2-phenylethyl)-5- (trifluoromethyl)pyrazole; l-ethyl- 4 4 -fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-s..(trifluoromethyl). lil-pyrazole; 4 -fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(trifluoromethyi)- H- imidazole; 4 4 -(methylsulfonyl)phenyl)-5-(2-thiophenyl)-2-(trifluoromethyl)1lH- imidazole; 71 5-(4-fluorophenyl)-2-methoxy-4-(4-(methylsulfonyl)phenyl)-6- (trifluoromethyl)pyridine; 2 -ethoxy-5-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-6- (trifluoromethyl)pyridine; 5-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(2-propynyloxy)-6- (trifluoromethyl)pyridine; 2-bromo-5-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-6- (trifluoromethyl)pyridine; 4 2 -(3-chloro-4-methoxyphenyl)-4,5-difluorophenyl)benzenesulfonamide; l-( 4 -fluorophenyl)-2-(4-(methylsulfonyl)phenyl)benzene; 5-difluoromethyl-4-(4-(methylsulfonyl)phenyl)-3-phenylisoxazole; 4-3ehl5phnlsxz.*-lbneesloaie 4 -(5-diloethyl-3-phenylisoxazol-4-yl)benzenesulfonamide; S..oxmty--peyioxzl4y~bneeuloaie 4 -(5-dfrmethyl-3-phenylisoxazol-4-yl)benzenesulfonamide; 1 4 2-(-ydro-2ymethylphenylisyoazol--yl)nzene lamide; nen 4 -(5-ehl-3phenylisycoazo--yl)enzeneulsfnlfonamide 1l-( 2 -(24-dluorophenyl)cyclopenten- 1-yl)-4-(methylsulfonyl)benzene; l-( 2 4 -trfluoro2methylphenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; l-( 2 4 -mehlophenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; l-( 2 -(4-diorophenyl)c4dmelyclopenten-1-yl)-4-hlufnlbnn; 0 l- 2 (-riloomtypenlcclpne-1y)4(methylsulfonyl)benzene; l-( 2 4 -methlhophenyl)4dmycyclopenten-1-yl)eylesulfonmnee; 2 4 -lorophenyl)-4,4-dimethylcyclopenten-1-yl)-4- (methylsulfonyl)benzene; 4 2 -(4-lorophenyl)-4,4-dimethylcyclopenten- 1-yl)benzenesulfonainde; 4 2 -(4-lorophenyl)-44dtycyclopenten- 1-yl)benzenesulfonamide; 4 2 -(4-lorophenyl)cyclopenten- 1-yl)benzenesulfonamide; -(2-(4-cehoophenyl)cyclopenten- 1-yl)enzeesulfonide zn l-(2-(4,-ethoyphenyl)cyclopenten- 1-yl)-4-(methylsulfonyl)benzene; 72 4-(2-(3-fluoro-4-methoxyphenyl)cyclopenten- -1-yl)benzenesulfonamide; 1-(2-(3-chloro-4-methoxyphenyl)cyclopenten-1-yl)-4- (methylsulfonyl)benzene; 4-(2-(3-chloro-4-fluorophenyl)cyclopenten- 1-yl)benzenesulfonamide; 4-(2-(2-methylpyridin-5-yl)cyclopenten-1-yl)benzenesulfonaniide; ethyl 2-(4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazol-2-yl)-2- benzyl-acetate; 2-(4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazol-2-yl)acetic acid; 2-(tert-butyl)-4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazole; 4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)-2-phenyloxazole; 4-(4-fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)phenyl)oxazole; and 4 4-(5-(3-fluoro-4-methoxyphenyl)-2-trifluoromethyl-4- oxazolyl)benzenesulfonamide; or a pharmaceutically acceptable salt thereof. 3. A product comprising a selective COX-2 inhibitor and a NK-1 receptor antagonist as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of an inflammatory disorder, wherein said selective COX-2 inhibitor is selected from the group consisting of: 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone; 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone; 5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-3-(3-fluorophenyl)-5H-furan-2- one; 5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-3-(2-propoxy)-5H-furan-2-one; 5-chloro-3-(4-(methylsulfonyl)phenyl)-2-(2-methyl-5-pyridinyl)pyridine; 2 -(3,5-difluorophenyl)-3-(4-(methylsulfonyl)phenyl)-2-cyclopenten- 1-one; 5(S)-5-ethyl-5-methyl-4-(4-(methylsulfonyl)phenyl)-3-(2-propoxy)-5H- furan-2-one; 73 5-ethyl-5-methyl-4-(4-(methylsulfonyl)phenyl)-3-(3,4-difluorophenyl)-5H- furan-2-one; 3-((2-thiazolyl)methoxy)-4-(4-(methylsulfonyl)phenyl)-5,5-dimethy1-5H- furan-2-one; 3-propyloxy-4-(4-(methylsulfonyl)phenyl)-5,5-dimethyl-5H-furan-2-one; 1-cyclopropylethoxy)-5,5-dimethyl-4-(4-methylsulfonyl)phenyl)-5H- furan-2-one; sodium 2-(4-chlorophenyl)-3-(4-(methylsulfonyl)phenyl)-4-oxo-2- pentenoate; 3-(cyclopropylmethoxy)-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-5H- furan-2-one; 3-(cyclopropylmethoxy)-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-2,5- dihydrofuiran-2-ol; ****3-isopropoxy-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-2,5-dihydrofuran- 2-ol; ,5-dimethyl-3-(3-fluorophenyl)-2-hydroxy-4-(4-(methylsulfonyl)phenyl)- 5-chloro-3-(4-(methylsulfonyl)phenyl)-2-(3-pyridinyl)pyridine; ::*4-(5-methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; 20 5-(4-fluorophenyl)-1- [4-(methylsulfonyl)phenyl] -3- (trifluoromethyl)pyrazole; 4-(5-(4-chlorophenyl)-3-(4-methoxyphenyl)- 1H-pyrazol-1- yl)benzenesulfonamide; 4-(3,5-bis(4-methylphenyl)-lH-pyrazol-1-yl)benzenesulfonamide; 4-(5-(4-chlorophenyl)-3-phenyl-1H-pyrazol- 1-yl)benzenesulfonamide; 4-(3,5-bis(4-methoxyphenyl)- li-pyrazol- 1-yl)benzenesulfonamide; 4 -(5-(4-chlorophenyl)-3-(4-methylphenyl)-1H-pyrazol-1- yl)benzenesulfonamide;
74- 4-(5-(4-chlorophenyl)-3-(4-nitrophenyl)-1H-pyrazol-1- yl)benzenesulfonamide; 4-(5-(4-chlorophenyl)-3-(5-chloro-2-thienyl)-1H-pyrazol-1- yl)benzenesulfonamide; 4 -(4-chloro-3,5-diphenyl-1H-pyrazol-1-yl)benzenesulfonamide; 4 -(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1- yl)benzenesulfonamide; 4-(5-phenyl)-3-(trifluoromethyl)-1H-pyrazol- 1-yl)benzenesulfonamide; 4-(5-(4-fluorophenyl)-3-(trifluoromethyl)- 1H-pyrazol-1- yl)benzenesulfonamide; e 4-(5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol- 1- yl)benzenesulfonamide; g~e. 4-(5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1- ylbenzenesulfonamide; 4-(5-(4-methylphenyl)-3-(trifluoromethyl)- 1H-pyrazol-1- yl)benzenesulfonaniide; 4-(4-chloro-5-(4-chlorophenyl)-3-(trifluoromethyl)- 1H-pyrazol-1- ee*yl)benzenesulfonamide; *see4-(3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol- 1- Goo**: 20 yl)benzenesulfonamide; 4-(3-(difluoromethyl)-5-phenyl- 1H-pyrazol-1-yl)benzenesulfonaniide; S. C 4 -(3-(difluoromethyl)-5-(4-methoxyphenyl)-1H-pyrazol-1- yl)benzenesulfonamide; 4 -(5-3-dfurmty)fluorolur-4-methoxypheny)3(rfuomtyl)- 1H-pyrazol- 1- yl)benzenesulfonamide; 4-(4-chloro-5-phenyl- 1H-pyrazol-.1-yl)benzenesulfonamide; 4-(5-(4-chlorophenyl)-3-(hydroxyphenyl)- 1H-pyrazol-1- Syl)benzenesulfonamide; 75 4-(5-(4-(N,N-dimethylamino)phenyl)-3-(trifluoromethyl)-1H-pyrazol- 1- yl)benzenesulfonamide; 5-(4-fluorophenyl)-6-(4-(methylsulfonyl)phenylbspiro [2.4lhept-5-ene; 4-(6-(4-fluorophenyl)spiro 6-(4-fluorophenyl)-7-(4-(methylsulfonyl)phenyl)spiro oct-6-ene; 5-(3-chloro-4-methoxyphenyl)-6-(4-(methylsulfonyl)phenylspiro [2.4lhept- 4-(6-(3-chloro-4-methoxyphenyl)spiro yl)benzenesulfonamide; 5-(3 ,5-dichloro-4-methoxyphenyl)-6-(4-(methylsulfonyl)phenyl)- Spiro [2.4]hept-5-ene; 5-(3-chloro-4-fluorophenyl)-6-(4-(methylsulfonyl)phenyl)spiro [2 ene; **4-(6-(3,4-dichlorophenyl)spiro [2.4]hept-5-en-5-yl)benzenesulfonamide; 2-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-(4- methylsulfonylphenyl)thiazole; 2-(2-chlorophenyl)-4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)thiazole; 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-methylthiazole; 4-4furpey)*-4mtysloylhnl -rfuooehlhaoe 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(2tiuoromthyiazole;
204-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(2enylninthiazole; .::4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-benzroylaminothiazole; 2-((3,5-dichlorophenoxy)methyl)-4-(4-fluorophenyl)-5-(4- (methylsulfonyl)phenyl)thiazole; 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-trifluoromethylthiazole; 1-methylsulfonyl-4-( 1, 1-dimethyl-4-(4-fluorophenyl)cyclopenta-2,4-dien-3- yl)benzene; 4-(4-(4-fluorophenyl)- 1, 1-dimethylcyclopenta-2,4-dien-3- yl)benzenesulfonamide; 5-(4-fluorophenyl)-6-(4-(methylsulfonyl)phenyl)spiro [2.4]hepta-4,6-diene; S4-(6-(4-fluorophenyl)spiro [2 .4lhepta-4,6-dien-5-yl)benzenesulfonamide; 76 6-(4-fluorophenyl)-2-methoxy-5-(4-(methylsulfonyl)phenyl)-pyridine-3- carbonitrile; 2-bromo-6-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)-pyridine-3- carbonitrile; 6-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)-2-phenyl-pyridine-3- carbonitrile; 4-(2-(4-methylpyridin-2-yl)-4-(trifluoromethyl)-1H-imidazol-1- yl)benzenesulfonamide; 4-(2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1- yl)benzenesulfonamide; 4-(2-(2-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1- yl)benzenesulfonamide; 3-(1-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)-1H-imidazol-2- yl)benzenesulfonamide; 2 -(1-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)-H-iyidazol-2- ylpyridine; 2-methyl-4-( 1-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)-1H-imidazol- 2-yl)pyridine; 2-methyl-6-( 1-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)- iR-imidazol- 20 2-yl)pyridine; 4 -(2-(6-methylpyridin-3-yl)-4-(trifluoromethyl)-lH-imidazol-1- yl)benzenesulfonamide; 2 3 4 -difluorophenyl)-1-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)-lH- imidazole; 4 2 4 -methylphenyl)-4-(trifluoromethyl)- 1H-imidazol-1- yl)benzenesulfonamide; 2-(4-chlorophenyl)- 1-(4-(methylsulfonyl)phenyl)-4-methyl-1H-imnidazole; 2 4 -chlorophenyl)-1-(4-(methylsulfonyl)phenyl)-4-phenyl-1H-imidazole; 2 4 -chlorophenyl)-4-(4-fluorophenyl)-1-(4-(methylsulfonyl)phenyl)-1H- imidazole; 77 2-(3-fluoro-4-methoxyphenyl)-1-(4-(methylsulfonyl)phenyl)-4- (trifluoromethyl)-lH-imidazole; 1-(4-(methylsulfonyl)phenyl)-2-phenyl-4-trifluoromethyl-lH-iniidazole; 2-(4-methylphenyl)-1-(4-(methylsulfonyl)phenyl)-4-trifluoromethyl-1H- imidazole; 4-(2-(3-chloro-4-methylphenyl)-4-(trifluoromethyl)- 1H-imidazol-1- yl)benzenesulfonamide; 2-(3-fluoro-5-methylphenyl)- 1-(4-(methylsulfonyl)phenyl)-4- (trifluoromaethyl)-lH-imidazole; 4-(2-(3-fluoro-5-methylphenyl)-4-(trifluoromethyl)- 1H-imidazol- 1- yl)benzenesulfonamide; 2-(3-methylphenyl)- 1-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)-1H- imidazole; 4-(2-(3-methylphenyl)-4-(trifluoromethyl)-1H-imidazol- 1- yl)benzenesulfonamide; 1-(4-(methylsulfonyl)phenyl)-2-(3-chlorophenyl)-4-(trifluoromethyl)- 1H- imidazole; 4-(2-(3-chlorophenyl)-4-(trifluoromethyl)- 1H-imidazol-1- yl)benzenesulfonan-ide; 20 4 -(2-phenyl-4-(trifluoromethyl)-1H-imidazol-1-yl)benzenesulfonamide; 4 -(2-(4-methoxy-3-chlorophenyl)-4-(trifluoromethyl)- 1H-imidazol-1- yl)benzenesulfonamide; l-allyl-4-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-5-(trifluoromethyl)- 1H-pyrazole; 4-(1-ethyl-4-(4-fluorophenyl)-5-(trifluoromethyl)- 1H-pyrazol-3- yl)benzenesulfonamide; N-phenyl-(4-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-5- (trifluoromethyl)-1H-pyrazol-1-yl)acetamide; ethyl (4-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-5-(trifluoromethyl)- 1H-pyrazol-1-yl)acetate; 78 4-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-1-(2-phenylethyl)- 1H- pyrazole; 4-(4-fluoropheny)-3-(4-(methylsulfonyl)pheny1)-1-(2-phenylethy)-5- (trifluoromethyl)pyrazole; l-ethyl-4-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-5-(trifluoromethyl)- iR-pyrazole; 5-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(trifluoromethyl)-lH- iniidazole; 4-(4-(methylsulfonyl)phenyl)-5-(2-thiophenyl)-2-(trifluoromethyl)-lH- imidazole; 5-(4-fluorophenyl)-2-methoxy-4-(4-(methylsulfonyl)phenyl)-6- (trifluoromethyl)pyridine; 2-etoxy-5-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-6- (trifluoromethyl)pyridine; 5-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-2-ponylxy-6 (trifluoromethyl-pyridinehlufnlpey)3peyioaoe 4-bromohy-5-4-fluorophenyl-4-(4-(ezhysulfonylmpheny); 4-**(rifluoromethyl-yridin sxzl4-lbneesloai 25:: 4 -(5-3cr--meth 0 4 -fluorophenyl)-(et--y)4-(methylsulfony~hnyl)benzene; 1-di(fluoro2methyl( yloete--y)4-(methylsulfonyl)phnl--heyioao e zn 1 4 2-3-hl-5-phenylsyopol4-ltenn)4(etylfonamide; nene 1 4 2-(2-dioroehlphenylioxazon-1-yl)b4(ezenesulfonmjdezne l-( 2 -(4-trfluoromyphenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; l-(2-(4-fu--methylphenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; -79- l-(2-(4-fluorophenyl)-4,4-dimethylcyclopenten- l-yl)-4- (methylsulfonyl)benzene; 4 -(2-(4-fluorophenyl)-4,4-dimethylcyclopenten- 1-yl)benzenesulfonamide; l-( 2 -(4-chlorophenyl)-4,4-dimethylcyclopenten-1-yl)-4- (methylsulfonyl)benzene; 4 2 -(4-chlorophenyl)-4,4-dimethylcyclopenten- 1-yl)benzenesulfonamide; 4 2 4 -fluorophenyl)cyclopenten-1-yl)benzenesulfonamide; 4 2 -(4-chlorophenyl)cyclopenten-1-yl)benzenesulfonamide; l-( 2 -(4-methoxyphenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; l-( 2 -(2,3-difluorophenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 4 2 3 -fluoro-4-methoxyphenyl)cyclopenten-1-yl)benzenesulfonamide; 6004,00 l-( 2 3 -chloro-4-methoxyphenyl)cyclopenten-1-yl)-4- (methylsulfonyl)benzene; Vooo' 4 2 3 -chloro-4-fluorophenyl)cyclopenten-1-yl)benzenesulfonaniide; 4 2 2 -methylpyridin-5-yl)cyclopenten-1-yl)benzenesulfonamide; ethyl 2 -(4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazol-2-yl)-2- benzyl-acetate; :06. 2 4 4 -fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazol-2-yl)acetic acid; 0000% 2 -(tert-butyl)-4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazole; Soo* 2 0 4 -l o op.y 5 e h l u f ny. .n l -p e y o a o e 20 4 4 -fluorophenyl)-2my-5-(4-(methylsulfonyl)phenyl)eyoxazole;an 4 -(5-(-fluoro-mhxphenyl)-2- trfurmethyl-5-4(ehlufnl -hnloaoe n 4. AS 4 -S(-loomethod frphey)trtentorpevethnyfln-nfamatr or a phracetcall ceta ble suhtat teherf. iv feciereif 80 wherein said selective COX-2 inhibitor is selected from the group consisting of: 3 -phenyl-4-(4-(methylsulfonyl)phenyl)-2-(SH)-furanone; 3 4 -difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone; 5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-3-(3-fluorophenyl)-SH-furan-2- one; 5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-3-(2-propoxy)-5H-furan.2-one; 5-chloro-3-(4-(methylsulfonyl)phenyl)-2-(2-methyl-5-pyridinyl)pyrijine; 2 -(3,5-difluorophenyl)-3-(4-(methylsulfonyl)phenyl)-2-cyclopenten1..one; 5(S)-5-ethyl-5-methyl-4-(4-(methylsulfonyl)phenyl)-3-(2-propoxy)-5H- fiiran-2-one; 5-ethyl-5-methyl-4-(4-(methylsulfonyl)phenyl)-3-(3,4-difluorophenyl..5H. furan-2-one; 2 -hialymoxy)-4-(4-(methylsulfonyl)phenyl)-5,5-dimethyl..5Hn--oe 150. furan-2-one; sodiu 20 pentenoate; 3 -(cyclopropylmethoxy)-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-5H- 0: furan-2-one; 3 -(cyclopropylmethoxy)-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-2,s- dihydrofuran-2-ol; 3 -isopropoxy-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-2,5.dihydrofuran. 2-ol; ,5-dimethyl-3-(3-fluorophenyl)-2-hydroxy-4-(4-(methylsulfonyl)phenyl)- 5-chloro-3-(4-(methylsulfonyl)phenyl)-2-(3-pyridinyl)pyridine; 4-(5-methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; 81 5-(4-fluorophenyl)-1- [4-(methylsulfonyl)phenyll -3- (trifluoromethyl)pyrazole; 4-(4-fluorophenyl)-5- [4-(methylsulfonyl)phenyl]-1-phenyl-3- (trifluoromethyl)pyrazole; 4-(5-(4-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-1- yl)benzenesulfonamide; 4-(3,5-bis(4-methylphenyl)- 1H-pyrazol-1-yl)benzenesulfonamide; 4-(5-(4-chlorophenyl)-3-phenyl-1H-pyrazol-1-yl)benzenesulfonamide; 4-(3,5-bis(4-methoxyphenyvl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-(5-(4-chlorophenyl)-3-(4-methylphenyl)-1H-pyrazol-1- yl)benzenesulfonamide; 4-(5-(4-chlorophenyl)-3-(4-nitrophenyl)- 1H-pyrazol-1- yl)benzenesulfonamide; 4-(5-(4-chlorophenyl)-3-(5-chloro-2-thienyl)-1H-pyrazol-1- yl)benzenesulfonamnide; 4-(4-chloro-3,5-diphenyl-1H-pyrazol-1-yl)benzenesulfonamide; 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1- yl)benzenesulfonamide; 4-(5-phenyl)-3-(trifluoromethyl)-1H-pyrazol- 1-yl)benzenesulfonamlae; 20 4-(5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1- yl)benzenesulfonamide; 4-(5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1- yl)benzenesulfonamide; 4-(5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1- ylbenzenesulfonamide; 4-(5-(4-methylphenyl)-3-(trifluoromethyl)- 1H-pyrazol-1- yl)benzenesulfonamide; 4-(4-chloro-5-(4-chloropheny1)-3-(trifluoromethy1)- 1H-pyrazol- 1- yIbenzenesulfonamide; 4-(3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol- 1- yl)benzenesulfonamide; STF S-S 7A 82 4-(3-(difluoromethyl)-5-phenyl- 1H-pyrazol-1-yL)benzenesulfonamide; 4-(3-(difluoromethyl)-5-(4-methoxyphenyl)-1H-pyrazol-1- yl)benzenesulfonamide; 4 -(3-cyano-5-(4-fluorophenyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-(3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-lH-pyrazol-1- yl)benzenesulfonamide; 4-(5-(3-fluoro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-l- yl)benzenesulfonamide; 4-(4-chloro-5-phenyl- 1H-pyrazol-1-yl)benzenesulfonamide; 4-(5-(4-chlorophenyl)-3-(hydroxyphenyl)-1H-pyrazol-1- yl)benzenesulfonamide; 4 -(5-(4-(N,N-dimethylamino)phenyl)-3-(trifluoromethyl)-1H-pyrazol- 1- yl)benzenesulfonamide; 5-(4-fluorophenyl)-6-(4-(methylsulfonyl)phenyl)spiro [2.4lhept-5-ene; 4-(6-(4-fluorophenyl)spiro 6 4 -fluorophenyl)-7-(4-(methylsulfonyl)phenyl)spiro [3.41 oct-6-ene; 5-(3-chloro-4-methoxyphenyl)-6-(4-(methylsulfonyl)phenyl)spiro 12.4] hept- 4-(6-(3-chloro-4-methoxyphenyl)spiro 20 yl)benzenesulfonamide; 0 0 5-(3,5-dichloro-4-methoxyphenyl)-6-(4-(methylsulfonyl)phenyl)- Spiro [2.4lhept-5-ene; 5-(3-chloro-4-fluorophenyl)-6-(4-(methylsulfonyl)phenyl)spiro [2.41 ene; 4-(6-(3,4-dichlorophenyl)spiro 2 -(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-(4- methylsulfonylphenyl)thiazole; 2 2 -chlorophenyl)- 4 4 -fluorophenyl)-5-(4-methylsulfonylphenyl)thiazole; 4 -fluorophenyl)- 4 4 -methylsulfonylphenyl)-2-methylthiazole; 4 4 -fluorophenyl)-5-( 4 -methylsulfonylphenyl)-2-trifluoromethylthiazole; S 4 4 -fluorophenyl)-5-( 4 -methysulfonylpheny)-2-(2-thieny)thiazole; 83 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-benzylaminothiazole; 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-( 1-propylamino)thiazole; 2-((3,5-dichlorophenoxy)methyl)-4-(4-fluorophenyl)-5-(4- (methylsulfonyl)phenyl)thiazole; 5-( 4 -fluorophenyl)-4-(4-methylsulfonylphenyl)-2-trifluoromethylthiazole; 1-methylsulfonyl-4-(1 ,1-dimethyl-4-(4-fluorophenyl)cyclopenta-2,4-dien-3- yl)benzene; 4-(4-(4-fluorophenyl)-1 ,1-dimethylcyclopenta-2,4-dien-3- yl)benzenesulfonamide; 5-(4-fluorophenyl)-6-(4-(methylsulfonyl)phenyl)spiro [2.4]hepta-4,6-diene; 4-(6-(4-fluorophenyl)spiro [2.4]hepta-4,6-dien-5-yl)benzenesulfonamide; 6 4 -fluorophenyl)-2-methoxy-5-(4-(methylsulfonyl)phenyl)-pyridine-3- carbonitrile; 2 -bromo-6-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)-pyridine-3 carbonitrile; 6-( 4 -fluorophenyl)-5-(4-(methylsulfonyl)phenyl)-2-phenyl-pyridine-3- carbonitrile; 4 2 4 -methylpyridin-2-yl)-4-(trifluoromethyl)-1H-imidazol-1- yl)benzenesulfonamide; 4 2 -(5-methylpyridin-3-yl)-4-(trifluoromethyl)- 1H-imidazol-1- yl)benzenesulfonamide; 4 2 2 -methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-l- yl)benzenesulfonamide; 3 -(l-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)- 1H-imidazol-2- yl)benzenesulfonamide; 2 -(l-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)- 1H-imidazol-2- yl)pyridine; 2 -rnethyl-4-(1-(4-(methylsulfonyl)phenyl)>4-.(trifluoromethyl)lH-imsdazolb 2 -yl)pyridine; 2-methyl-6-( 1-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)- 1H-imidazol- 2 -yl)pyridine; T- C S 'Irc 84- 4 2 -(6-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1- yl)benzenesulfonamide; 2-(3 ,4-difluorophenyl)- 1-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)-1H- imidazole; 4-(2-(4-methylphenyl)-4-(trifluoromethyl)-lH-imidazol-1- yl)benzenesulfonamide; 2-( 4 -chlorophenyl)-1-(4-(methylsulfonyl)phenyl)-4-methyl-1H-imidazole; 2-(4-chlorophenyl)-1-(4-(methylsulfonyl)phenyl)-4-phenyl-1H-imidazole; 2-( 4 -chlorophenyl)-4-(4-fluorophenyl)-1-(4-(methylsulfonyl)phenyl)-1H- imidazole; 2 -(3-fluoro-4-methoxyphenyl)-1-(4-(methylsulfonyl)phenyl)-4- (trifluoromethyl)-1H-imidazole; l-(4-(methylsulfonyl)phenyl)-2-phenyl-4-trifluoromethyl- 1H-imidazole; 2 4 -methylphenyl)-1-(4-(methylsulfonyl)phenyl)-4-trifluoromethyl- 1H- imidazole; 4 2 -(3-chloro-4-methylphenyl)-4-(trifluoromethyl)-H-imidazol-1- yl)benzenesulfonamide; 2 -(3-fluoro-5-methylphenyl)-1-(4-(methylsulfonyl)phenyl)-4- (trifluoromethyl)-1H-imidazole; 20 4 2 -(3-fluoro-5-methylphenyl)-4-(trifluoromethyl)- 1H-imidazol-1- yl)benzenesulfonamide; 2 3 -methylphenyl)-1-(4-(methylsulfonyl)phenyl)4(trifluoromethyl)-lH- imidazole; 4 2 -(3-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1- yl)benzenesulfonamide; l-(4-(methylsulfonyl)phenyl)-2-(3-chlorophenyl)-4-(trifluoromethyl)-1H- imidazole; 4-(2-(3-chlorophenyl)-4-(trifluoromethyl)- 1H-imidazol-1- yl)benzenesulfonamide; 4-(2-phenyl-4-(trifluoromethyl)-1H-imidazol- 1-yl)benzenesulfonamide; 85 4-(2-(4-methoxy-3-chlorophenyl)-4-(trifluoromethyl)-1H-imidazol-1- yl)benzenesulfonamide; 1-allyl-4-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-5-(trifluoromethyl)- 1H-pyrazole; 4-(1-ethyl-4-(4-fluorophenyl)-5-(trifluoromethyl)-lH-pyrazol-3- yl)benzenesulfonamiide; N-phenyl-(4-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-5- (trifluoromethyl)-1H-pyrazol-1-yl)acetamide; ethyl (4-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-5-(trifluoromethyl)- 1H-pyrazol-1-yl)acetate; 4-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-1-(2-phenylethyl)-1H- pyrazole; 4-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)- 1-(2-phenylethyl)-5- (trifluoromethyl)pyrazole; l-ethyl-4-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-5-(trifluoromethyl)- 1H-pyrazole; 4 -fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(trifluoromethyl)-1H- imidazole; 4 -(4-(methylsulfonyl)phenyl)-5-(2-thiophenyl)-2-(trifluoromethyl)-lH- imidazole; S-(4-fluorophenyl)-2-methoxy-4-(4-(methylsulfonyl)phenyl)-6- (trifluoromethyl)pyridine; 2 -ethoxy-5-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-6- (trifluoromethyl)pyridine; 5-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(2-propynyloxy)-6- (trifluoromethyl)pyridine; 2-bromo-5-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-6- (trifluoromethyl)pyridine; 4-(2-(3-chloro-4-methoxyphenyl)-4,5-difluorophenyl)benzenesulfonamide; 1-(4-fluorophenyl)-2-(4-(methylsulfonyl)phenyl)benzene; 5-difluoromethyl-4-(4-(methylsulfonyl)phenyl)-3-phenylisoxazole; 86 4-(3-ethyl-5-phenylisoxazol-4-yl)benzenesulfonamide; 4-(5-difluoromethyl-3-phenylisoxazol-4-yl)benzenesulfonamide; 4-(5-hydroxymethyl-3-phenylisoxazol-4-yl)benzenesulfonamide; 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide; 1-(2-(4-fluorophenyl)cyclopenten- 1-yl)-4-(methylsulfonyl)benzene; 1-(2-(4-fluoro-2-methylphenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 1-(2-(4-chlorophenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 1-(2-(2,4-dichlorophenyl)cyclopenten-1-yl)4-(methylsulfonyl)benzene; 1-(2-(4-trifluoromethylphenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 1-(2-(4-methylthiophenyl)cyclopenten- 1-yl)-4-(methylsulfonyl)benzene; 1-(2-(4-fluorophenyl)-4,4-dimethylcyclopenten-1-yl)-4- (methylsulfonyl)benzene; 4-(2-(4-fluorophenyl)-4,4-dimethylcyclopenten- 1-yl)benzenesulfonamidde; 1-(2-(4-chlorophenyl)-4,4-dimethylcyclopenten- l-yl)- 4 (methylsulfonyl)benzene; 4-(2-(4-chlorophenyl)-4,4-dimethylcyclopenten-1-yl)benzenesulfonamide; 4-(2-(4-fluorophenyl)cyclopenten-1-yl)benzenesulfonamide; 4-(2-(4-chlorophenyl)cyclopenten-1-yl)benzenesulfonamide; 1-(2-(4-methoxyphenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 1-(2-(2,3-difluorophenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 4-(2-(3-fluoro-4-methoxyphenyl)cyclopenten-1-yl)benzenesulfonamide; 1-(2-(3-chloro-4-methoxyphenyl)cyclopenten-1-yl)-4- (methylsulfonyl)benzene; 4-(2-(3-chloro-4-fluorophenyl)cyclopenten-1-yl)benzenesulfonamide; 4-(2-(2-methylpyridin-5-yl)cyclopenten- 1-yl)benzenesulfonamide; ethyl 2-(4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazol-2-yl)- 2 benzyl-acetate; 2-(4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazol-2-yl)acetic acid; 2-(tert-butyl)-4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazole; 4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)-2-phenyloxazole; -4-(4-fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)phenyl)oxazole; and -87- 4 -(5-(3-fluoro-4-methoxyphenyl)-2-trifluoromethyl-4- oxazolyl)benzenesulfonamide; or a pharmaceutically acceptable salt thereof. S. S S *5*S A use according to claim 1, a composition according to claim 2, a product according to claim 3 or a method according to claim 4 wherein the NK-1 receptor antagonist is a compound of formula I: X R 4 (I) R2 N R R wherein: R 1 is selected from the group consisting of: Ci-6alkyl, substituted with one or more of the substituents selected from: S S S. the group heterocycle, wherein the heterocycle is selected from consisting of: benzimidazolyl, imidazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, pyrazinyl, pyrazolyl, pyridyl, pyrrolyl, tetrazolyl, thiadiazolyl, triazolyl, and 88 S S *5 See. *555 S C S. C ~e C S. C C S S .5CC C S S S S C C *5 piperidinyl, and wherein the heterocycle is unsubstituted or substituted with one or more substituent(s) selected from: C1-6alkyl, unsubstituted or substituted with halo, -CF 3 -OCH 3 or phenyl, (ii) Ci-6alkoxy, (iii) oxo, (iv) thioxo, cyano, (vi) -SCH 3 (vii) phenyl, (viii) hydroxy, (ix) trifluoromethyl, (x -(CH2)m-NR 9 R 10 wherein m is 0, 1 or 2, and R 9 and RIO are independently selected from: hydrogen, (II) Ci..oalkyl, (III) hydroxyCi-6alky1, and (IV) phenyl, 20 (xi) -NR 9 CORiO, wherein R9 and Rio0 are as defined above, and (xii) -CONR 9 RO, wherein R9 and RiO are as defined above, R2 and R 3 are independently selected from the group consisting of: hydrogen; Ci-6alkyl C2-alkenyl, and phenyl; X is R 4 is -89- Z M R 5 is phenyl, unsubstituted or substituted with halo; R 6 R 7 and R 8 are independently selected from the group consisting of: hydrogen, Ci-alkyl, halo, and -CF 3 Y is and Z is hydrogen or Ci-alkyl; or a pharmaceutically acceptable salt thereof. 6. A use according to claim 1, a composition according to claim 2, a product according to claim 3 or a method according to claim 4 wherein the NK-1 receptor antagonist is a compound of formula II: A YI R A (II) wherein: A 1 is fluorine or CF 3 A 2 is fluorine or CFa; A 3 is fluorine or hydrogen; R 6 is a 5-membered or 6-membered heterocyclic ring containing 2 or 3 nitrogen atoms optionally substituted by =S or a C-4alkyl group, and optionally substituted by a group of the formula ZNR7R8 where Z is Ci-6alkylene or C3-6cycloalkylene; R 7 is hydrogen, Cli4alkyl, C3-7cycloalkyl or C3-7cycloalkylCi-4alkyl, or C2-4alkyl substituted by Cl4alkoxy or hydroxyl; R 8 is hydrogen, C-4alkyl, C3-7cycloalkyl or C3-7cycloalkylC1-4alkyl, or C2-4alkyl substituted by one or two substituents selected from Cl4alkoxy, hydroxyl or a 4, 5 or 6 membered heteroaliphatic ring containing one or two heteroatoms selected from N, O and S; or R 7 R 8 and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by a hydroxy group, and optionally containing a double bond, which ring may "optionally contain an oxygen or sulphur ring atom, a group S(0) or S(0)2 or a second nitrogen atom which will be part of a NH or NR c moiety where Rc is Ci-4alkyl optionally substituted by hydroxy or C14alkoxy; or R 7 R 8 and the nitrogen atom to which they are attached form a non-aromatic azabicyclic ring system of 6 to 12 ring atoms; or Z, R 7 and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms which may optionally contain an oxygen ring atom; X is an alkylene chain of 1 to 4 carbon atoms optionally substituted by oxo; and Y is a C14alkyl group optionally substituted by a hydroxyl group; with the proviso that ifY is C-4alkyl, R 6 is susbstituted at least by a group of formula ZNR 7 R 8 as defined above; or a pharmaceutically acceptable salt thereof. 7. A use according to claim 1, a composition according to claim 2, a product according to claim 3 or a method according to claim 4 wherein the NK-1 receptor antagonist is a compound of formula III: -91- 2 J, Z R (III) R N R (0)P A I 12 R 13 R 12 wherein: R 2 and R 3 are independently selected from the group consisting of: hydrogen, C1-6alkyl, C2-6alkenyl, and phenyl; R 6 R 7 and R 8 are independently selected from the group consisting of: hydrogen, C1-6alkyl, fluoro, chloro, 15 bromo, iodo, and -CF 3 R 1 R 12 and R 1 3 are independently selected from the group consisting of: fluoro, chloro, bromo, and iodo; A is unsubstituted 1-6alkyl; B is selected from the group consisting of: -92- N-9 N x H N-N N I x x N-N N 0 H N-N N H N-N N 0 H N-N N 0 X\ H N-N N-N a r r r x N-N N x 1 N H H N x N-N N x N N x N 0 1 x H 'N x N H H N S N S p is O or 1; X is selected from: -PO(OH)O- e wherein M+ is a pharmaceutically acceptable monovalent counterion, -PO(O-) 2 2M+, -PO(O-) 2 D2+, wherein D 2 is a pharmaceutically acceptable divalent counterion, -CH(R 4 )-PO(OH)O- wherein R 4 is hydrogen or C1.3alkyl, -CH(R4)-PO(O) 2 2M+, -CH(R4)-PO(O-) 2 D2+, -CO-CH 2 CH 2 -C0 2 M+, -93- -CH(CH 3 )-O-CO-R 5 wherein R 5 is selected from the group consisting of: NH M H2 M ONN, OH 0 CO 2 M CO02M' O NCO NH: .CO2 M 9 C. 9* 9* (vii) Co 2 -M+ 0- and Y is and Z is hydrogen or C1-6alkyl; or a pharmaceutically acceptable salt thereof. 8. A use according to claim 1, a composition according to claim 2, a product according to claim 3 or a method according to claim 4 wherein Wit he NK-1 receptor antagonist is a compound of formula IV: 94- (IV) K.N H d wherein R' represents hydrogen, hydroxy, Ci..oalkyl, C2-6alkenyl, C3-7'cycloalkyl, C3-7cycloalkylCl-4alkyl, C1.6alkoxy, fluoroCi.ealkoxy, Ci..oalkoxyCli4alkyl, Cl-6alkoxyCi-4alkoxy, fluoroC1-6alkoxyCl-4alkyl, C2-6alkenyloxy, C3..7CYCloalkoxy, C3-7CYCloalkylCl-4alkoxy, phenoxy, 10 benzyloxy, cyano, halogen, NRaRb, SRa, SORa, SO 2 Ra, OSO 2 R1a, NRaCORl 4 CORa, CO 2 Ra or CONRaRb where Ra and Rb each independently represent hydrogen, C1-4alkyl or fluoroCl-4alkyl; R 2 represents hydrogen, halogen, C1-6alkyl or Cl-6alkoxy; or Ri and R 2 may be joined together such that there is formed a 5- or 15 6-membered saturated or unsaturated ring containing one or two atoms selected from nitrogen, oxygen and sulphur, which ring is optionally substituted by a group selected from Ci-4alkyl, CF 3 =0 or =S; *R 3 represents hydrogen, halogen, CI-6alkyl, fluoroCl-6alkyl, C1-6alkoxy, fluoroCi-6alkoxy, C3-7cycloalky1, Ca-7cycloalkylCi~alkyl, cyano, SRa, SORa, SO 2 Ra, NRaRb, NRaCORl 4 CORa, CO 2 Ra, CONRaRb or Ci-4alkyl substituted by cyano, CO 2 Ra or CONRaRb where Ra and Rb are as previously defined; R 4 represents hydrogen, halogen, C1.6alkyl, C1i6alkoxy, CF 3 OCF 3 NO 2 CN, SRa, SORa, SO 2 Ra, CO 2 Ra, CONRaRb, C2-6alkenyl, C2-6alkynyl or Ci~alkyl substituted by C1-4alkoxy, where Ra and Rb are as previously defined; and the broken line represents an optional double bond; or a pharmaceutically acceptable salt thereof. 9. A use according to claim 1, a composition according to claim 2, a product according to claim 3 or a method according to claim 4 wherein the NK-1 receptor antagonist is a compound of formula V: R 7 R N R 2 (V) R e R R or a pharmaceutically acceptable salt thereof, wherein S: Y is (CH 2 )n wherein n is an integer from 1 to 4, and wherein any one S 10 of the carbon-carbon single bonds in said (CH 2 )n may optionally be replaced by a carbon-carbon double bond, and wherein any one of the carbon atoms of said (CH 2 )n may optionally be substituted with R 4 and wherein any one of the carbon atoms of said (CH 2 )n may optionally be substituted with R 7 15 Z is (CH 2 )m wherein m is an integer from 0 to 6, and wherein any one of the carbon-carbon single bonds of (CH 2 )m may optionally be replaced by a carbon-carbon double bond or a carbon-carbon triple bond, and any one of the carbon atoms of said (CH 2 )m may optionally be substituted with R8; R 1 is hydrogen or C-l.alkyl optionally substituted with hydroxy, C14alkoxy or fluoro; R 2 is a radical selected from hydrogen, C 1 i straight or branched alkyl, C3-7cycloalkyl wherein one of the CH 2 groups in said cycloalkyl may optionally be replaced by NH, oxygen or sulphur; aryl selected from phenyl and naphthyl; heteroaryl selected from indanyl, thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl and 96 quinolyl; phenyl-C2-6alkyl, benzhydryl and benzyl, wherein each of said aryl and heteroaryl groups and the phenyl moieties of said benzyl, phenyl C2-6alkyl and benzhydryl may optionally be substituted with one or more substituents independently selected from halo, nitro, C1..6 alkyl, C1..6alkoxy, trifluoromethyl, amino, Obo6alkylamino, Cl-6alkyl-O-CO, CI-6alkyl-O-CO- Ci..oalkyl, Ci..oalkyl-CO-O, Cio6alkyl-CO-Cl-6alkyl-O-, C1..6alkyl-CO, Ci..oalkyl-CO-Ci-6alkyl-, di-Ci..oalkylamino, -CONH-CI..oalkyl, Ci..oalkyl-CO-NH-Ci-6alkyl, -NHCOH and -NHCO-Cr-6alkyl; and wherein one of the phenyl moieties of said benzhydryl may optionally be replaced by naphthyl, thienyl, furyl or pyridyl; is hydrogen, phenyl or Ci..oalkyl; or R 2 and R5 together with the carbon to which they are attached, form a saturated ring having from 3 to 7 carbon atoms wherein one of the OH 2 groups in said ring may optionally be replaced by oxygen, NH or 15 sulfur; R 3 is aryl selected from phenyl and naphthyl; heteroaryl selected from indanyl, thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl and quinolyl; and cycloalkyl having 3 to 7 carbon atoms wherein one of the (CH 2 groups in said cycloalkyl. may 20 optionally be replaced by NH, oxygen or sulphur; wherein each of said aryl and heteroaryl groups may optionally be substituted with one or more substituents, and said C3..7cycloalkyl may optionally be substituted with one or two substituents, each of said substituents being independently selected from halo, nitro, Ci..oalkyl, CI-6alkoxy, trifluoromethyl, amino, C1.6alkylamino, -CO-NH- C1..6alkyl, C1.6alkyl-CO-NH-Clo6alkyl, -NHCOH and -NHCO-Ci.oalkyl; R 4 and R 7 are each independently selected from hydroxy, halogen, halo, amino, oxo, cyano, methylene, hydroxymethyl, halomethyl, Ci..oalkylamino, di-Cl-6alkylamino, Ci..oalkoxy, Cl-6alkyl-O-CO, Clioalkyl-O-CO-Clioalkyl, Ci-6alkyl-CO-O, Clioalkyl-CO-C 1-6alkyl-O-, -97- Clialkyl-CO-, Ci-6alkyl-CO-Cl-ealkyl, and the radicals set forth in the definition of R 2 R 6 is -NHCOR S -NHCH 2 R 9 S0 2 R8 or one of the radicals set forth in any of the definitions of R 2 R 4 and R 7 R8 is oximino (=NOH) or one of the radicals set forth in any of the definitions of R2, R4 and R 7 R 9 is Ci-ealkyl, hydrogen, phenyl or phenylCl-alkyl; with the proviso that when m is 0, R s is absent, when R 4 R 6 R 7 or R 8 is as defined in R 2 it cannot form together with the carbon to which it is attached ,a ring with R 5 and when R 4 and R 7 are attached to the same carbon atom, then either each of R 4 and R 7 is independently selected from hydrogen, fluoro and Cl-6alkyl, or R 4 and R 7 together with the carbon :i to which they are attached, for a C3-6 saturated carbocyclic ring that forms a spiro compound with the nitrogen-containing ring to which they are 15 attached; or a pharmaceutically acceptable salt thereof. A use according to claim 1, a composition according to claim 2, a product according to claim 3 or a method according to claim 4 wherein S 20 the NK-1 receptor antagonist is a compound of formula VI: N ICH-R 1 (VI) R 5 12 R R' R 4 wherein: radicals R are phenyl radicals optionally 2- or 3-substituted by a halogen atom or a methyl radical; R 1 is optionally substituted phenyl, cyclohexadienyl, naphthyl, indenyl or optionally substituted heterocycle; -98- R 2 is H, halogen, OH, alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkyloxy, alkylthio, acyloxy, carboxy, optionally substituted alkyloxycarbonyl, benzyloxycarbonyl, amino or acylamino; R 3 is optionally 2-substituted phenyl; R 4 is OH or fluorine when R 5 is H; or R 4 and R 5 are OH; or R 4 and R 5 together form a bond; or a pharmaceutically acceptable salt thereof. 11. A use according to claim 1, a composition according to claim 2, a product according to claim 3 or a method according to claim 4 wherein the NK-1 receptor antagonist is a compound of formula VII: *R Q Ar-T-CO- -CH 2 -C-CH 2 -CH-Am A- (VII) Ar' wherein: Ar represents an optionally substituted mono-, di- or tricyclic aromatic or heteroaromatic group; T represents a bond, a hydroxymethylene group, a 20 C14alkoxymethylene group or a Cl-5alkylene group; Ar' represents a phenyl group which is unsubstituted or substituted by one or more substituents selected from halogen, preferably chlorine or fluorine, trifluoromethyl, C14alkoxy, C14alkyl where the said substituents may be the same or different; a thienyl group; a benzothienyl group; a naphthyl group; or an indolyl group; R represents hydrogen, C1-4alkyl, o)-Ci4alkoxyC14alkyl, or )-C2-4alkanoyloxyC2-4alkyl; Q represents hydrogen; -99- or Q and R together form a 1,2-ethylene, 1,3-propylene or 1,4- butylene group; Am represents the radical 2 1, in which X 1 X 2 and Xa, together with the nitrogen atom to which they are attached, form an azabicyclic or azatricyclic ring system optionally substituted by a phenyl or benzyl group; and A- represents a pharmaceutically acceptable anion. 12. A use according to claim 1, a composition according to claim 2, a product according to claim 3 or a method according to claim 4 wherein the NK-1 receptor antagonist is a compound of formula VIII R 3 R 1 (VIII) R---X wherein: 15 R 1 represents an optionally substituted aralkyl, aryloxyalkyl, 'heteroaralkyl, aroyl, heteroaroyl, cycloalkylcarbonyl, aralkanoyl, S. heteroarylalkanoyl, aralkoxycarbonyl or arylcarbamoyl group or the acyl C group of an a-amino acid optionally N-substituted by a lower alkanoyl or carbamoyl-lower alkanoyl group; R 2 represents cycloalkyl or an optionally substituted aryl or heteroaryl group; R 3 represents hydrogen, alkyl, carbamoyl or an alkanoyl or alkenoyl group optionally substituted by carboxy or esterified or amidated carboxy; R 4 represents an optionally substituted aryl group or an optionally partially saturated heteroaryl group; -100- X 1 represents methylene, ethylene, a bond, an optionally ketalised carbonyl group or an optionally etherified hydroxymethylene group; X 2 represents alkylene, carbonyl or a bond; and X 3 represents carbonyl, oxo-lower alkyl, oxo(aza)-lower alkyl, or an alkyl group optionally substituted by phenyl, hydroxymethyl, optionally esterified or amidated carboxy, or (in other than the a-position) hydroxy; or a pharmaceutically acceptable salt thereof. 13. A use according to claim 1, a composition according to claim 2, a product according to claim 3 or a method according to claim 4 wherein the NK-1 receptor antagonist is a compound of formula IX: R 3 R -Y-A-N CONHCHCON (IX) 15 wherein: S z X is CH or N; and Z is 0 or N-R 5 in which R 5 is hydrogen or lower alkyl; R2 is hydroxy or lower alkoxy; R 3 is hydrogen or optionally substituted lower alkyl; R4 is optionally substituted ar(lower)alkyl; A is carbonyl or sulfonyl; and Y is a bond or lower alkenylene; or a pharmaceutically acceptable salt thereof. -101- 14. A use according to claim 1, a composition according to claim 2, a product according to claim 3 or a method according to claim 4 wherein the NK-1 receptor antagonist is a compound of formula X: H 1 N R2 H (X) wherein: R 1 is aryl selected from indanyl, phenyl and naphthyl; heteroaryl selected from thienyl, furyl, pyridyl and quinolyl; and cycloalkyl having 3 to 7 carbon atoms, wherein one of said carbon atoms may optionally be 10 replaced by nitrogen, oxygen or sulfur; wherein each of said aryl and heteroaryl groups may optionally be substituted with one or more substituents, and said C3-7cycloalkyl may optionally be substituted with one or two substituents, said substituents being independently selected from chloro, fluoro, bromo, iodo, nitro, Cl-ioalkyl optionally substituted with from one to three fluoro groups, Ci-loalkoxy optionally substituted with from one to three fluoro groups, amino, Ci-loalkyl-S-, Cli-oalkyl-S(O)-, Ci-ioalkyl-S0 2 phenyl, phenoxy, Cl-loalkyl-SO 2 NH-, S:Ci-loalkyl-SO 2 NH-C-loakyl-, Ci-loalkylamino-diCi-loalkyl-, cyano, hydroxy, cycloalkoxy having 3 to 7 carbon atoms, Ci-ealkylamino, Cledialkylamino, 20 HC(O)NH- and Cl-loalkyl-C(O)NH-; and R 2 is thienyl, benzhydryl, naphthyl or phenyl optionally substituted with from one to three substituents independently selected from chloro, bromo, fluoro, iodo, cycloalkoxy having 3 to 7 carbon atoms, Ci-loalkyl optionally substituted with from one to three fluoro groups and Ci-loalkoxy optionally substituted with from one to three fluoro groups; or a pharmaceutically acceptable salt thereof. -102- A use according to claim 1, a composition according to claim 2, a product according to claim 3 or a method according to claim 4 wherein the NK-1 receptor antagonist is a compound of formula XI: R 2 I H N -R R wherein: R 1 is a C-4alkoxy group; R 2 is 6 N N I N N-N 10 R 3 is a hydrogen or halogen atom; R 4 and R 5 may each independently represent a hydrogen or halogen atom, or a C-4alkyl, C-4alkoxy or trifluoromethyl group; R 6 is a hydrogen atom, a Ci-4alkyl, (CH2)mcyclopropyl, -S(O)nCl4alkyl, phenyl, NR 7 R 8 s CH 2 C(O)CF 3 or trifluoromethyl group; R 7 and R8 may each independently represent a hydrogen atom, or a Cl4alkyl or acyl group; x represents zero or 1; n represents zero, 1 or 2; and m represents zero or 1; or a pharmaceutically acceptable salt thereof. 103 16. A use according to claim 1, a composition according to claim 2, a product according to claim 3 or a method according to claim 4 wherein the NK-1 receptor antagonist is a compound of formula XII: R8 R4 NH 1I (XII) wherein: m is zero, 1, 2 or 3; n is zero or 1; o is zero, 1 or 2; p is zero or 1; R is phenyl, 2- or 3-indolyl, 2- or 3-indolinyl, benzothienyl, benzofuranyl, or naphthyl; which R groups may be substituted with one or two halo, C1..3alkoxy, trifluoromethyl, CI-4alkyl, phenyl-Cl-3alkoxy, or Ci-4alkanoyl groups; R1 is trityl, phenyl, diphenylmethyl, phenoxy, phenylthio, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, indolinyl, indolyl, benzothienyl, hexamethyleneiminyl, benzofuranyl, tetrahydropyridinyl, quinolinyl, isoquinolinyl, reduced quinolinyl, reduced isoquinolinyl, phenyl-(Ci-4alkyl)-, phenyl-(Ci-4alkoxy)-, quinolinyl-(Cl-4alkyl)-, isoquinolinyl-(Cl-4alkyl)-, reduced quniolinyl-(Cl-4alkyl)-, reduced isoquinolinyl-(CI- 4 alkyl)-, benzoyl-(C1..3alkyl)-, Ci-4alkyl, or -NH-CH2-R 5 any one of which R' groups may be substituted with halo, Ci4alkyl, C14alkoxy, trifluoromethyl, amino, Ci-4alkylarnino, di(Ci-4alkyl)amnino, or C2A4alkanoylamino; 104 or any one of which R' groups may be substituted with phenyl, piperazinyl, C3a8cycloalky1, benzyl, Ci-4alkyl, piperidinyl, pyridinyl, pyrimidinyl, C26alkanoylamnino, pyrrolidinyl, C2..alkanoyl, or Cl-4alkoxycarbonyl; any one of which groups may be substituted with halo, Cl4alkyl, Cl-4alkoxy, trifluoromethyl, amino, C1-4alkylamino, di(Cl-4alkyl)amino, or C2A4alkanoylamino; or R' is amino, a leaving group, hydrogen, Ci-4alkylamino, or di(Cl-4alkyl)amino; R 5 is pyridyl, anilino-(Cl-3alkyl)-, or anilinocarbonyl; R 2 is hydrogen, Cl-4alkyl, Cl-4alkylsulfonyl, carboxy-(Ci..aalkyl)-, Cl-alkoxycarbonyl-(Cl.3alkyl)-, or -CO-R6; R 6 is hydrogen, Ci-4alkyl, Cl..3haloalkyl, phenyl, Cka3alkoxy, Ci-3hydroxyalkyl, amino, Cl-4alkylamnino, di(Ci-4alkyl)amino, or -(CH2)q-R 7 15 q is zero to 3; R 7 is carboxy, Cl-4alkoxycarbonyl, Ci-4alkylcarbonyloxy, amino, Cl-4alkylamino, di(Cl-4alkyl)amino, C1.6alkoxycarbonylamino, or phenoxy, phenylthio, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, indolinyl, indolyl, benzothienyl, benzofuranyl, quinolinyl, phenyl-(Ci-4alkyl)-, see*.: 20 quinolinyl-(Cl-4alkyl)-, isoquinolinyl-(Cl-4alkyl)-, reduced quinolinyl- ~~(Ci-4alkyl)-, reduced isoquinolinyl-(iakl- ezy-1.akl :aa any one of which aryl or heterocyclic R 7 groups may be substituted with halo, trifluoromethyl, Ci-4alkoxy, C1-4alkyl, amino, Ci-4alkylaMino, di(Cl-4alkyl)amino, or C2A4alkanoylamino; or any one of which R7 groups may be substituted with phenyl, piperazinyl, C3..8cycloalkyl, benzyl, piperidinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, C2.6alkanoyl, or Cl-4alkoxycarbonyl; any of which groups may be substituted with halo, trifluoromethyl, amino, C1..4alkoxy, Ci-4alkyl, Ci-4alkylamino, di(Ci-4alkyl)amino, or C2-4alkanoylamino; R8 is hydrogen or C1-6alkyl; 105 RWis phenyl, phenyl-(Ci-6alkyl)-, C3.8cycloalkyl, C1..8alkyl, naphthyl, C2-8alkenyl, or hydrogen; any one or which groups except hydrogen may be substituted with one or two halo, Cisalkoxy, Ci..salkylthio, nitro, trifluoromethyl, or Ci..3alkyl groups; and R 4 is hydrogen or Ci-3alkyl; with the proviso that if R' is hydrogen or halo, RWis phenyl, phenyl-(Ci-6alkyl)-, C3acycloalkyl, C5.acycloalkenyl, or naphthyl; or a pharmaceutically acceptable salt thereof. *17. A use, composition, product or method according to any one of the preceding claims wherein the NK-1 receptor antagonist is orally active, long acting and CNS-penetrant. 6 15 18. A use according to claim 1, a composition according to claim 2, a product according to claim 3 or a method according to claim 4 wherein the NK-1 receptor antagonist is selected from the classes of compounds described in EP-A-0577394, WO-A-9508549, WO-A-9518124, WO-A-9523798 or WO-A-9605181. *Gt: *006 19. A use according to claim 1, a composition according to claim *O 2, a product according to claim 3 or a method according to claim 4 wherein the NK-1 receptor antagonist is selected from 4 3 2 4 -triazolo)methyl)-2(S)-(3,5-bis(trifluoromethyl)benzyloxcy)-3(S) phenyl-morpholine; l, 2 4 -triazolo)methyl)-2(S)-(3,5-bis(trifluoromethyl)benzyloxy)-3(R)- phenyl-morpholine; 4 3 -(5-oxo-1H,4H- 1,2,4-triazolo)methyl)-2(S)-(3,s.. bis(trifluoromethyl)benzyloxy)-3(S)-phenyl.morpholine; .2()(-R-35bstilooehlpey~toy--S-4furpey) 4 3 -(5-oxo- 1H,4H-1 2 4 -triazolo)methyl)morpholine; 106 1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(dimethyla-ino) methyl-i ,2,3-triazol-4-yl)methyl-3-(S)-phenylmorpholine; 1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(dimethylamjno) methyl-1,2,3-triazol-4-yl)methy-3-(S)-(4-fluorophenyl)morpholine; 1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4- fluorophenyl)-4-(1,2,4-triazol-3-yl)methylmorpholine; 2-(S)-(3,5-bis(trifluoromethyl)benzyloxy)-3-(S)-phenyl-4-(3-(5-oxo-lH,4H. 1,2,4-triazolo)methyl)morpholine N-oxide; 2-(S)-(3,5-bis(trifluoromethyl)benzyloxy)-3-(S)-phenyl-4-(3-(4- (ethoxycarbonyloxy-1-ethyl)-5-oxo-1H-1,2,4-triazolo)methyl)morpholine; 1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)- 4 3 4 -monophosphoryl-5-oxo-1H-1,2,4-triazolo)methyl)morpholine; 1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)- 1-monophosphoryl-5-oxo-1H- 1,2,4-triazolo)methyl)morpholine; 2 -(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl). 4-(3-(2-monophosphoryl-5-oxo-1H-1 ,2,4-triazolo)methyl)morpholine; l-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)- 4 3 -(5-oxyphosphoryl-1H-1,2,4-triazolo)methyl)morpholine; l-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)- 20 1-monophosphoryl-5-oxo-4H-1 ,2,4-triazolo)methyl)morpholine; 3 R,5R,6S)-3-(2-methoxy-5-(trifluoromethoxy)phenyl)-6-phenyl-1-oxa-7- aza-spiro [4.Sldecane; (3R,5R,6S)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-6-phenyl- 1-oxa-7-aza- Spiro (3R,5R,6S)-7-benzyl-3- [2-methoxy-5-(trifluoromethoxy)pheny1lJ-6-phenyl- 1- oxa-7-aza-spiro decane; (3R, 5R,6S)-3-(2-methoxy-5-trifluoromethoxyphenyl)-6-phenyl- 1-oxa-7-aza- Spiro [4.51 decane; (3R, 5R,6S)-3 ,6-bis(phenyl)- 1-oxa-7-aza-spiro decane; (3R,5R,6S)-7-benzyl-3-(2-methoxy-5-trifluoromethoxyphenyl)-6-phenyl- 1- oxa-7-aza-spiro decane; 107 (t)-3R*5R*,S*)3-(-metoxyhenl)-6pheyl1-oxa-7- (phenylmethoxycarbonyl)aza-spiro decane; (3R,5R,6S)-3-(2-methoxyphenyl)-6-phenyl-1-oxa-7-aza-spiro (3S, 5R,6S)-3-(2-cyclopropoxy-5-(trifluoromethoxy)phenyl)-6-phenyll1oxa. 7-aza-spiro [4.51 decane; (3R, 5R,6S)-3- [2-cyclopropoxy-5-(trifluoromethoxy)phenyll -6-phenyl-1-oxa- 7-aza-spiro [4.51 decane; (3S, 5R [2-cyclopropoxy-5-(trifluoromethyl)phenyl -6-phenyl- 1-oxa-7- aza-spiro decane; se. 10 (2S,3S)-cis-3-(2-methoxybenzylamino)-2-phenylpiperidine; (3aS, 4S, 7aS)-7,7-diphenyl-4-(2-methoxyphenyl)-2- methoxyphenyl)propionyl] perhydroisoindol-4-ol; see+ 1- [3-(3,4-dichlorophenyD- 1- [(3-isopropoxyphenyl)acetylJ -3- piperidinyl] ethyl] -4-phenyl-1-azabicyclo [2,2,21 octane; 4S)2bny--35dmtybnol--4qioiymty)4 piperidineamine; HO~ /NN 2 S,3S)-3-(2-methoxy-5-trifluoromethoxybenzy)..amno.2 phenylpiperidine; 2 -methoxy-5-tetrazol-1-yl-benzyl)-( [2S,3S] -2-phenyl-piperidin-3-yl)-amine; 2 -methoxy-5-(5-trifluoromethyl-tetrazol- 1-yl)-benzyl] [2S,3S] -2-phenyl- piperidin-3-yl)-amine; and [N-(2-methoxybenzyl)acetylaminol 1H-indol-3-yl)-2- [N-(2-(4-piperidin- 1- yl)piperidin-1-yl)acetylaminolpropane; a pharmaceutically acceptable salt thereof. 108 A process for preparing a pharmaceutical composition comprising combining a selective COX-2 inhibitor and a NK-1 receptor antagonist with a pharmaceutically acceptable carrier, wherein said selective COX-2 inhibitor is selected from the group consisting of: 3 -phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)..furanone; 3 3 4 -difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)4furanone; 5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-3-(3-fluorophenyl)Hfuran2- one; 5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-3-(2-propoxy).5H.furan2one; 3 4 -(methylsulfonyl)phenyl)-2-(2-methyl..spyridinyl)pyridine; 2-(3 ,5-difluorophenyl)-3-(4-(methylsulfonyl)phenyl)-2cyclopenten-1-one; (S)-5-ethyl-5-methyl-4-(4-(methylsulfonyl)phenyl)3(2-propoxy)-5H- furan-2-one; 5-ethyl-5-methyl-4-(4-(methylsulfonyl)phenyl)-3(3,4..difluorophenyl)-5H- furan-2-one; 3 2 -thiazolyl)methoxy)-4-(4-(methylsulfonyl)phenyl)-,.dimethyl.5H- furan-2-one; 3 -propyloxy- 4 4 -(methylsulfonyl)phenyl)-5,s..dimethylbsH-uran2-one; 3 -(l-cyclopropylethoxy)-5,5-dimethyl4(4-methylsulfonyl)phenyl).5H- ftiran-2-one; .:sodium 2 4 -chlorophenyl)-3-(4-(methylsulfonyl)phenyl)4oxo-2 pentenoate; 3 -(cyclopropylmethoxy)-5,s-dimethyl.4(4..(methylsulfonyl)phenyl).SH furan-2-one; 3 -(cyclopropylmethoxy)-,5-.dimethyl.4-.(4.(methylsulfonyl)phenyl..2,5-. dihydrofuran-2-ol; 3 -isopropoxy-5,5-dimethyl-4(4-.(methylsulfonyl)phenyl)>25-dihydrofuran. 2-ol; 5,5-dimethyl- 3 -(3-fluorophenyl).2hydroxy-4-.(4-(methylsulfonyl)phenyl). 2 109 5-chloro-3-(4-(methylsulfonyl)phenyl)-2-(3-pyridinyl)pyridine; 4 -(5-methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; 5-(4-fluorophenyl)-1- [4-(methylsulfonyl)phenyl] -3- (trifluoromethyl)pyrazole; 4-(4-fluorophenyl)-5- [4-(methylsulfonyl)phenyl] -1-phenyl-3- (trifluoromethyl)pyrazole; 4-(5-(4-chlorophenyl)-3-(4-methoxyphenyl)- 1H-pyrazol-1- yl)benzenesulfonamide; 4-(3,5-bis(4-methylphenyl)- 1H-pyrazol-1-yl)benzenesulfonamide; 4 4 -chlorophenyl)-3-phenyl-1H-pyrazol-1-yl)benzenesulfonamide; 4-(3,5-bis(4-methoxyphenyl)- 1H-py-razol- 1-yl)benzenesulfonamide; 4 -(5-(4-chlorophenyl)-3-(4-methylphenyl)- 1H-pyrazol- 1- yl)benzenesulfonainide; 4 -(5-(4-chlorophenyl)-3-(4-nitrophenyl)-1H-pyrazol- 1- yl)benzenesulfonam-ide; 4 4 -chlorophenyl)-3-(5-chloro-2-thienyl)-1H-pyrazol-l- yl)benzenesulfonaniide; 4 4 -chloro-3,5-diphenyl-lH-py-razol-1-yl)benzenesulfonamide; 4 -(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1- 20 yl)benzenesulfonamide; 4-(5-phenyl)-3-(trifluoromethyl)- iR-pyrazol- 1-yl)benzenesulfonamide; a. 4 -(5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-l- yl)benzenesulfonamide; 4-(5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1- yl)benzenesulfonamide; 4-(5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1- yl)benzenesulfonamide; 4-(5-(4-methylphenyl)-3-(trifluoromethyl)- 1H-pyrazol-1- yl)benzenesulfonamide; 4 4 -chloro-5-(4-chlorophenyl)-3-(trifluoromethyl)1lHpyrazopl-.. yl)benzenesulfonamide; 110 4 -(3-(difluoromethyl)-5-(4-methylphenyl)-lH-pyrazol-l-. yl)benzenesulfonamide; 4-3(ilooehl--hnll-przl1y~eznsloaie 4 -(3-(difluoromethyl)-5-(4-methoxyphenyl)- 1H-pyrazol-1- yl)benzenesulfonamide; 4-3cao5(-loohnl-Hprzl1y~eznsloaie 4 3 -(difluoromethy)-5-(3-fluoro-4-methoxypheny)-lH-pyrazol-l-. yl)benzenesulfonamide; 4 3 -fluoro-4-methoxypheny)-3-(trifluoromethy).1Hpyrazol-l- yl)benzenesulfonamide; 4-4clr--hnll-yazl1y~eznsloaie 4 4 -chlorophenyl)-3-(hydroxyphenyl)- 1H-pyrazol-1- yl)benzenesulfonamide; 4 4 -(N,N-dimethylamino)pheny1)-3-(trifluoromethyl)1lH.pyazol-l-1 yl)benzenesulfonamide; 4 -fluorophenyl)-6-(4-(methylsulfonyl)phenyl)spiro [2.4lhept-5-ene; 4 6 4 -fluorophenyl)spiro 2 4 6 4 -fluorophenyl)-7-(4-(methylsulfonyl)phenyl)spiro[13.41 oct-6-ene; 3 -chloro-4-methoxyphenyl)-6-(4-(methylsulfonyl)phenyl)spiro [2.4lhept- 20 4 6 3 -chloro-4-methoxyphenyl)spiro [2.4]hept-5-en-5- yl)benzenesulfonamide; 3 ,S-dichloro-4-methoxypheny)-6-(4-(methylsulfony)pheny). spiro [2.41 5-( 3 -chloro-4-fluorophenyl)-6-(4-(methylsulfonyl)phenyl)spiro [2.41 ene; 4-(6-(3,4-dichlorophenyl)spiro 2 4 2 -(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-(4. methylsulfonylphenyl)thiazole; 2 2 -chlorophenyl)- 4 4 -fluoropheny)-5-(4-methylsulfonylpheny1)thiazole; 4 -fluorophenyl)- 4 4 -methylsufonylpheny)-2-methylthiazole; ill 4 4 -fluorophenyl)-5-(4-methylsulfonylphenyl)-2-trifluoromethylthiazole; 4 4 -fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(2-thienyl)thiazole; 4 -(4-fluorophenyl)-5-(4-methylsulfonylpheny1)-2-benzylaininothiazole; 4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-( 1-propylamino)thiazole; 2-((3,5-dichlorophenoxy)methyl)-4-(4-fluorophenyl)-5-(4- (methylsulfonyl)phenyl)thiazole; 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-trifluoromethylthiazole; 1-methylsulfonyl-4-( 1, 1-dimethyl-4-(4-fluorophenyl)cyclopenta-2,4-dien-3- yl)benzene; 4-(4-(4-fluorophenyl)-1 ,1-dimethylcyclopenta-2,4-dien-3- yl)benzenesulfonamide; 5-(4-fluorophenyl)-6-(4-(methylsulfonyl)phenyl)spiro hepta-4,6-diene; 4-(6-(4-fluorophenyl)spiro [2 .4lhepta-4,6-dien-5-yl)benzenesulfonamide; 6-( 4 -fluorophenyl)-2-methoxy-5-(4-(methylsulfonyl)phenyl)-pyridine-3- carbonitrile; 2 -bromo-6-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)-pyridine-3- carbonitrile; 6-( 4 -fluorophenyl)-5-(4-(methylsulfonyl)phenyl)-2-phenyl-pyridine-3- carbonitrile; 20 4 -(2-(4-methylpyridin-2-yl)-4-(trifluoromethyl)- 1H-imidazol-1- ylbenzenesulfonamide; 4 2 -(5-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-l- yl)benzenesulfonamide; 4 -(2-(2-methylpyridin-3-yl)-4-(trifluoromethyl)- 1H-imnidazol- 1- yl)benzenesulfonamide; l-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)- 1H-imidazol-2- yl)benzenesulfonamide; l-( 4 -(methylsulfonyl)phenyl)-4-(trifluoromethyl)1lH-imidazob2- yl)pyridine; 2-methyl-4-( l-( 4 -(methylsulfonyl)phenyl)-4-(trifluoromethyl) 1H-imidazol- 2-yl)pyridine; 112 2-methyl-6-( 1-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)-lH-iiazol. 2-yl)pyridine; 4 2 -(6-methylpyridin-3-yD)-4-(trifluoromethyl)- 1H-imidazol-1- yl)benzenesulfonamide; 2 4 -difluorophenyl)-1-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)1lH imidazole; 4 4 -methylphenyl)-4-(trifluoromethyl)-1H-imidazol-l- yl)benzenesulfonamide; 2 4 -chlorophenyl)--(4-(methylsulfonyl)phenyl)-4-methyllH-imidazole; 2-(4-chlorophenyl)- l-(4-(methylsulfonyl)phenyl)-4-phenyl-lH-imidazole; 2 4 -chloropheny)-4-(4-fluoropheny)--(4.(methysufony)pheny)-.1H imidazole; 2 -(3-fluoro-4-methoxyphenyl)- 1-(4-(methylsulfonyl)phenyl)-4- (trifluoromethyl)- 1H-imidazole; l-( 4 -(methylsulfonyl)phenyl)-2-phenyl-4-trifluoromethylblH.inidazole; 2-(4-methylphenyl)- l-( 4 -(methylsulfonyl)phenyl)-4-trifluoromethyl.H. imidazole; 4 2 -(3-chloro-4-methylpheny)-4-(trifluoromethy)-Himdazo...1. yl)benzenesulfonamide; 2 3 -fluoro-5-methylpheny)-l-(4-(methylsulfony)pheny>.4. (trifluoromethyl)-1H-inudazole; 4 2 -(3-fluoro-5-methylphenyl)-4-(trifluoromethyl)-lH-imidazol-l-. yl)benzenesulfonamide; 2-(3-methylphenyl)- 1-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)-H. imidazole; 4-( 2 -(3-methylphenyl)-4-(trifluoromethyl)-lH-imidazol-l- yl)benzenesulfonamide; l-(4-(methylsulfonyl)phenyl)-2-(3-chlorophenyl)-4-(trifluoromethyl)- 1H- imidazole; 4-(2-(3-chlorophenyl)-4-(trifluoromethyl)- 1H-imidazol- 1- yl)benzenesulfonamide; 113 4 2 -phenyl- 4 -(trifluoromethyl)-1H-imidazol-1-yl)benzenesulfonamide; 4 2 -(4-methoxy-3-chlorophenyl)-4(trifluoromethy)1Himdazol-l-. yl)benzenesulfonamide; l-allyl- 4 4 -fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-5-(trifluoromethyl). 1H-pyrazole; yl)benzenesulfonamide; N-phenyl-(4-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl..s. (trifluoromethyl)-1H-pyrazol-1-yl)acetamide; ethyl 4 4 -fluorophenyl)-3-(4-(methylsulfonyl)phenyl).5-(trifluoromethyl). lH-pyrazol-1-yl)acetate; 4 4 -fluorophenyl)-3-(4-(methylsufonyl)phenyl)i...(2.phenylethyl)lH- pyrazole; 4 4 -fluorophenyl)-3-(4-(methylsulfonyl)phenyl)..1.(2..phenylethyl).s.. (trifluoromethyl)pyrazole; l-ethyl- 4 -(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-5..(tirifluoromethyl). IH-pyrazole; 4 -fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(trifluoromethyl). H- imidazole; 20 4 4 -(methylsulfonyl)phenyl)-5-(2-thiophenyl>2-(trifluoromethyl) 1H- imidazole; 4 -fluorophenyl)-2-methoxy-4-(4-(methylsulfonyl)phenyl).6 (trifluoromethyl)pyridine; 2 -ethoxy-5-(4-fluorophenyl)4(4-(methylsufonyl)pheny)-6- (trifluoromethyl)pyridine; 4 -fluorophenyl)-4-4-(methylsulfonyl)phenyl)2(2-propyyloxy..6- (trifluoromethyl)pyridine; 2 -bromo-5-(4-fluorophenyly..4-(4..{methylsulfonyl)phenyl..6 (trifluoromethyl)pyridine; 4 2 3 -chloro-4-methoxyphenyl)-4,5-difluorophenyl)benzenesulfonamjide; l-( 4 -fluorophenyly..2-.(4(methylsulfonyl)phenyl)benzen; 114 5-difluoromethyl-4-(4-(methylsulfonyl)phenyl)-3-phenylisoxazole; 4-(3-ethyl-5-phenylisoxazol-4-yl)benzenesulfonamide; 4-(5-difluoromethyl-3-phenylisoxazol-4-yl)benzenesulfonamide; 4-(5-hydroxymethyl-3-phenylisoxazol-4-yl)benzenesulfonamide; 4-(5-methyl-3-phenylisoxazol-4-yL)benzenesulfonamide; 1-(2-(4-fluorophenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 1-(2-(4-fluoro-2-methylphenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 1-(2-(4-chlorophenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 1-(2-(2,4-dichlorophenylcyclopenten-1-yl)-4-(methylsulfonyl)benzene; 1-(2-(4-trifluoromethylphenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 1-(2-(4-methylthiophenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 1-(2-(4-fluorophenyl)-4,4-dimethylcyclopenten-1-yl)-4- (methylsulfonyl)benzene; 4-(2-(4-fluorophenyl)-4,4-dimethylcyclopenten- 1-yl)benzenesulfonaniide; 1-(2-(4-chlorophenyl)-4,4-dimethylcyclopenten-1-yl)-4- (methylsulfonyl)benzene; 4-(2-(4-chlorophenyl)-4,4-dimethylcyclopenten-1-yl)benzenesulfonamide; 4-2(-lorpey*ycoetn1**bneesloaie 4-(2-(4-lorophenyl)cyclopenten-1-yl)benzenesulfonamide; 20 1-(2-(4-methoxyphenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 1-(2-(2,3-difluorophenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 4-(2(3fluoro4methoxypheny)cyclopenten1y)benzenesulfonapmjde; 1-(2-(3-chloro-4-methoxyphenyl)cyclopenten- l-yl)-4- (methylsulfonyl)benzene; 4-(2-(3-chloro-4-fluorophenyl)cyclopenten- 1-yl)benzenesulfonamide; 4-(2-(2-methylpyridin-5-yl)cyclopenten-1-y1)benzenesulfonanmjde; ethyl 2 4 -(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazol-2-yl)-2- benzyl-acetate; 2 -(4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazol-2-yl)acetic acid; 2 -(tert-butyl)-4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazole; 4 4 -fluorophenyl)-5-(4-(methylsulfonyl)phenyl)-2-phenyloxazole; 115 4 4 -fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)phenyl)oxazole; and 4 3 -fluoro-4-methoxyphenyl)-2-trifluoromethyl-4. oxazolyl)benzenesulfonaniide; or a pharmaceutically acceptable salt thereof. 21. The use of a NK-1 receptor antagonist for the manufacture of a medicament for the combined use with a selective cyclooxygenase-2 inhibitor for preventing or reducing the risk of developing an inflammatory disorder, for halting or slowing the progression of an inflammatory disorder, or for preventing or reducing the risk of occurrence or recurrence of an inflammatory disorder, wherein said selective COX-2 inhibitor is selected from the group consisting of: 3-hnl4(-(ehlufny hnl--(H-uaoe 3 3 4 -difluorophenyl)-4-(4(methylsulfony)phenyl)2.(5H)-furanone; 4 -(4-(methylsulfonyl)phenyl)3(3fluorophenyl)5H-fran-2. one; 4 (4(methylsulfonyl)phenyl)3.(2propoxy)5H.furan2one; 20 2 3 ,5-difluorophenyl)3(4(methylsulfonyl)phenyl)2cyclopentenlone; 9 (S)-5-ethyl-5-methyl-4-(4(methylsulfonyl)phenyl)3.(2propoxy)-5H- 2~ furan-2-one; 5-ethyl-5-methyl-4-(4-(methylsulfonyl)phenyl)3(3,4-dijfluorophenyl)5H. furan-2-one; 3 2 -thiazolyl)methoxy)-4-(4-(methylsulfonyl)phenyl)..,s.dimethyls5H furan-2-one; 3 -propyloxy- 4 4 -(methylsulfonyl)phenyl)-,5-dimethyl.sHfran2-one; 3 -(l-cyclopropylethoxy)-5,5-dimethyl-4-(4-methylsulfonyl)phenyl)5H- furan-2-one; sodium 2 4 -chlorophenyl)-3-(4(methylsulfonyl)phenyl)4ox-2- pentenoate; 116 0 0 00 0* 00 0 0000 0000 3 -(cyclopropylmethoxy)-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-5H. furan-2-one; 3 -(cyclopropylmethoxy)-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-2,5-. dihydrofuran-2-ol; 3 -isopropoxy-5,5-dimethy-4-(4-(methylsulfony1)phenyl).25-ihydroffiran. 2-ol; 5,S-dimethyl-3-(3-fluoropheny)-2-hydroxy-4-(4(methysufony)pheny). 5-chloro-3-(4-(methylsulfonyl)phenyl)-2-(3-pyridinyl)pyridine; 10 4 -(5-methyl-3-phenyl-4-isoxazolyl)benzenesulfonanmjde; 5-(4-fluorophenyl)-1- [4-(methylsulfonyl)phenyl] -3- (trifluoromethyl)pyrazole; 4-(4-fluorophenyl)-5- [4-(methylsulfonyl)phenyll -1-phenyl-3- (trifluoromethyl)pyrazole; 4 4 -chlorophenyl)-3-(4-methoxypheny)-lH-pyrazol-1.. yl)benzenesulfonamide; 4 -(3,5-bis(4-methylphenyl)- 1H-pyrazol-1-yl)benzenesulfonamide; 4 -(5-(4-chlorophenyl)-3-phenyl- lH-pyrazol-1-yl)benzenesulfonamide; 4 3 ,S-bis(4-methoxyphenyl)-1H-pyrazol- 1-yl)benzenesulfonamide; 20 4 4 -chlorophenyl)-3-(4-methylphenyl)- 1H-pyrazol-1- yl)benzenesulfonamide; 4 4 -chlorophenyl)-3-(4-nitrophenyl)-1H-pyrazol-l-. yl)benzenesulfonamide; 4 -(5-(4-chlorophenyl)-3-(5-chloro-2-thienyl)-1H-pyrazol- 1- yl)benzenesulfonamide; 4-(4-chloro-3,5-diphenyl- lH-pyrazol-1-yl)benzenesulfonamide; 4 4 -chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-l- yl)benzenesulfonamide; 4 -(5-phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4 -(5-(4-fluorophenyl)- 3 -(trifluoromethyl)-1H-pyrazol-1- yl)benzenesulfonamide; 117 4 4 -methoxyphenyl)-3-(trifluoromethyl)-lH-pyrazoll- yl)benzenesulfonamide; 4 -(5-(4-chlorophenyl)-3-(difluoromethyl)- 1H-pyrazol-1- yl)benzenesulfonamide; 4 4 -methylphenyl)-3-(trifluoromethyl)-lH.pyrazol.1. yl)benzenesulfonamide; 4 4 -chloro-5-(4-chloropheny1)-3-(trifluoromethyl)1H-pyrazol-l-. yl)benzenesulfonamide; 4 3 -(difluoromethyl)-5-(4-methylphenyl)-H-pyrazol-l-. yl)benzenesulfonamide; 4 3 -(difluoromethy)-5-(4-methoxypheny)-lHpyrazo..1.. yl)benzenesulfonamide; 4 -(3-cyano-5-(4-fluorophenyl)- lH-pyrazol-1-yl)benzenesulfonamide; 4 3 -(difluoromethy1)-5-(3-fluoro4-methoxypheny)1lH-pyazol-l-1 yl)benzenesulfonamide; 4 3 -fluoro-4-methoxyphenyl)-3-(trifluoromethyl). H-pyrazol-1- yl)benzenesulfonamide; 4 4 -chloro-5-pheny-lH-pyrazo1-y1)benzenesulfonamide; 20 4 4 -chlorophenyl)-3-(hydroxyphenyl)1Hpyrazol.1. yl)benzenesulfonamide; a, a. 4 4 -(N,N-dimethylamino)phenyl)-3-(trifluoromethyl).1H-pyrazol1.. yl)benzenesulfonamide; 4 -fluorophenyl)-6-(4-(methylsulfonyl)phenyl)spiro [2.4]hept-5-ene; 4 6 4 -fluorophenyl)spiro 2 4 6 4 -fluorophenyl)-7-(4-(methylsulfonyl)phenyl)spiro oct-6-ene; 5-3clr--ehxpey)6(4(ehlufnlpey pr[2.4]hept- 4 6 3 -chloro-4-methoxyphenyl)spiro [2 .4lhept-5-en-5- yl)benzenesulfonamide; 118 5-(3 ,5-dichloro-4-methoxyphenyl)-6-(4-(methylsulfonyl)phenyl)- Spiro 3 -chloro-4-fluorophenyl)-6-(4-(methylsulfonyl)phenyl)spiro ene; 4 -(6-(3,4-dicfflorophenyl)spiro 2-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-(4- methylsulfonylphenyl)thiazole; 2 2 -chlorophenyl)-4-(4-fluorophenyl).5-.(4..methylsulfonylphenyl)thiazole; 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-methylthiazole; 4 4 -fluorophenyl)-5-(4-methylsulfonylphenyl)-2-trifluoromethylthiazole; 4 4 -fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(2-thienyl)thiazole; 4 4 -fluorophenyl)-5-(4-methylsulfonylphenyl)-2-benzylanminothiazole; 4 4 -fluorophenyl)-5-(4-methylsulfonylphenyl)-2-( 1-propylamino)thiazole; 2 -((3,5-dichlorophenoxy)methyl)-4-(4-fluorophenyl)-5-(4- (methylsulfonyl)phenyl)thiazole; 4 -fluorophenyl)-4-(4-methylsulfonylphenyl)-2-trifluoromethylthiazole; 1-methylsulfonyl-4-( 1, 1-dimethyl-4-(4-fluorophenyl)cyclopenta-2,4-dien-3- yl)benzene; 4-(4-(4-fluorophenyl)- 1, 1-dimethylcyclopenta-2,4-dien-3- *ee. 20 yl)benzenesulfonamide; S-( 4 -fluorophenyl)-6-(4-(methylsulfonyl)phenyl)spiro [2.41 hepta-4,6-diene; 4 6 -(4-fluorophenyl)spiro 2 .4]hepta-4,6-dien-5-yl)benzenesulfonamide; 6 4 -fluorophenyl)-2-methoxy-5-(4-(methylsulfonyl)phenyl).pyridine3- carbonitrile; 2 -bromo-6-( 4 -fluorophenyl)-5-(4-(methylsulfonyl)phenyl).pyidine.3 carbonitrile; 6 4 -fluorophenyl)-5-(4-(methylsulfonyl)phenyl)-2-phenyl-pyridine3- carbonitrile; 4 2 4 -methylpyridin-2-yl)-4-(trifluoromethyl)-H-imidazol.1. yl)benzenesulfonamide; 119 4-(2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-l- yl)benzenesulfonamide; 4-(2-(2-methylpyridin-3-yl)-4-(trifluoromethyl)- 1H-imidazol- 1- yl)benzenesulfonamide; 3-(1-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)-1H-imidazol-2- yl)benzenesulfonamide; 2-(l-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)-1H-imidazol-2- yl)pyridine; 2-methyl-4-(1-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)- 1H-imidazol- 2-yl)pyridine; e~g. 2-methyl-6-(l-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)-1H-imidazol- 2-yl)pyridine; 4-(2-(6-methylpyridin-3-y1)-4-(trifluoromethy1)-lH-imidazol-1- yl)benzenesulfonamide; 2-(3,4-difluorophenyl)-1-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)-1H- imidazole; 4-(2-(4-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-l- yl)benzenesulfonamide; 2-(4-chlorophenyl)-1-(4-(methylsulfonyl)phenyl)-4-methyl-1H-imidazole; 2-(4-chlorophenyl)-l-(4-(methylsulfonyl)phenyl)-4-phenyl-1H-imidazole; 2-(4-chlorophenyl)-4-(4-fluorophenyl)- 1-(4-(methylsulfonyl)pheny1)-1H- imidazole; 2-(3-fluoro-4-methoxyphenyl)-l-(4-(methylsulfonyl)phenyl)-4- (trifluoromethyl)-1H-imidazole; l-(4-(methylsulfonyl)phenyl)-2-phenyl-4-trifluoromethyl-lH-imidazole; 2 -(4-methylphenyl)-1-(4-(methylsulfonyl)phenyl)-4-trifluoromethyl-1H- imidazole; 4-(2-(3-chloro-4-methylphenyl)-4-(trifluoromethyl)- 1H-imidazol- 1- yl)benzenesulfonamide; 2 -(3-fluoro-5-methylphenyl)-1-(4-(methylsulfonyl)phenyl)-4- (trifluoromethyl)- 1H-imidazole; 120 4 2 3 -fluoro-5-methylphenyl)-4-(trifluoromethyl).lH-imsdazol-l- yl)benzenesulfonamide; 2 3 -methylphenyl)-1-(4-(methylsulfonyl)phenyl)4.(trifluoromethyl). H- imidazole; 4 2 -(3-methylphenyl)-4-(trifluoromethy)-H-imjdazo...1 yl)benzenesulfonamide; 1-( 4 -(methylsulfony)phenyl)-2-(3-choropheny)4(trifluoromethyl).1H- imidazole; 4 2 3 -chlorophenyl)-4-(trifluoromethy)-lH-imidazol-l- yl)benzenesulfonamide; 4 2 -phenyl- 4 -(trifluoromethy)-1H-imdazo1..y1)benzenesulfonamide; 4 2 4 -methoxy-3-chlorophenyl)-4-(trifluoromethyl)1H..jmjdazol. yl)benzenesulfonamide; -allyl- 4 4 -fluorophenyl)-3-(4-(methylsulfonyl)phenyl)5.(trifluoromethy)- 1H-pyrazole; 4 -(l-ethyl- 4 -(4-fluoropheny1)-5-(trifluoromethyl)1lH..pyazo13. yl)benzenesulfonamide; a a N-phenyl-(4-(4-fluorophenyl)3(4(methysufony)pheny)5- 0a 2 et( 4 4 -fluorophenyl)-3-(4-(methylsulfonyl) nyl)2pyltlrmeHyl lpyrazol-1yceae a 4 4 -fluorophenyl)-3-(4-(methylsulfonyl)phenyl)..(2.phenylethyl)15. 2 tiloehlpyrazole; 1el 4 4 -fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-5-(t(2.phenylethyl)..5. (tioomylprazole; l-etl 4 lH-pyazole; flohey) 4 4 -(methylsulfonyl)phenyl)...2tiohny)2(trifluoromethyl)..IH. imidazole; 121 4 -fluorophenyl)-2-methoxy-4-(4-(methylsulfonyl)phenyl)-6- (trifluoromethyl)pyridine; 2-ethoxy-5-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-6. (trifluoromethyl)pyridine; 5-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(2-propynyloxy)-6- (trifluoromethyl)pyridine; 2-bromo-5-(4-fluoropheny)-4-(4-(methysufony)pheny)-6- (trifluoromethyl)pyridine; 4 2 -(3-chloro-4-methoxyphenyl)-4,5-difluorophenyl)benzenesulfonamide; l-( 4 -fluorophenyl)-2-(4-(methylsulfonyl)phenyl)benzene; 5-difluoromethyl-4-(4-(methylsulfonyl)phenyl)-3-phenylisoxazole; 4 -(8-ethyl-5-phenylisoxazol-4-yl)benzenesulfonamide; 4 -(5-difluoromethyl-3-phenylisoxazol-4-yl)benzenesulfonamide; 4-5hdoxmty*-peyioxzl4y*bneeuloa*e 4 -(5-hyxmethyl-3-phenylisoxazol-4-yl)benzenesulfonamide; -(2-metyl-3phenylisycoazo--yl)enzeneulnamidle; zn l-( 2 -(4-fluoro-2myphenyl)cyclopenten- 1-yl)-4-(methylsulfonyl)benzene; 1-( 2 4 -lorop2-eyh~yclpheny-)cyc )-openteny).4.(metyl~bunznyenzne 0*-iclrpeylccoetn--l--mehlufny~enee l-( 2 -(4-chiloromyphenyl)cyclopenten- 1-yl)-4-(methylsulfonyl)benzene; l-( 2 24 -dichlorophenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 2 -(4-trfluoromyphenyl)dmtcyclopenten- 1-yl)-4-ehsufnlbzn; l{(mtytipey~ylpne-1y)4(methylsulfonyl)benzene; 25 2 -(4-lorophenyl)-4,4-dimethylcyclopenten- l-yl)-4- (methylsulfonyl)benzene; 4 2 4 -lorophenyl)-4,4-dimethylcyclopenten-1-yl)benzenesulfonanide; 4-(2-(4-lorophenyl)-44dtycyclopenten- 1-yl)benzenesulfonamide; 4-(2-(4-lorophenyl)cyclopenten- 1-yl)benzenesulfonamide; 4 2 4 -cehloophenyl)cyclopenten-1-yl)enzeesulfonide zn 1-(2--metoyphenyl)cyclopenten- l-yl)-4-(methylsulfonyl)benzene; 0-_ 122 4 2 3 -fluoro-4-methoxyphenyl)cyclopenten-1 -yl)benzenesulfonamjde. l-( 2 3 -chloro-4-methoxyphenyl)cyclopenten-l-yl)-4- (methylsulfonyl)benzene; 4-2(-hoo4furpey~yloetn1y~eznsloaie 4 2 2 -methylpyridin-5syl)cyclopenten-. -yl)benzenesulfonamide; ethyl 2 4 4 -fluorophenyl)5(4(methysulfonyl)phenyl)oxazol 2 yl)- 2 benzyl-acetate; 2 4 4 fluorophenyl)5.(4(methylsufo~hnyl)heny1oxazol)cti acid; 4 4 fluorophenyl)5-(4(4..(methfoylulfnynyl)peyl2phe 4 4 fluorophenyl)2mehy5(4(m ethluoylulfonyl)henle;an 4-5(3fuoo4-ehoyhey) andlormthl4 oxazolyl)benzenesulfonamide; :9 or a pharmaceutically acceptable salt thereof. 22. The use of a selective cyclooxygeriase-2 inhibitor for the preparation of a medicament for the combined use with a NK-1 receptor antagonist for preventing or reducing the risk of developing an inflammatory disorder, .see*: 20 for halting or slowing the progression of an inflammatory disorder, or for preventing or reducing the risk of occurrence or recurrence of an inflammatory disorder, wherein said selective COX-2 inhibitor is selected from the group consisting of: 3-(3,4dfurpey)4(-mtysufnlpey)2(H-uaoe one; 2-(3 ,5-dfurpey)3(-mtyslonlpey)2ccoetnloe 123 5(S)-5-ethyl-5-methyl-4-(4-(methylsulfonyl)phenyl)-3-(2-propoxy)-SH- furan-2-one; 5-ethyl-5-methyl-4-(4-(methylsulfonyl)phenyl)-3-(3,4..difluorophenyl)-5H. furan-2-one; 3 2 -thiazoly1)methoxy)-4-(4-(methylsulfonyl)phenyl)-5,5-dimethy..5H. furan-2-one; 3 -propyloxy-4-(4-(methylsulfonyl)phenyl).5,5-dimethyl..SH.furan-2-one; 3 -(l-cyclopropylethoxy)-5,5-dimethyl-4-(4-methylsulfonyl)phenyl)-5H. furan-2-one; sodium 2 4 -chlorophenyl)-3-(4-(methylsulfonyl)phenyl)-4-oxo-2- pentenoate; 3 -(cyclopropylmethoxy)-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-5H- furan-2-one; 3 -(cyclopropylmethoxy)-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-2,5. dihydrofuran-2-ol; 3 -isopropoxy-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl).2,5..dihydrofuran. 2-ol; 5,5-dimethyl-3-(3-fluorophenyl)-2-hydroxy-4-(4-(methylsulfonyl)phenyl). 5-chloro-3-( 4 -(methylsulfony1)phenyl)-2(3pyridinyl)pyridine; 4 -(5-methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; 5-(4-fluorophenyl)-1- [4-(methylsulfonyl)phenyll -3- (trifluoromethyl)pyrazole; 4-(4-fluorophenyl)-5-[14-(methylsulfonyl)phenyl] -phenyl-3- (trifluoromethyl)pyrazole; 4 4 -chlorophenyl)-3-(4-methoxyphenyl).lHprazol.1 ylbenzenesulfonamide; 4-(3 ,5-bis(4-methylphenyl)- 1H-pyrazol- 1-yl)benzenesulfonamide; 4 -(5-(4-chlorophenyl)-3-phenyl- lH-pyrazol-1-yl)benzenesulfonamide; 4-(3 ,5-bis(4-methoxyphenyl)- lH-pyrazol-1-y1)benzenesulfonamide; 124 4 -(5-(4-chlorophenyl)-3-(4-methylphenyl)- 1H-pyrazol-1- yl)benzenesulfonamide; 4 -(5-(4-chlorophenyl)-3-(4-nitrophenyl)- 1H-pyrazol- 1- yl)benzenesulfonamide; 4 4 -chlorophenyl)-3-(5-chloro-2-thienyl)-lH-pyrazol-1- yl)benzenesulfonamide; 4 4 -chloro-3,5-dipheny-lH-pyrazo-1-y)benzenesufonamAde; 4 4 -chlorophenyl)-3-(trifluoromethyl)-lH-pyrazol-l- yl)benzenesulfonamide; 4 -(5-phenyl)- 3 -(trifluoromethyl)-lH-pyrazol-1-yl)benzenesulfonamiae; 4 4 -fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol- 1- S yl)benzenesulfonamide; 4 4 -methoyphenyl)-3-(trifluoromethyl)- H-pyrazol-- yl)benzenesulfonamide; 0* 15 4 4 -chlorophenyl)-3-(rifluoromethyl)-H-pyrazol- yl)benzenesulfonamide; 4 -(3-dfurmty)5-( 4 -methylphenyl)-3-tilooehl1H-pyrazol-1- 6 yl)benzenesulfonamide; Se.' 4 -(3-chiloromet4-hlrohey1)-3rfluoromthpety)-Hpyrazol-l- 4 -(5-3-di o4-ehxphnl--(trifmehy-5(4mthopen1) H-ylHprazol- *S 30 yl)benzenesulfonamide; 3- R7- 4 -3-iloromhl-5-phenyl- 1H-pyrazol-1-yl)benzenesulfonamide; 013 F 1- 125 4-(5-(4-chlorophenyl)-3-(hydroxyphenyl)-1H-pyrazol-1- yl)benzenesulfonamide; 4 -(5-(4-(N,N-dimethylamino)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1- yl)benzenesulfonamide; 5-(4-fluorophenyl)-6-(4-(methylsulfonyl)phenyl)spiro 4-(6-(4-fluorophenyl)spiro [2.4]hept-5-en-5-yl)benzenesulfonamide; 6-(4-fluorophenyl)-7-(4-(methylsulfonyl)phenyl)spiro oct-6-ene; 5-(3-chloro-4-methoxyphenyl)-6-(4-(methylsulfonyl)phenyl)spiro [2.41 hept- 4-(6-(3-chloro-4-methoxyphenyl)spiro [2.4]hept-5-en-5- yl)benzenesulfonamide; 0 5-(3,5-dichloro-4-methoxyphenyl)-6-(4-(methylsulfonyl)phenyl)- 0 0 0. Spiro [2.4]hept-5-ene; 5-(3-chloro-4-fluorophenyl)-6-(4-(methylsulfonyl)phenyl)spiro ene; 4-(6-(3,4-dichlorophenyl)spiro 2 -(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-(4- methylsulfonylphenyl)thiazole; :00.0 2 2 -chlorophenyl)-4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)thiazole; 00.0 20 5-( 4 -fluorophenyl)-4-(4-methylsulfonylphenyl)-2-methylthiazole; .o 4 4 -fluorophenyl)-5-(4-methylsulfonylphenyl)-2-trifluoromethylthiazole; 0 0 oo...o 4 4 -fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(2-thienyl)thiazole; 4 4 -fluorophenyl)-5-(4-methylsulfonylphenyl)-2-benzylaminothiazole; 4 4 -fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(1-propylamino)thiazole; 2 -((3,5-dichlorophenoxy)methyl)-4-(4-fluorophenyl)-5-(4- (methylsulfonyl)phenyl)thiazole; 4 -fluorophenyl)-4-(4-methylsulfonylphenyl)-2-trifluoromethylthiazole; 1-methylsulfonyl-4-(1, 1-dimethyl-4-(4-fluorophenyl)cyclopenta-2,4-dien-3- yl)benzene; 4-(4-(4-fluorophenyl)-1, 1-dimethylcyclopenta-2,4-dien-3- Syl)benzenesulfonamide; 126 4 -fluorophenyl)-6-(4-(methylsulfonyl)phenyl)spiro hepta-4,6-diene; 4 -(6-(4-fluorophenyl)spiro[1 2 4 hepta-4,6-dien-5-yl)benzenesulfonamide; 6 4 -fluorophenyl)-2-methoxy-5-(4-(methylsulfonyl)phenyl)pyridine3- carbonitrile; 2 -bromo-6-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)..pyicine-3 carbonitrile; 6 4 -fluoropheny)-5-(4-(methylsulfonyl)phenyl)-2-pheny1..pyrdine.3 carbonitrile; 4 2 -(4-methylpyridin-2-yl)-4-(trifluoromethyl)-lHimidazol-l. yl)benzenesulfonamide; 4 2 -(5-methylpyridin-3-yl)-4-(trifluoromethyl)..lHimidazol-l-. yl)benzenesulfonamide; *:eo 4 2 2 -methylpyridin-3-yl)-4-(trifluoromethyl).. H-imidazol- 1- I. yl)benzenesulfonamide; 0 15 3 4 -(methylsulfonyl)phenyl)-4-(trifluoromethyl) 1H-imidazol-2- yl)benzenesulfonamide; 2 4 -(methylsulfonyl)phenyl)-4-(trifluoromethyl)..lHjijdazol.2 yl)pyridine; o o 2 -methyl-4-(1-(4-(methylsufony)pheny)4(trifluoromethyl).1Hjimdaz1.. *oo 20 2-yl)pyridine;
250. 2-(3 4 -lurphyl-(4-(methylsulfonyl)phenyl)4(trifluoromethyl) 1H...daol o -yim ide; 0 oc 4 2 -(6-methylpheinyl)-4-(trifluoromethyl)-H-imidazol-l- yl)benzenesulfonamide; 2-(4-chlorophenyl)- l-( 4 -(methylsulfony)pheny)-4-methy...H-imidazole; 2-4clrpey)l(-mtyslonlpey)4pey-Hiiaoe 127 2-(4-chlorophenyl)-4-(4-fluorophenyl)-1-(4-(methylsulfonyl)phenyl)-1H- imidazole; 2-(3-fluoro-4-methoxyphenyl)- 1-(4-(methylsulfonyl)phenyl)-4- (trifluoromethyl)- iR-imidazole; 1-(4-(methylsulfonyl)phenyl)-2-phenyl-4-trifluoromethylblH-imidazole; 2 -(4-methylphenyl)-1-(4-(methylsulfonyl)phenyl)-4-trifluoromethyl.1H imidazole; 4 -(2-(3-chloro-4-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-l- yl)benzenesulfonamide; 2 -(3-fluoro-5-methylphenyl)-1-(4-(methylsulfonyl)phenyl)-4- (trifluoromethyl)- 1H-imidazole; 4-(2-(3-fluoro-5-methylphenyl)-4-(trifluoromethyl)- 1H-imidazol- 1- yl)benzenesulfonamide; 2-(3-methylphenyl)- 1-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)- 1H- imidazole; 4-(2-(3-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1- yl)benzenesulfonamide; l-(4-(methylsulfonyl)phenyl)-2-(3-chlorophenyl)-4-(trifluoromethyl)-lH- imidazole; 20 4 2 -(3-chlorophenyl)-4-(trifluoromethyl)-1H-i-idazol-1- yl4benzenesulfonamide; 4 -(2-phenyl-4-(trifluoromethyl)-1H-imidazol-1-yl)benzenesulfonamide; 4-(2-(4-methoxy-3-chlorophenyl)-4-(trifluoromethyl)- 1H-imidazol-1- yl)benzenesulfonamide; 1-allyl-4-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-5-(trifluoromethyl)- 1H-pyrazole; 1-ethyl-4-(4-fluorophenyl)-5-(trifluoromethyl)- 1H-pyrazol-3- yl)benzenesulfonamide; N-phenyl-(4-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-5- (trifluoromethyl)-1H-pyrazol-1-yl)acetamide; 128 ethyl (4-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-5-(trifluoromethyl). lH-pyrazol-1-yl)acetate; 4 -(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-1-(2-phenylethyl)1H- pyrazole; 4 -(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)- 1-(2-phenylethyl)-5- (trifluoromethyl)pyrazole; l-ethyl-4-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl).5.(trifluoromethyl). 1H-pyrazole; 4 -fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(trifluoromethyl)1lH imidazole; 4 -(4-(methylsulfonyl)phenyl)-5-(2-thiophenyl)-2-(trifluoromethyl)lH- imidazole; 5-(4-fluorophenyl)-2-methoxy-4-(4-(methylsulfonyl)phenyl)6. (trifluoromethyl)pyridine; 15 2 -ethoxy-5-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)6. (trifluoromethyl)pyridine; 4 -fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(2-propynyloxy).6 (trifluoromethyl)pyridine; 2 -bromo-5-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)6- 20 (trifluoromethyl)pyridine; 4 2 3 -chloro- 4 l-( 4 -fluorophenyl)-2-(4-(methylsulfonyl)phenyl)benzene; 0. 90: -difluoromethyl-4-(4-(methylsulfonyl)phenyl).3-phenylisoxazole; 4 3 -ethyl-5-phenylisoxazol-4-ylenzenesulfonamide; 4-5hdoyehl3peyioxzl4y~eznsloaie 4 -(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide; l-( 2 -(4-fluorophenyl)cyclopenten- l-yl)-4-(methylsulfonyl)benzene; l-( 2 4 -fluoro-2-methylphenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; l1-( 2 -(4-chlorophenyl)cyclopenten- l-yl)- 4 -(methylsulfonyl)benzene; l-( 2 2 ,4-dichlorophenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 129 l-( 2 4 -trifluoromethylphenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; l-( 2 4 -methylthiophenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; l-( 2 4 -fluorophenyl)-4,4-dimethylcyclopenten-1-yl)-4- (methylsulfonyl)benzene; 4 2 4 -fluorophenyl)-4,4-dimethylcycopenten.1yl)benzenesulfonamide; l-( 2 4 -chlorophenyl)-4,4-dimethylcyclopenten- l-yl)- 4 (methylsulfonyl)benzene; 4 2 -(4-chlorophenyl)-4,4-diniethylcyclopenten- 1-yl)benzenesulfonamide; 4 2 4 -fluorophenyl)cyclopenten-1-yl)benzenesulfonamide; 4 2 4 -chlorophenyl)cyclopenten-1-yl)benzenesulfonamide; l-( 2 4 -methoxyphenyl)cyclopenten-1-yl).4.(methylsulfonyl)benzene; l-( 2 2 3 -difluorophenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 4 2 3 -fluoro- 4 -methoxyphenyl)cyclopenten-1-y1)benzenesulfonamide; l-( 2 3 -chloro-4-methoxyphenyl)cyclopenten-1-yl)-4- 15 (methylsulfonyl)benzene; 4 2 3 -chloro-4-fluorophenyl)cyclopenten..1.yl)benzenesulfonamide; 4 2 2 -methylpyridin-5-yl)cyclopenten-1-yl)benzenesulfonanmjde; ethyl 2 4 4 -fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazol2yl)2. benzyl-acetate; 2 4 4 -fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazol2yl)acetic acid; 2 -(tert-butyl)-4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazole; 4 4 -fluorophenyl)-5-(4-(methylsulfonylphenyl)-2-phenyloxazole; 4 4 -fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)phenyl)oxazole; and 4 3 -fluoro-4-methoxyphenyl)-2-trifluoromethyl-4- oxazolyl)benzenesulfonamide; or a pharmaceutically acceptable salt thereof. 23. A use, composition, product or method according to any one of the preceding claims wherein the inflammatory disorder is selected from 130 rheumatoid arthritis, degenerative joint diseases, osteoarthritis, bursitis, tendinitis, ankylosing spondylitis, gout and synovitis. 24. Use of a selective COX-2 inhibitor and a NK-1 receptor antagonist for the manufacture of a medicament for the treatment or prevention of inflammatory disorders, wherein said selective COX-2 inhibitor is selected from the group consisting of: 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone; 3 4 -difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone; 5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-3-(3-fluorophenyl).SHfuran.2 one; 4 4 -(methylsulfonyl)phenyl)-3-(2-propoxy).SH-furan-2.one; -chloro-3-(4-(methylsulfonyl)phenyl)-2-(2-methybspyridinyl)pyr.idine; 2-(3,5-d1ifuorophenyl)- 3 -(4-(methysulfonyl)phenyl)2cyclopenten-1-one; 15 5(S)-5-ethyl-5-methyl-4-(4-(methylsulfonyl)phenyl)3(2propoy)-5H- furan-2-one; 5-ethyl-5-methyl-4-(4-(methylsulfonyl)phenyl).3.(3,4..difluorophenyl).5H- furan-2-one; 3 2 -thiazolyl)methoxy)-4-(4-(methylsulfonyl)phenyl)5,Sdimethyl-5H- furan-2-one; 3 -propyloxy- 4 -(4-(methylsulfonyl)phenyl)-,5.dimethyl..H.furan-2..one; 1-cyclopropyettioxy)-5,5-dimethyl-4-(4methylsulfonyl)phenyl).5H. furan-2-one; sodium 2 4 -chlorophenyl)-3-(4-(methylsulfonyl)phenyl)4.oxo.2. pentenoate; 3 -(cyclopropylmethoxy)-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl).5H- furan-2-one; 3 -(cyclopropylmethoxy)-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl).2,s.. dihydrofuran-2-ol; .3-isopropoxy-5,5-dimethyl- 4 -(4-(methylsulfonyl)phenyl)-2,5-dihydroffiran. 2-ol; 131 5,5-dimethyl-3-(3-fluorophenyl)-2-hydroxy-4-(4-(methylsulfonyl)phenyl)- 5-chloro-3-(4-(methylsulfonyl)phenyl)-2-(3-pyridinyl)pyridine; 4-(5-methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; 5-(4-fluorophenyl)-1-[14-(methylsulfonyl)phenyl] -3- (trifluoromethyl)pyrazole; 4-(4-fluorophenyl)-5- [4-(methylsulfonyl)phenyll -1-phenyl-3- (trifluoromethyl)pyrazole; 4-(5-(4-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-1- yl)benzenesulfonamide; 4-(3,5-bis(4-methylphenyl)-1H-pyrazol- 1-yl)benzenesulfonamide; 4-(5-(4-chlorophenyl)-3-phenyl-1H-pyrazol- 1-yl)benzenesulfonamide; 4 -(3,5-bis(4-methoxyphenyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-(5-(4-chlorophenyl)-3-(4-methylphenyl)-1H-pyrazol- 1- ylbbenzenesulfonamide; 4 -(5-(4-chlorophenyl)-3-(4-nitrophenyl)-1H-pyrazol- 1- yl)benzenesulfonamide; 4 -(5-(4-chlorophenyl)-3-(5-chloro-2-thienyl)-1H-pyrazol-1- yl)benzenesulfonamide; 4 4 -chloro-3,5-diphenyl-lH-pyrazol-1-yl)benzenesulfonamide; 4 -(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1- yl)benzenesulfonamide; 4 -(5-phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonarnide; 4-(5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol- 1- 4-(5-(4-mhophenyl)-3-(ifluoromethyl)-H-pyrazol- yl)benzenesulfonamide; 4-(5-(4-cehlphenyl)-3-(difluoromethyl)- 1H-pyrazol-- FAyl)benzenesulfonamide; -132- 4 4 -chloro-5-(4-chlorophenyl)-3-(trifluoromethyl)-lH-pyrazol- 1- yl)benzenesulfonamide; 4 -(3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol-l- yl)benzenesulfonamide; 4 -(3-(difluoromethyl)-5-phenyl-1H-pyrazol-1-yl)benzenesulfonamide; 4 -(3-(difluoromethyl)-5-(4-methoxyphenyl)-1H-pyrazol-l- yl)benzenesulfonamide; 4-(3-cyano-5-(4-fluorophenyl)-1H-pyrazol- 1-yl)benzenesulfonamide; 4 3 -(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-lH-pyrazol-l-. yl)benzenesulfonamide; 4 -(5-(3-fluoro-4-methoxyphenyl)-3-(trifluoromethyl)-lH-pyrazol-l- yl)benzenesulfonamide; 4-(4-chloro-5-phenyl- 1H-pyrazol-1-yl)benzenesulfonamide; 4 -(5-(4-cffiorophenyl)-3-(hydroxyphenyl)- 1H-pyrazol- 1- 1 5 yl)benzenesulfonamide; 4 4 -(N,N-dimethylamino)phenyl)-3-(trifluoromethyl)-lH-pyrazol yl)benzenesulfonamide; 4 -fluorophenyl)-6-(4-(methylsulfonyl)phenyl)spiro 4 6 -(4-fluorophenyl)spiro [2.4]hept-5-en-5-yl)benzenesulfonamide; 6 4 -fluorophenyl)-7-(4-(methylsulfonyl)phenyl)spiro oct-6-ene; S-( 3 -chloro-4-methoxyphenyl)-6-(4-(methylsulfonyl)phenyl)spiro hept- 4 -(6-(3-chloro-4-methoxyphenyl)spiro [2.4]hept-5-en-5- yl)benzenesulfonamide; 5-(3,5-dichloro-4-methoxyphenyl)-6-(4-(methylsulfonyl)phenyl). Spiro [2.4]hept-5-ene; 3 -chloro-4-fluorophenyl)-6-(4-(methylsulfonyl)phenyl)spiro ene; ,4-dichlorophenyl)spiro 2-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-(4- ,~~thysu~onypheny)thiazole; 133 2 2 -chlorophenyl)-4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)thiazole; 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-methylthiazole; 4 4 -fluorophenyl)-5-(4-methylsulfonylphenyl)-2-trifluoromethylthiazole; 4 -(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(2-thienyl)thiazole; 4 4 -fluorophenyl)-5-(4-methylsulfonylphenyl)-2-benzylaminothiazole; 4 -(4-fluorophenyl)-5-(4-methylsulfonylphenyl)-2-( 1-propylamino)thiazole; 2-((3,5-dichlorophenoxy)methyl)-4-(4-fluorophenyl)-5-(4- (methylsulfonyl)phenyl)thiazole; 4 -fluorophenyl)-4-(4-methylsulfonylphenyl)-2-trifluoromethylthiazole; 1-methylsulfonyl-4-(1, 1-dimethyl-4-(4-fluorophenyl)cyclopenta-2,4-dien-3- yl)benzene; 4-(4-(4-fluorophenyl)-1, 1-dimethylcyclopenta-2,4-dien-3- yl)benzenesulfonamide; 5-( 4 -fluorophenyl)-6-(4-(methylsulfonyl)phenyl)spiro [2.4]hepta-4,6-diene; 15 4-(6-(4-fluorophenyl)spiro hepta-4,6-dien-5-yl)benzenesulfonamide; 6 4 -fluorophenyl)-2-methoxy-5-(4-(methylsulfonyl)phenyl)-pyricdine-3- carbonitrile; 2 -bromo-6-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl).pyridine-3. carbonitrile; 6 4 -fluorophenyl)-5-(4-(methyllsulfonyl)phenyl)-2-phenyl-pyridine.3 carbonitrile; 4 2 -(4-methylpyridin-2-yl)-4-(trifluoromethyl)-J.H-imidazo1-1- yl)benzenesulfonamide; 4 2 -(5-methylpyridin-3-y1)-4-(trifluoromethyl)-lH-imdazol-l- yl)benzenesulfonamide; 4 2 2 -methylpyridin-3-yl)-4-(trifluoromethyl) 1H-imidazol-1- yl)benzenesulfonamide; l-( 4 -(methylsulfonyl)phenyl)-4-(trifluoromethyl H-imidazol-2- yl)benzenesulfonamide; l-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyly H-imidazol-2- Syl)pyridine; 134 2-methyl-4-( l-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)-1H-imidazol- 2-yl)pyridine; 2 -methyl-6-(1-(4-(methylsulfonyl)pheny1)-4-(trifluoromethyl)...Hjimidazol1 2-yl)pyridine; 4 2 -(6-methylpyridin-3-yl)-4-(trifluoromethyl)-lH-imidazol1.. yl)benzenesulfonam-ide; 2-(3,4-difluorophenyl)- 1-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)- 1H- inidazole; 4 4 -methylphenyl)-4-(trifluoromethyl)-1H-imidazol-l- yl)benzenesulfonamide; 2 4 -chlorophenyl)-1-(4-(methylsulfonyl)phenyl)-4-methyl- iR-imidazole; 2-(4-chlorophenyl)- 1-(4-(methylsulfonyl)phenyl)-4-phenyl-1H-imidazole; 2 4 -chlorophenyl)-4-(4-fluorophenyl)--(4-(methylsulfonyl)phenyl)lH- imidazole; 15 2 3 -fluoro-4-methoxyphenyl)-1-(4-(methylsulfonyl)phenyl)-4- (trifluoromethyl)-1H-imidazole; l-( 4 -(methylsulfonyl)phenyl)-2-phenyl-4-trifluoromethyl-lH-iniidazole; 2 4 -methylphenyl)-1-(4-(methylsulfonyl)phenyl)-4-trifluoromethyl4lH imidazole; 20 4 2 3 -chloro-4-methylphenyl)-4-(trifluoromethyl)-1H-imidazol- 1- yl)benzenesulfonamide; 2 -(3-fluoro-5-methylphenyl)-1-(4-(methylsulfonyl)phenyl)-4- (trifluoromethyl)- 1H-imidazole; 4 2 -(3-fluoro-5-methylphenyl)-4-(trifluoromethyl)-1H-imidazol- 1- yl)benzenesulfonamide; 2-(3-methylphenyl)- 1-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl)- 1H- imidazole; 4 2 3 -methylphenyl)-4.(trifluoromethyl)- H-imidazol- 1- yl)benzenesulfonamide; l-( 4 -(methylsufony)pheny)-2-(3-chlorophenyl)-4-(trifluoromethyl) 1H- imidazole; 135 4 2 -(3-chlorophenyl)-4-(trifluoromethyl)-lH-imidazol-1- yl)benzenesulfonamide; 4-(2-phenyl-4-(trifluoromethyl)- lH-imidazo-1-y1)benzenesulfonaniide; 4 2 -(4-methoxy-3-chloropheny)-4-(trifluoromethy)1H-imdazol-l1. yl)benzenesulfonamide; l-allyl- 4 -(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl).5.(trifluoromethyl)- 1H-pyrazole; 4 -(l-ethyl-4-(4-fluorophenyl)-5-(trifluoromethyl)1Hpyrazol3. yl)benzenesulfonamide; N-phenyl-( 4 -(4-fluiorophenyl)-3-(4-(methylsulfonyl)phenyl)s.. (trifluoromethyl)-1H-pyrazol-1-yl)acetamide; a ethyl 4 4 -fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-5-(trifluoromethyl)- lH-pyrazol-1-yl)acetate; a 4 4 -fluorophenyl)-3-(4-(methylsulfonyl)phenyl)..1.(2-phenylethyl)..H- pyrazole; 4 4 -fluorophenyl)-3-(4-(methylsulfonyl)phenyl).1.(2-.phenylethyl)-5 (trifluoromethyl)pyrazole; l-ethyl-4-( 4 -fluorophenyl)-3(4(methylsulfonyl)phenyl)-5.(trifluoromethyl). 1H-Dvrazole; 5-( 4 -fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(trifluoromethyl)-lH- a imidazole; 4 4 -(methylsulfonyl)phenyl)-5-(2-thiophenyl)2(trifluoromethyl)1lH imidazole; 4 -fluorophenyl)-2-methoxy-4-(4-(methylsulfonyl)phenyl).6. (trifluoromethyl)pyridine; 2 -ethoxy-5-(4-fluorophenyl)4.(4-.(methylsutfonyl)phenyl..6 (trifluoromethyl)pyridine; 4 -fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(2-propynyoxy..6- (trifluoromethyl)pyridine; 2-bromo-5-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl..6 (trifluoromethyl)pyridine; 136 4 2 -(3-chloro-4-methoxyphenyl)-4,5-difluorophenyl)benzenesulfonainide; l-(4-fluorophenyl)-2-(4-(methylsulfonyl)phenyl)benzene; 5-difluoromethyl-4-(4-(methylsulfonyl)phenyl)-3-phenylisoxazole; 4-(3-ethyl-5-phenylisoxazol-4-yl)benzenesulfonamide; 4-(5-difluoromethyl-3-phenylisoxazol-4-yl)benzenesulfonamide; 4-(5-hydroxymethyl-3-phenylisoxazol-4-yl)benzenesulfonamide; 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonaniide; l-(2-(4-fluorophenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; l-(2-(4-fluoro-2-methylphenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 1-(2-(4-chlorophenyl)cyclopenten- 1-yl)-4-(methylsulfonyl)benzene; l-(2-(2,4-dichlorophenyl)cyclopenten-1-yL)-4-(methylsulfonyl)benzene; boo"**l-(2-(4-trifluoromethylphenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; too* l-(2-(4-methylthiophenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 1-(2-(4-fluorophenyl)-4,4-dimethylcyclopenten- l-yl)-4- (methylsulfonyl)benzene; 4-(2-(4-fluorophenyl)-4,4-dimethylcyclopenten-1-yl)benzenesulfonamide; 1-(2-(4-chlorophenyl)-4,4-dimethylcyclopenten- l-yl)-4- (methylsulfonyl)benzene; 4-(2-(4-chlorophenyl)-4,4-dimethylcyclopenten-1-yl)benzenesulfonamide; 4 -(2-(4-fluorophenyl)cyclopenten- 1-yl)benzenesulfonamide; 4-(2-(4-chlorophenyl)cyclopenten- 1-yl)benzenesulfonamide; l-(2-(4-methoxyphenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 1-(2-(2,3-difluorophenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 4-(2-(3-fluoro-4-methoxyphenyl)cyclopenten-1-yl)benzenesulfonamide; 1-(2-(3-chloro-4-methoxyphenyl)cyclopenten-1-yl)-4- (methylsulfonyl)benzene; 4-(2-(3-chloro-4-fluorophenyl)cyclopenten- 1-yl)benzenesulfonamide; 4-(2-(2-methylpyridin-5-yl)cyclopenten-1-yl)benzenesulfonamide; ethyl 2 -(4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazol-2-yl)-2- benzyl-acetate; 2-(4-(4-fluorophenyl)-5-( 4 -(methylsulfonyl)phenyl)oxazol-2-yl)acetic acid; <0tVTC 137 2-(tert-butyl)-4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phelyl)oxazole; -4 fluorophenyl)-5-(4-(methylsulfonyl)phenyl)-2-phenyloxazole; 4-(4-fluorophenyl)-2- methyl-5-(4-(methylsulfonyl)phenyl)oxazole; and 4-(5-(3-fluoro-4-methoxyphenyl)-2- trifluoromethyl-4-oxazolyl)benzenesulfonamide; or a pharmaceutically acceptable salt thereof, wherein said medicament is substantially as hereinbefore described. A pharmaceutical composition when prepared by the process of claim 26. A method of preventing or reducing the risk of developing an inflammatory disorder, for halting or slowing the progression of an inflammatory disorder, or for preventing or reducing the risk of occurrence or recurrence of an inflammatory disorder, said method comprising administration of an NK-l receptor antagonist combined with administration of a selective cycloxygenase-2 inhibitor, wherein said COX-2 inhibitor is selected from the group consisting of: 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone; 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone; '5 5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-3-(3-fluorophenyl)-5H-furan-2- one; 5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-3-(2-propoxy)-5H-furan-2-one; 5-chloro-3-(4-(methylsulfonyl)phenyl)-2-(2-methyl-5-pyridinyl)pyridine; 2-(3,5-difluorophenyl)-3-(4-(methylsulfonyl)phenyl)-2-cyelopenten-1-one-, 5(S)-5-ethyl-5-methyl-4-(4-(methylsulfonyl)phenyl)-3-(2-propoxy)-5H- furan-2-one; 5-ethyl-5-methyl-4-(4-(methylsulfonylphenyl)-3-(3,4-clifluorophenyl)-5H- furan-2-one; 00* 3-((2-thiazolyl)methoxy)-4-(4-(methylsulfonyl)phenyl)-5,5-dimethyl-5H- furan-2-one; 3-propyloxy-4-(4-(methylsulfonyl)phenyl)-5,5-dimethyl-5H-furan-2-one; 1-cyclopropylethoxy)-5,5-dimethyl-4-(4-methylsulfonyl)phenyl)-5H- furan-2-one; sodium 2-(4-chlorophenyl)-3-(4-(methylsulfonyl)phenyl)-4-oxo-2- pentenoate; [R:\LIB3H]021 2 I .doc :sxc 138 3 -(cyclopropylmethoxy)-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)-5H- furan-2-one; 3 -(cyclopropylmethoxy)-5,5-dimethy-4-(4-(methysufony)pheny).2,5. dihydrofuran-2-ol; 3 -isopropoxy-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)..25.dihydrofuran- 2-ol; 5,5-dimethy-3-(3-fluoropheny)-2-hydroxy-4-(4-(methysufonyl)pheny). 5-chloro-3-( 4 -(methylsulfonyl)pheny1)-2-(3-pyridinyl)pyricline; 4 -(5-methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; 5-(4-fluorophenyl)-1- [4-(methylsulfonyl)phenylj -3- (trifluoromethyl)pyrazole; 4-(4-fluorophenyl)-5- [4-(methylsulfonyl)phenyl] -1-phenyl-3- (trifluoromethyl)pyrazole; 4 4 -chlorophenyl)-3-(4-methoxypheny)-lH-pyrazol-. 1 yl)benzenesulfonamide; 4-(3,5-bis(4-methylphenyl)- lH-pyrazol-1-yl)benzenesulfonamide; 4 -(5-(4-chlorophenyl)-3-phenyl- lH-pyrazol-1-yl)benzenesulfonamjde; 4-(3,5-bis(4-methoxyphenyl)- 1H-pyrazol- 1-yl)benzenesulfonamide; 20 4 -(5-(4-chlorophenyl)-3-(4-methylphenyl)- 1H-pyrazol-1- yl)benzenesulfonamide; 4 4 -chlorophenyl)-3-(4-nitrophenyl)-lH-pyrazoli... yl)benzenesulfonamide; 4-(5-(4-chlorophenyl)-3-(5-cluoro-2-thyl)-H-pyrazol...1. 4-(4-phloro-35-dtiphl-1omty-H-pyrazol- -yl)benzenesulfonamide; 4-(5-(4-lorophenyl)-3-(trifluoromethyl)- 1H-pyrazol-l- yl)benzenesulfonamide; 139 4 4 -methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-l-. yl)benzenesulfonamide; 4 -(5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-l-. yl)benzenesulfonamide; 4 4 -methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1.. yl)benzenesulfonamide; 4 4 -chloro-5-(4-chloropheny)-3-(trifluoromethy)-lH-pyrazopl... yl)benzenesulfonamide; 4 -(3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol-l1. yl)benzenesulfonamide; 4-3(ilooehl--hnll-przl1y~eznsloaie 4 -(3-(difluoromethyl)-5-(4-methoxyphenyl)-H-pyrazol.1. yl)benzenesulfonamide; 4-(3-cyano-5-(4-fluorophenyl)- lH-pyrazol-1-yl)benzenesulfonamide; 4 3 -(difluoromethyl)-5-(3-fluoro-4-methoxypheny)1IHpyazol-l- yl)benzenesulfonamide; 4 3 -fluoro-4-methoxyphenyl)-3-(trifluoromethyl). H-pyrazol-1- yl)benzenesulfonamide; 4 4 -chloro-5-phenyl-1H-pyrazol-1-yl)benzenesulfonanmjde; 4 4 -chlorophenyl)-3-(hydroxyphenyl)-lHpyrazol-l yl)benzenesulfonamide; 4 4 -(N,N-dimethylamino)phenyl)-3-(trifluoromethyl)1lHpyrazol.1. yl)benzenesulfonamide; 4 -fluorophenyl)-6-(4-(methylsulfonyl)phenyl)spiro [2.4lhept-5-ene; 4-(6-(4-fluorophenyl)spiro 2 4 6-(4-fluorophenyl)-7-(4-(methylsulfonyl)phenyl)spiro oct-6-ene; 3 -chloro-4-methoxypheny1)-6-(4-(methylsulfonyl)phenyl)spiro [2.4]hept- 4 -(6-(3-chloro-4-methoxyphenyl)spiro [2.4lhept-5-en-5- yl)benzenesulfonamide; 140 5-(3 ,5-dichloro-4-methoxyphenyl)-6-(4-(methylsulfonyl)phenyl)- spiro 5-(3-chloro-4-fluorophenyl)-6-(4-(methylsulfonyl)phenyl)spiro [2 ene; 4-(6-(3,4-dichlorophenyl)spiro [2 4 2-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-(4- methylsulfonylphenyl)thiazole; 2 2 -chlorophenyl)-4-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)tffiazole; 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-methyltfiazole; 4 4 -fluoropheny1)-5-(4-methylsulfonylphenyl)-2-trifluoromethylthiazole; 4 4 -fluorophenyl)-5-(4-methylsulfonylphenyl)-2-(2-thienyl)thiazole; 4 4 -fluoropheny)-5-(4-methylsulfonylpheny1)-2-benzylaminothiazole; 4-4furpey)*-4mtysloylhnl -lpoplmn~haoe 2-((3,5-dichlorophenoxy)methyl)-4-(4-fluorophenyl).5(4- (methylsulfonyl)phenyl)thiazole; 4 -fluorophenyl)-4-(4-methylsulfonylphenyl)-2-trifluoromethylthiazole; 1-methylsulfonyl-4-( 1, l-dimethyl-4-(4-fluorophenyl)cyclopenta2,4-dien-3. yl)benzene; 4-(4-(4-fluorophenyl)-1, l-dimethylcyclopenta-2,4-dien-3- 20 ylbenzenesulfonamide; 4 -fluorophenyl)-6-(4-(methylsulfonyl)phenyl)spiro [2.4]hepta-4,6-diene; 4-(6-(4-fluorophenyl)spiro 2 4 lhepta-4,6-dien-5-yl)benzenesulfonan de; 6 4 -fluorophenyl)-2-methoxy-5-(4-(methylsulfonyl)phenyl)-py.jijne.3- carbonitrile; furpey)--4(ehlufoy~hnl--hey-yiie3 carbonitrile; 4 -urohenyin2y1))5-4-(mthyfuo1)hyl)..2..Heny1..pazol e..3. yl)benzenesuli'onamide; 14 1 4 2 -(5-methylpyridin-3-yl)-4-(trifluoromethyl)-lH-imidazol-l-1 yl)benzenesulfonamide; 4-(2-(2-methylpyridin-3-y1)-4-(trifluoromethy)-lH-imidazol-l- yl)benzenesulfonamide; 1-(4-(methylsulfony1)pheny1)-4-(trifluoromethy)-lH-imidazol.2. yl)benzenesulfonamide; 2-(l-(4-(methylsulfony1)phenyl)-4-(trifluoromethyl)1Hini~dazol12- yl)pyridine; 2-methyl-4-(1-(4-(methylsulfonyl)phenyl)-4-(trifluoromethyl) 1H-imidazol- 2-yl)pyridine; 2 -methyl-6-(l-(4-(methylsulfony1)phenyl)-4-(trifluoromethyly..1Hjimdazo.. 2-yl)Pyridine; 4 2 -(6-methylpyridin-3-yl)-4-(trifluoromethyl)-lHiidazol-l-. yl)benzenesulfonamide; 2 3 4 -difluoropheny1)-1-(4-(methylsulfony1)pheny1)-4(trifluoromethyl)lH- imidazole; 4 2 4 -methylphenyl)-4-(trifluoromethyl)-lH-irmjdazoll yl)benzenesulfonamide; 2-(4-chlorophenyl)- l-(4-(methylsulfonyl)phenyl)-4-methyl- 1H-iinidazole; 2-(4-chlorophenyl)-4-(4-fluorophenyl)-1-(4-(methylsulfonyl)phenyl) 1H- imidazole; 2 3 -fluoro-4-methoxyphenyl)-1-(4-(methylsulfonyl)phenyl).4- (trifluoromethyl)-1H-imidazole; 1-4(ehlufnlpey)2pey--rfurmty-Hiiaoe 2 4 -methylphenyl)-1-(4-(methylsulfonyl)phenyl)y4-.tiifluoromethy..1H imidazole; 4 2 3 -chloro-4-methylpheny1)-4-(trifluoromethyl)lHimidazol-l-1 yl)benzenesulfonamide; 2-(3-fluoro-5-methylphenyl)- 1-(4-(methylsulfonyl)phenyl)-4- (trifluoromethyl)-1H-imidazole; 142 4 -(2-(3-fluoro-5-methylphenyl)-4-(trifluoromethy)-lH-iidazol-l-. yl)benzenesulfonamide; 2 -(3-methylphenyl)-1-(4-(methylsulfonyl)phenyl)-4-(trifluoromethy)1H- imidazole; 4-(2-(3-methylphenyl)-4-(trifluoromethyl)-H-imidazol-l-.. yl)benzenesulfonamide; 1-( 4 -(methylsulfony1)pheny1)-2-(3-chloropheny)-4(trifluoromethyl)lH- imidazole; 4-(2-(3-chlorophenyl)-4-(trifluoromethyl)-lH-imidazol-l yl)benzenesulfonaniide; 4 2 -phenyl- 4 -(trifluoromethy)-1H-imidazol1-y1)benzenesulfonamide; 4 -(2-(4-methoxy-3-chlorophenyl)-4-(trifluoromethyl)ylHjimdazo.ll- .9 *~.yl)benzenesulfonamide; l-allyl- 4 4 -fluorophenyl)-3-(4-(methylsulfonyl)phenyl)&5(trifluoromethyl)- 1H-pyrazole; l-ethyl-4-(4-fluorophenyl)-5-(trifluoromethyl).. H-pyrazol-3- yl)benzenesulfonamide; N-phenyl-(4-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-5-. (trifluoromethyl)-1H-pyrazol- 1-yl)acetamide; ethyl 4 4 -fluorophenyl)-3-(4-(methylsulfonyl)phenyl)5(trifluoromethyl). 1H-pyrazol-1-yl)acetate; 4 4 -fluorophenyl)-3-(4-(methylsulfonyl)phenyl)1.(2phenylethyl)lH- pyrazole; 4 4 -fluorophenyl)-3-(4-(methylsulfonyl)phenyl)1..(2-phenylethyl)5- (trifluoromethyl)pyrazole; l-ethyl- 4 -(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)5-(trifluoromethyl) 1H-pyrazole; 4 -fluorophenyl)- 4 4 -(methylsulfonyl)phenyl)-2-(trifluoromethyl). H- imidazole; 4 -(4-(methylsulfonyl)pheny1)-5-(2-thiophenyl)-2-(trifluoromethy) 1W- imidazole; 143 4 -fluorophenyl)-2-methoxy-4-(4-(methylsulfonyl)phenyl).6 (trifluoromethyl)pyridine; 2 -ethoxy-5-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-6. (trifluoromethyl)pyridine; 5-4furpey)4(-mtyslfnlpey)2(-rpnlx)6 (trifluoromethyl)pyridine; 2-bromo-5-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)6- (trifluoromethyl)pyridine; 4-2(-hoo4mtoyhnl-,-dfurpey~eznsloaie l-( 4 -fluorophenyl)-2-(4-(methylsulfonyl)phenyl)benzene; 5-difluoromethyl-4-(4-(methysufony)pheny)-3-phenylisoxazole; 4 3 -ethyl-5-phenylisoxazol-4-yl)benzenesulfonamide; 4 -(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide; l-(2-(4-fluorophenyl)cyclopenten- l-yl)- 4 -(methylsulfonyl)benzene; l-( 2 4 -fluoro- 2 -methylpheny)cyclopenten-1-y)-4-(methylsulfonyl)benzene; l-(2-(4-chlorophenyl)cyclopenten- l-yl)-4-(methylsulfonyl)benzene; l-( 2 2 4 -dichlorophenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; l-( 2 4 -trifluoromethylphenyl)cyclopenten-1-y1)-4(methylsulfony1)benzene; l-( 2 4 -methylthiophenyl)cyclopenten-1-y)-4-(methylsulfonyl)benzene; l-( 2 4 -fluorophenyl)-4,4-dimethylcyclopenten-1-y).4 (methylsulfonyl)benzene; 4 2 4 -fluorophenyl)-4,4-dimethylcyclopenten- 1-yl)benzenesulfonamide; l-( 2 4 -chlorophenyl)-4,4-dimethylcyclopenten- l-yl)-4- (methylsulfonyl)benzene; 4 -(2-(4-chlorophenyl)-4,4-dimethylcyclopenten- l-yl)benzenesulfonamide; 4-(2-(4-fluorophenyl)cyclopenten- l-yl)benzenesulfonamide; 4 2 -(4-chlorophenyl)cyclopenten-1-yl)benzenesulfonamide; l-( 2 -(4-methoxyphenyl)cyclopenten-1-y1)-4-(methylsulfonyl)benzene; l-( 2 -(2,3-difluorophenyl)cyclopenten-1-yl)-4-(methylsulfonyl)benzene; 144 4-2(-loo4mtoyhnlccoetn1y~eznsloaie 1-(2-(3-chloro-4-methoxyphenyl)cyclopenten- l-yl)-4- (methylsulfonyl)benzene; 4-(2-(3-chloro-4-fluorophenyl)cyclopenten-1-yl)benzenesulfonamde; 4-(2-(2-methylpyridin-5-yl)cyclopenten-1-yl)benzenesulfonamide; ethyl 2-(4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazol-2-yl)-2 benzyl-acetate; 2-(4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazol-2-yl)acetic acid; 2-(tert-butyl)-4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazole; 4 -(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)-2-phenyloxazole; 4 4 -fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)phenyl)oxazole; and 4-(5-(3-fluoro-4-methoxyphenyl)-2-trifluoromethyl-4- oxazolyl)benzenesulfonamnide; or a pharmaceutically acceptable salt thereof. Dated 21 January, 2003 Merck Sharp Dohme Limited Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9810920.0A GB9810920D0 (en) | 1998-05-21 | 1998-05-21 | Therapeutic use |
GB9810920 | 1998-05-21 | ||
PCT/GB1999/001632 WO1999059635A1 (en) | 1998-05-21 | 1999-05-19 | Use of a cox-2 inhibitor and a nk-1 receptor antagonist for treating inflammation |
Publications (2)
Publication Number | Publication Date |
---|---|
AU3948699A AU3948699A (en) | 1999-12-06 |
AU758983B2 true AU758983B2 (en) | 2003-04-03 |
Family
ID=10832454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU39486/99A Ceased AU758983B2 (en) | 1998-05-21 | 1999-05-19 | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1079863A1 (en) |
JP (1) | JP2002515461A (en) |
AU (1) | AU758983B2 (en) |
CA (1) | CA2327585A1 (en) |
GB (1) | GB9810920D0 (en) |
WO (1) | WO1999059635A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003082191A2 (en) | 2002-03-28 | 2003-10-09 | Merck & Co., Inc. | Substituted 2,3-diphenyl pyridines |
KR20040072004A (en) | 2003-02-07 | 2004-08-16 | 삼성에스디아이 주식회사 | Emitting compound for electroluminescence device and device using thereof |
ATE342722T1 (en) | 2003-05-07 | 2006-11-15 | Osteologix As | TREATMENT OF CARTILAGE/BONE DISEASES WITH WATER SOLUBLE STRONTIUM SALTS |
WO2006081088A2 (en) * | 2005-01-24 | 2006-08-03 | Pozen Inc. | Compositions and therapeutic methods utilizing a combination of a protein extravasation inhibitor and an nsaid |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2287404A (en) * | 1994-03-15 | 1995-09-20 | Pfizer | Antiinflammatory and analgesic compositions |
WO1996031509A1 (en) * | 1995-04-04 | 1996-10-10 | Glaxo Group Limited | IMIDAZO[1,2-a]PYRIDINE DERIVATIVES |
WO1997021445A1 (en) * | 1995-12-12 | 1997-06-19 | Omeros Medical Systems, Inc. | Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL106142A (en) * | 1992-06-29 | 1997-03-18 | Merck & Co Inc | Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them |
GB9426103D0 (en) * | 1994-12-23 | 1995-02-22 | Merck Sharp & Dohme | Therapeutic agents |
WO1997025988A1 (en) * | 1996-01-17 | 1997-07-24 | Eli Lilly And Company | Methods of treating or preventing pain or nociception |
GEP20022636B (en) * | 1996-08-14 | 2002-02-25 | Searle & Co Us | 4-[5-Methyl-3-Phenylisoxazol-4-Yl] Benzenesulfonamide, Its Crystal Structure B, Pharmaceutical Composition Containing The Same, Methods For Treatment Or Prophylaxis Of Disorders Caused By Cyclooxygen-2 |
US5750549A (en) * | 1996-10-15 | 1998-05-12 | Merck & Co., Inc. | Cycloalkyl tachykinin receptor antagonists |
-
1998
- 1998-05-21 GB GBGB9810920.0A patent/GB9810920D0/en not_active Ceased
-
1999
- 1999-05-19 CA CA002327585A patent/CA2327585A1/en not_active Abandoned
- 1999-05-19 AU AU39486/99A patent/AU758983B2/en not_active Ceased
- 1999-05-19 JP JP2000549299A patent/JP2002515461A/en not_active Withdrawn
- 1999-05-19 WO PCT/GB1999/001632 patent/WO1999059635A1/en not_active Application Discontinuation
- 1999-05-19 EP EP99922393A patent/EP1079863A1/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2287404A (en) * | 1994-03-15 | 1995-09-20 | Pfizer | Antiinflammatory and analgesic compositions |
WO1996031509A1 (en) * | 1995-04-04 | 1996-10-10 | Glaxo Group Limited | IMIDAZO[1,2-a]PYRIDINE DERIVATIVES |
WO1997021445A1 (en) * | 1995-12-12 | 1997-06-19 | Omeros Medical Systems, Inc. | Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis |
Also Published As
Publication number | Publication date |
---|---|
WO1999059635A1 (en) | 1999-11-25 |
JP2002515461A (en) | 2002-05-28 |
GB9810920D0 (en) | 1998-07-22 |
EP1079863A1 (en) | 2001-03-07 |
CA2327585A1 (en) | 1999-11-25 |
AU3948699A (en) | 1999-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU760735B2 (en) | A method for treating inflammatory diseases by administering a thrombin inhibitor | |
US11957657B2 (en) | Combination therapies using immuno-dash inhibitors and PGE2 antagonists | |
AU7466298A (en) | Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders | |
AU1408699A (en) | Cox-2 inhibitors in combination with nmda-blockers for treating pain | |
US20230372372A1 (en) | Combination therapies using caspase-1 dependent anticancer agents and pge2 antagonists | |
WO2001087343A2 (en) | Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor | |
EP1058559A1 (en) | Combination of a selective nmda nr2b antagonist and a cox-2 inhibitor | |
AU758983B2 (en) | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation | |
US11559537B2 (en) | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | |
AU764875B2 (en) | Combination of a GABA-A alpha 5 inverse agonist and COX-2 inhibitor, NSAID, estrogen or vitamin | |
US20040097573A1 (en) | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation | |
AU715358B2 (en) | Therapeutic composition for arthritis | |
CZ9903642A3 (en) | Use of cyclooxygenase-2 inhibitors for prevention of cardiovascular diseases | |
MXPA99009495A (en) | Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |